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Abstract 
The pathophysiology of acute post-stroke hyperglycaemia (PSH) is important as 
hyperglycaemia affects the majority of stroke patients, and is consistently associated with 
poorer outcome in terms of survival, disability and markers of brain injury such as infarct 
expansion.  There appears to be an interaction between brain arterial patency and 
hyperglycaemia that has not been fully characterised. 
This thesis initially reviews the literature on hyperglycaemia and stroke before focusing on 
animal models of PSH and clinical trials of insulin treatment for PSH in two systematic 
reviews with meta-analysis.  The thesis then looks at the relationship between glucose 
profiles and clinical outcome in a historical population receiving IV thrombolysis for acute 
ischaemic stroke, specifically exploring alternative indices of glycaemic state to compare 
the optimal predictive index for functional outcome as measured by the modified Rankin 
scale. 
The main body of the thesis details a prospective observational clinical study which 
recruited 108 patients within 6 hours of acute ischaemic stroke.  These patients had careful 
monitoring of blood glucose levels over a 48 hour period and detail brain imaging 
including CT perfusion scanning to examine the ischaemic penumbra, CT angiography on 
admission and at 24-48 hours to document brain arterial patency with follow-up CT brain 
imaging to assess outcome infarct volume.  The relationship between 48 hour blood 
glucose profiles, clinical outcome and imaging findings is then explored.  
The main findings of the thesis are summarized below. 
• Animal models of PSH have shown that hyperglycaemia exacerbates infarct 
volume in MCA occlusion models but studies are heterogeneous, and do not 
address the common clinical problem of PSH because they have used either the 
streptozotocin model of type I diabetes or extremely high glucose loads.  
• Animal models show that insulin has a non-significant and significantly 
heterogeneous effect on infarct growth. 
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• Clinical trials of insulin for post stroke hyperglycaemia have shown no benefit in 
terms of improved functional outcomes or mortality.   Insulin is associated with an 
increased risk of hypoglycaemia. 
• In a historical cohort mean capillary blood glucose over 48 hours was more 
predictive of clinical outcome that admission blood glucose or two consecutive 
elevated glucose measurements. 
• A high proportion of acute stroke patients have a blood glucose level above 
7mmol/L within 6 hours of onset.  Different patterns of blood glucose levels define 
different populations. 
• Higher admission and mean glucose levels correlate with larger infarct volumes.  
Larger core perfusion lesion volumes are associated with a greater risk of mortality.  
Admission hyperglycaemia is more harmful than hyperglycaemia after 6 hours. 
• In patients with angiographic evidence of an arterial occlusion infarct volume 
varies significantly with glycaemic status.  In some populations late 
hyperglycaemia is associated with better imaging outcomes.  
• Tandem occlusions are associated with bad outcomes after ischaemic stroke. 
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CT Computerised Tomography 
CTA CT angiography 
CTP CT perfusion 
DEFUSE Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evaluation  
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EPITHET Echoplanar Imaging Thrombolytic Evaluation Trial 
FBG fasting blood glucose 
GIST UK United Kingdom Glucose Insulin in Stroke Trial 
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GLUT-1 Glucose Transporter 1 
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H Hours 
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HOMA Homeostasis Model Assessment - a measure of insulin resistance 
HR Hazard ratio 
ICA Internal Carotid Artery 
ICH Intra-cerebral haemorrhage 
ICU Intensive Care Unit  
IFG Impaired Fasting Glucose  
IGF Insulin like growth factor  
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IGT Impaired Glucose Tolerance  
IIT Intensive insulin therapy  
IQR Intra-Quartile Range 
IRS-1 Insulin receptor substrate 1 
IV Intravenous 
LACS lacunar syndrome 
L-NMMA NG-monomethyl-L-arginine  
LSD Fisher's Least Significant Difference test 
MAST-E Multicentre Acute Stroke Trial 
MCA  Middle Cerebral Artery 
MCAO Middle Cerebral Artery Occlusion  
MCBG Mean Capillary Blood Glucose 
MI Myocardial Infarction 
MONICA MONItoring of trends and determinants in CArdiovascular diseases 
MRA MRI angiography 
MRI Magnetic Resonance Imaging 
MRS Magnetic Resonance Spectroscopy  
mRS modified Rankin scale 
mRs-SI modified Rankin scale Structured Interview 
MTT Mean Transit Time  
N Number 
NBM nil by mouth  
NCCT Non-Contrast CT scan 
NHS National Health Service 
NICE-SUGAR Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation 
NIHSS National Institute of Health Stroke Scale 
NINDS National Institute of Neurological Disorders and Stroke  
NOS Nitric Oxide Synthase  
OCSP Oxfordshire Community Stroke Project 
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OGTT Oral Glucose Tolerance Test  
OR Odds Ratio 
OVID a bibliographic database 
OXVASC Oxford Vascular Study 
PACS Partial Anterior Circulation Syndrome 
PAI-1 Plasminogen Activator Inhibitor-1 
PCA Posterior Communicating Artery 
PET Positron Emission Tomography 
PFO Patent Foramen Ovale 
POCS Posterior Circulation Syndrome 
POSH Post Stroke Hyperglycaemia and Brain Arterial Patency study 
PROACT II PROlyse for Acute Cerebral Thromboembolism 
PROGRESS Perindopril Protection Against Recurrent Stroke Study  
PSH Post Stroke Hyperglycaemia 
PWI Perfusion Weighted Imaging (MRI) 
RCT Randomised Controlled Trial 
REACH Reduction of Atherothrombosis for Continued Health  
ROS Reactive oxygen species 
r-proUK recombinant pro-urokinase  
RR Relative Risk 
rtPA recombinant tissue –Plasminogen Activator 
SD Standard deviation 
SELESTIAL Spectroscopic Evaluation of Lesion Evolution in Stroke: Trial of Insulin for Acute Lactic acidosis 
sICH symptomatic Intra-Cerebral Haemorrhage 
SITS  Safe Implementation of Thrombolysis in Stroke 
SITSMOST Safe Implementation of Thrombolysis in Stroke: Monitoring Study 
SPSS a statistical software package 
STZ Streptozotocin 
TACS Total Anterior Circulating Syndrome 
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TCD Transcranial Doppler  
THIS Treatment of Hyperglycaemia in Ischaemic Stroke trial  
TIA Transient Ischaemic Attack 
TIBI Thrombolysis in brain ischaemia 
TIMI Thrombolysis in myocardial infarction 
TOAST Trial of ORG 10172 in Acute Stroke Treatment 
TUCSON Transcranial Ultrasound in Clinical SONothrombolysis 
UK  United Kingdom 
UKPDS United Kingdom Prospective Diabetes Study 
VISTA Virtual International Stroke Trial Archive 
VOF Venous Output Function 
VSMCs Vascular Smooth Muscle Cells 
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1 Introduction – sugar and stroke 
1.1 Fundamental concepts in Stroke 
1.1.1 Epidemiology – stroke is important 
Stroke is the third leading cause of death worldwide after coronary disease and cancer.  
Every year an estimated 150.000 people in the UK have a stroke.  It is also the most 
common cause of severe disability.1  The Stoke Association (www.stroke.org.uk) estimate 
that more than 250,000 people in the UK live with disabilities due to stroke. 
The UK economy is also drained by stroke.  One recent study estimated that the societal 
cost of stroke in the UK amount to £8.9 billion a year.  Stroke treatment accounts for 
approximately 5% of total NHS expenditure.2 
1.1.2 Pathophysiology of stroke 
An ischaemic stroke occurs when the blood supply to the brain is interrupted resulting in 
destruction of brain tissue.  Stroke is a syndrome of end organ damage with many different 
causes.  The most common causes are atherothromboembolism3, 4, intracranial small vessel 
disease5-7 and cardiac embolisation8, 9.  Atrial fibrillation is the most common cause of 
cardiac embolisation in the developed world10-13. 
Different systems for stroke aetiological subtype classification have been used to 
categorise the probable cause of an ischaemic stroke in clinical reseach.14, 15 Classification 
of stroke subtype may be useful in different scenarios.  Subtyping may be necessary for a 
clinical trial or to clearly define populations in an epidemiological or genetic study.  Stroke 
subtyping may also be important in clinical decision making.16 The merits of different 
classification systems have been debated.   
The TOAST system (Trial of Org 10172 in Acute Stroke Treatment) was widely used in 
many papers.14, 16 TOAST uses five subtypes of ischaemic stroke (large-artery 
atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other determined 
aetiology and stroke of undetermined aetiology) to classify strokes.  There were several 
weaknesses in TOAST; the classification of lacunar stroke was inexact, patients with 2 co-
existing definite causes of stroke would be classified as ‘stroke of undetermined aetiology’ 
and TOAST was accused of discouraging detailed diagnostic investigation.16  
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More recently the computerised Causative Classification of Stroke (CCS) system has been 
shown to allow reliable classification of stroke subtypes by using an evidence-based 
algorithm.15  CCS is a revision of TOAST in which the ‘undetermined cause’ category was 
subdivided and recent advances in diagnostic techniques have been considered.17The 
computerised version of CCS is available for academic use online.18 
The A-S-C-O system attempts to phenotype stroke.19  A stands for atherosclerosis, S stands 
for small vessel disease, C for cardiac source and O for other.  Each phenotype is scored 
for probability.  The quality of evidence to support each diagnosis is also graded.  A-S-C-O 
has been praised for it’s comprehensive approach,20  although it does not always reduce the 
incidence of ‘undetermined’ causes of stroke.21 
One study comparing A-S-C-O, CCS and TOAST concluded that no classification system 
was clearly superior.22 
Clinically, stroke syndromes can be classified by the arterial blood supply of the area of 
brain that has been injured to produce a neurological deficit.23, 24 
1.1.3 Ischaemic Penumbra 
The concept of the ischaemic penumbra is important in the development of modern acute 
stroke therapies.  The penumbra was first defined in animal studies, initially using rats25 
and later primates26 in experiments that identified areas of electrical inactivity after the 
onset of focal ischaemia implying that areas of tissue were dysfunctional but not dead.  
This tissue was distinct from the infarct core which had no activity and was dead.  When 
blood flow was restored to these penumbral areas a degree of functional improvement was 
observed but the core tissue was unable to regain electrical activity.25  Earlier human 
studies looked at the effect of systemic hypotension on cerebral blood flow (CBF) and 
noted that focal neurological signs appear when CBF falls below 31.5 ml/100g/min.27  
Further animal studies showed that cellular survival and functional recovery of neurons 
was related to both residual blood flow and duration of ischaemia.28, 29  It was recognised 
that urgent revascularisation might be important therapeutically for stroke patients.30  The 
concept of a therapeutic window in acute stroke treatment was established.29 
Positron emission tomography studies looking at cerebral blood flow and oxygen 
consumption in humans within 18 hours of a first ischaemic stroke revealed 3 patterns of 
perfusion and oxygen consumption.  The first pattern of greatly reduced perfusion and 
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oxygen consumption suggested tissue infarction and predicted a poor clinical outcome.  
The second pattern showed a moderate to large perfusion reduction and a moderate or large 
reduction in oxygen consumption and was felt to represent the ischaemic penumbra.  This 
pattern was associated with variable outcomes.  The third pattern showed an increase in 
perfusion associated with some areas of reduced perfusion with normal or slightly reduced 
oxygen consumption.  This pattern probably represented tissue oligaemia and predicted a 
good outcome.31  Later PET studies confirmed the existence of potentially viable areas of 
tissue up to 17 hours after an ischaemic stroke.32 
1.1.4 Stroke thrombolysis 
The concept of stroke thrombolysis has existed for some time although initial trials with 
urokinase and streptokinase were unsuccessful.33, 34  Thrombolysis aims to re-open an 
occluded artery, restore blood flow and save the ischemic penumbra. 
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group was 
the first clinical trial to show that the use of tissue plasminogen activator in acute 
ischaemic stroke was associated with an improved clinical outcome.35  Initially stroke 
thrombolysis was considered safe below 3 hours but more recent trials such as ECASS-III 
(European Cooperative Acute Stroke Study III) and observational studies have suggested 
that good outcomes are likely up to 4.5 hours.36-38  The IST-3 trial suggested treatment up 
to 6 hours may be beneficial.39 
1.2 Pre-stroke hyperglycemia 
The physiological state of a patient does not begin at the moment that they have a stroke.  
A patient may have had abnormal glucose metabolism for some time before they have a 
stroke.  Post-stroke hyperglycaemia cannot be discussed without some consideration of 
pre-stroke hyperglycaemia. 
1.2.1 Hyperglycemia as a risk factor for cardiovascular events 
Abnormal blood glucose levels are associated with an increased risk of cardiovascular 
events such as myocardial infarction or stroke as evidenced in a large meta-analysis of 20 
studies combined data from 95783 patients over 12.4 years which found a relationship 
between blood glucose levels and the risk of cardiovascular events.40   
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A 2004 paper by Tanne and colleagues explored the link between fasting plasma glucose 
levels and the risk of incident ischaemic stroke,41 using data from 13999 patients who were 
screened for inclusion in a cardiovascular disease secondary prevention randomised control 
trial.  All patients had a fasting blood glucose level checked at the baseline of the trial.  
From this prospectively recruited cohort they were able to identify 576 verified cases of 
ischaemic stroke or TIA.  The median fasting glucose level was between 90 and 99mg/dl.  
When compared to this group patients with a lower blood glucose (80-89mg/dl) had a 
greater risk of stroke with an odds ratio of 1.27 (95% CI 1.02-1.6) while patients with 
higher glucose levels had an even higher risk of stroke.  A patient with fasting blood 
glucose levels above 140mg/dl had an odds ratio for risk of ischaemic stroke of 2.82 (95% 
CI 2.32-3.43).  There appears to be a J-shaped curve for the relationship between fasting 
blood glucose and risk of ischaemic stroke (see Figure 1 below). 
 
Figure 1 - The relationship between fasting blood glucose and ischaemic stroke risk (Tanne 
2004) 
A similar J-shaped curve was also seen in a meta-analysis of 102 studies that examined the 
relationship between diabetes mellitus, fasting plasma glucose and vascular outcomes such 
as ischaemic stroke,42 (Figure 2 below) with lowest risk at 5.2mmol/L and increased risk at 
lower and higher levels of fasting plasma glucose.  More studies are needed to elucidate 
the link between lower fasting glucose levels and vascular risk.   
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Figure 2 - Meta-analysis of risk for ischaemic stroke by baseline fasting glucose 
concentration 
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A large Korean study43 using data from 652,901 men identified 10954 strokes.  A linear 
relationship between fasting blood glucose level and risk of stroke was observed for 
glucose levels above 5.6mmol/L.  The p-value for this linear trend was <0.0001. 
In an analysis of data from 13116 non-diabetic men in the Whitehall study there appears to 
be a relationship between increasing post oral glucose tolerance test glucose level and 
death from stroke.44  Risk of death from stroke began to increase as post-challenge glucose 
levels increased above 4.6mmol/L.  For every 1mmol/L increase in plasma glucose above 
this level there was an increase in the adjusted risk of stroke (Hazard ratio 1.17, 95% CI 
1.04-1.31). 
Hyvarinen and colleagues combined data from 21706 patients enrolled in 13 cohort studies 
to look at the relationship between fasting plasma glucose and plasma glucose level at 2 
hours after an oral glucose load.45  In men an elevated post-challenge glucose level more 
strongly predicted mortality than fasting plasma glucose.  In women fasting plasma 
glucose level was a stronger predictor of death. 
Hyperglycemia also appears to be a risk factor for peri-operative stroke during carotid 
endartectomy.  One retrospective observational study examined the records of 1201 
patients who underwent endartectomy.46  All of these patients had a blood glucose level 
checked at least 3h hours before the start of the operation.    When the blood glucose levels 
were dichotomised at 200mg/dl (11.1mmol/l) it was found that pre-operative glucose 
readings above this level were associated with an increased odd ratio of stroke (OR 2.78, 
95% confidence interval 1.37-5.67, p=0.005).  Hyperglycemia was also associated with an 
increased risk of MI or death. 
1.2.2 Hyperglycemia and clinical outcomes in critical care 
Hyperglycemia is also associated with poor outcomes in critically unwell patient groups.  
In a large retrospective cohort study Falcigila and colleagues looked at data from 259040 
patients in 173 American intensive care units.47  When compared with normoglycemic 
patients, hyperglycemic patients are at an increased risk of death with the risk increasing as 
the plasma glucose level increases.  This effect varies with reason for admission to the 
intensive care unit.  For stroke patients a blood glucose level of above 300mg/dl 
(16.6mmol/l) is associated with a risk of death with a hazard ratio of 8.49 (95% CI 4.46-
16.2, P<0.0001). 
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1.2.3 Insulin resistance  
Insulin resistance is an abnormal physiological state in which a normal amount of insulin 
produces a subnormal physiological response.  The gold standard for the identification of 
insulin resistance is a euglycemic hyperinsulinaemic clamp.  Most patients with Type II 
Diabetes Mellitus have insulin resistance.  In one study of 72 non-diabetic patients with a 
recent TIA or stroke 36 patients had impaired insulin sensitivity.48 In another study 52% of 
patients were found on investigation to have insulin resistance or previously unknown 
diabetes after a TIA or stroke.49 
Homeostasis model assessment or HOMA is an accurate and less inconvenient method of 
assessing insulin sensitivity.50A model is used to predict the homeostatic concentrations of 
glucose and insulin based on fasting blood samples allowing researchers to estimate insulin 
sensitivity and β-cell function51.  In a paper published in 2000 Hanson and colleagues 
established that HOMA results correlated with euglycemic hyperinsulinaemic clamp 
results to an acceptable degree.52  
Pathophysiologically, insulin resistance appears to be determined by defective muscle 
glycogen synthesis.53 
1.2.4 Insulin Resistance and risk of stroke 
Insulin resistance has been posited as a risk factor atherothrombotic stroke.54  As part of a 
cohort study looking at cardiovascular disease in northern Sweden 94 cases of first ever 
stroke in patients without diabetes were found to have elevated pre-stroke proinsulin 
levels.55  In the Helsinki Policeman population study hyperinsulinaemia was associated 
with increased stroke risk (age-adjusted hazard ratio, 2.12; 95% CI, 1.28 to 3.49) although 
this was not independent of other risk factors such as obesity.56   
In another Finnish study the patients with the higher insulin levels appeared to have a 
greater risk of stroke but when adjusted for lipid levels, blood pressure and obesity this 
effect was no longer statistically significant.57 
In a 1999 paper, Folsom and colleagues58 found that an elevated fasting plasma insulin 
level increased the risk of stroke after correction for other risk factors with a relative risk 
ratio of 1.14 (CI 1.01-1.3, p=0.03).  When the highest quartile of insulin levels was 
compared with the lowest quartile the corrected relative risk increased to 2.11. 
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A 1999 paper by Wannamethee and colleagues looked at the association between non-
fasting insulin concentrations and risk of stroke.59.  Men with diabetes were at a 
significantly increased risk of stroke.  There was also an apparent J-shaped relationship 
between non-fasting insulin levels and stroke risk with the lowest risk seen in patients with 
insulin levels of between 6.65 and 9.8 mU/L.  
Several papers have suggested that insulin resistance as characterised by a homeostasis 
model assessment (HOMA) is associated with risk of incident ischaemic stroke 60 Patients 
with higher insulin levels may be at a greater risk of ischaemic stroke (HR 2.83, 95% CI 
1.34-5.99).61  Insulin resistance may be a modifiable risk factor for stroke that should 
trigger pharmacological intervention.62  The evidence for this is not completely consistent 
as demonstrated in a 2009 paper by Tanne and colleagues,63 insulin sensitivity status was 
assessed using HOMA.  Incident strokes occurred in 137/2938 patients but there was no 
apparent increased risk of stroke with increased insulin resistance in this population. 
Elevated pro-insulin levels may be associated with an increased risk of stroke.55  In a 
prospective cohort study 94 patients with first ever ischaemic stroke and 178 randomly-
selected controls were compared.  The highest tertile of pro-insulin levels was associated 
with an increased risk of stroke after adjustment for other risk factors (OR 3.4, 95% CI 1.4 
to 8.4).  The risk was even greater in women with and odds ratio of 13.7 (95% CI 1.3 to 
146). 
1.2.5 Impaired Glucose Tolerance and Risk of Stroke 
We cannot be sure that impaired glucose tolerance is a risk factor for stroke. 
Impaired glucose tolerance as defined by an oral glucose tolerance test was not associated 
with the risk of stroke in a 1998 paper.64  In this study 6547 adults had an oral glucose 
tolerance test to define if they had normal glucose metabolism, impaired glucose tolerance 
or diabetes.  The prevalence of stroke was 1.82% in the normal group, 2.17% in the 
impaired glucose tolerance group and 4.96% in the diabetic group.  In this study impaired 
glucose tolerance was associated with an adjusted risk ratio of 0.9 (95% CI 0.5-1.6) for 
non-fatal stroke while diabetes mellitus was associated with an adjusted risk ratio of 1.6 
(95% CI 1 – 2.6).  Similar results were seen in a 2006 Finnish study where stroke occurred 
more frequently in patients with impaired glucose tolerance although this was not 
statistically significant (RR 1.48, 95% CI 0.91-2.41, p=0.12).65 
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A secondary analysis of data from the Dutch TIA Trial suggests that impaired glucose 
tolerance may be associated with recurrent stroke in a population of patients who have 
experienced a minor stroke or TIA.66  In this study 3127 patients were enrolled.  Over 2.6 
years 272 patients had a stroke.  Impaired glucose tolerance (IGT) was diagnosed on a non-
fasting glucose sample and defined as a glucose level of between 7.8 and 11mmol/L.   IGT 
was associated with an increased risk of recurrent stroke (HR 1.8, 95% CI 1.1 to 3).  
Diabetes was associated with an even greater risk (HR 2.8, 95% CI 1.9-4.1).  Interestingly 
patients with blood glucose levels below 4.6mmol/L also had an increased stroke risk (HR 
1.5, 95% CI 1 to 2.2). 
Impaired glucose tolerance has been identified as a risk factor for stroke in a Japanese 
population as described in a 2008 paper by Oizumi and colleagues.67  Glucose tolerance at 
baseline was defined in a cohort of 2938.  Impaired glucose tolerance was associated with 
an increased risk of stroke (OR 1.87, 95% CI 1.73-2.03) as was diabetes mellitus (OR 3.57, 
95% CI 3.21-3.98). 
It has also been reported that the ‘metabolic syndrome’ is associated with an increased risk 
of incident stroke or TIA.68  The ‘metabolic syndrome’ is a controversial entity with debate 
over the existence and definition of the syndrome.69, 70 In 2005 the American Diabetes 
Association and the European Association for the Study of Diabetes issued a joint 
statement to say that the metabolic syndrome was imprecisely defined and that it’s 
pathogenesis was uncertain.69 This statement concluded that there is not enough 
information available to clearly define this syndrome and that the term may not be useful. 
1.2.6 Insulin resistance as a risk factor for carotid artery disease 
An association between insulin resistance and carotid artery disease has been reported. A 
Swedish study from 1967 found a relationship between angiographically defined disease of 
the major cerebral blood vessels and impaired glucose tolerance as defined by an oral 
glucose tolerance test.71  More severe disease was associated with a greater extent of 
disease on angiogram. 
The Insulin Resistance and Atherosclerosis Study (IRAS) found a significant relationship 
between carotid intima thickness and insulin resistance in white or Hispanic people but not 
in black people.72  Carotid intima thickness was generally greater than average in 
hyperglycemic or diabetic people.73  Similar findings have been made in other studies.74   
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Diabetic patients have a high prevalence of carotid artery occlusive disease75 with 20% 
found to have a degree of carotid artery occlusive disease in one study.  Measures of 
hyperglycemia did not appear to be related to carotid disease although higher systolic 
blood pressure, higher cholesterol and reduced adiposity were.  Another study found that 
while diabetes mellitus predicted increased carotid intima-media thickness plasma insulin 
levels did not.76 
Insulin resistance may be an important pathophysiological factor in atherothrombotic 
stroke.54  In a small angiography study patients with atherothrombotic stroke had severe 
insulin resistance and compensatory hyperinsulinaemia while the lacunar or cardioembolic 
patients did not.  Increased insulin resistance defined by HOMA-IR is associated with 
intracrainial atherosclerosis diagnosed on MR or digital subtraction angiography.77   
The Lausanne Stroke Registry found a significant relationship between large artery stroke 
and diabetes mellitus.78  In this study 31% of non-diabetic patients had a large artery stroke 
compared to 42% of diabetic patients (p<0.0001).  In this population diabetes mellitus is 
associated with an increased risk of large artery stroke with an odds ratio of 2.02 (95% CI 
1.31-3.02, p=0.002). 
A study of 415 926 ischemic stroke patients found that carotid stenosis was significantly 
more prevalent in diabetic patients (5.2% vs.4.2%, <0.0001).79 It has also been suggested 
that insulin resistance is a risk factor for sub-clinical cerebral infarction associated with 
thickening of the carotid intimal media.80 
1.2.7 Insulin resistance and lacunar stroke 
A 1996 study by Zunker and colleagues suggests that insulin levels are higher in patients 
with ischaemic stroke.81  In a prospective study insulin levels were checked in patients 
with lacunar disease, subcortical arteriosclerotic encephalopathy and stroke due to large 
vessel disease.  Insulin levels were significantly higher in lacunar stroke patients than in 
other groups.  The authors conclude that elevated insulin levels may represent a 
pathophysiological factor in the development of cerebral small vessel disease. 
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1.2.8 Diabetes and stroke 
In a large meta-analysis recently published in The Lancet individual patient data from 
698782 participants in 102 studies were combined.42 In this cohort diabetes mellitus was 
associated with an increased hazard ratio of 2.27 for ischaemic stroke (95% CI 1.95-2.65)  
An early description of this association was made in 1972 Paffenbarger published data 
from a cohort study involving 3991 Longshoremen who were followed up for 18.5 years.82  
At baseline these men were assessed for cardiovascular risk factors including diabetes 
mellitus and impaired glucose tolerance.  Paffenbarger found that patients with impaired 
glucose tolerance had a risk ratio of 1.97 for death from stroke while patients with diabetes 
mellitus had an even greater risk ratio of 2.96. 
The Rochester Community Study,83 The Honolulu Heart Programme84 and large British.85  
and American86 studies have clearly established diabetes as a risk factor for stroke.  A 
similar picture has been seen in Sweden,87  Japan88  and Hong Kong 89 In the Hong Kong 
study diagnosis of diabetes was previously unrecognised in 19% of patients who presented 
with an ischaemic stroke.  Diabetes is associated with an increased risk of stroke after 
myocardial infarction. 90 
Recurrent stroke also appears to be more likely in patients with diabetes91  as seen in the 
Leigh Valley Stroke Programme where diabetes was found to convey an increased relative 
risk of 5.6 for recurrent stroke (p<0.0001). 
1.2.9 Diabetes and outcome after stroke 
Diabetes appears to be a poor prognostic marker in stroke.92  Diabetic patients have an 
increased risk of death and recurrent stroke or myocardial infarction.93  In one study 
diabetes was associated with an increased incidence of limb weakness, dysarthria, 
ischaemic stroke and lacunar stroke.94  Diabetic patients also appeared to have higher 3 
month Rankin scores and more severe Barthel scores.   This paper was a large population 
based study combining several European databases so it is possible that some diagnostic 
accuracy (for both lacunar stroke and diabetes) has been compromised. 
Tuttolomondo and colleagues did not report significant outcome differences between 
diabetic and non-diabetic patients in their 2008 paper.95  Diabetic patients in this cohort 
had better scores on the Scandinavian Stroke Scale than non-diabetics.  The authors felt 
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that this may be due to the higher prevalence of lacunar stroke in the diabetic population.  
Lacunar strokes may result in lower levels of disability. 
In a 2007 Spanish language paper Ortega-Casarrubios and colleagues looked at patient 
outcomes in a cohort of 2213 stroke patients, 661 (29.9%) of whom had a history of 
diabetes.96  In this cohort patients with diabetes had significantly higher rates of in-hospital 
complications (OR: 1.377; CI 95%: 1.053-1.799) such as urinary tract infection, multi-
organ failure, neurological deterioration and recurrent stroke.  Despite these findings there 
did not seem to be any association between diabetes mellitus and severity of initial stroke, 
mortality, length of hospital stay or stroke outcome.  
Another study suggests that diabetes does not seem to influence the motor or functional 
outcome of patients who enter rehabilitation after a first ischaemic stroke.97  In a 
prospective observational study 395 patients were assessed for diabetes and entered into a 
rehabilitation programme.  Both the diabetic and non-diabetic patients were observed to 
make a significant and progressive improvement in all outcome measures (P<0.01) with no 
differences between groups.  The paper does not explicitly state that outcomes were 
assessed by research staff blinded to the diabetic status of the patients so there is a 
possibility that a degree of bias could have distorted these results.  However these results 
suggest that a mechanism other then poor rehabilitation potential may be responsible for 
the poor clinical outcomes after stroke. 
In another study using data from VISTA (the Virtual International Stroke Trial Archive) 
predictive models were developed for cardiac death and serious cardiac events after 
stroke.98  Diabetes was found to predict a cardiac event with an odds ratio of 2.11 (95% CI 
1.39-3.21, p<0.0001). 
A very large American study assessed the quality of care and clinical outcomes amongst 
diabetic patients admitted to hospital after an ischaemic stroke.79  In this study data were 
obtained from 415 926 ischemic stroke patients admitted to 1070 American hospitals 
between 2003 and 2008.  In this cohort 130 817 (31%) had diabetes.  Patients with diabetes 
who presented within two hours of stroke onset were less likely to receive treatment with 
alteplase than non-diabetics (adjusted odds ratio 0.83; 95% CI, 0.79-0.88, p<0.0001).  
Patients with diabetes also had an increased risk of death (adjusted OR, 1.12; 95% CI, 
1.08-1.15). 
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In a prospective observational study involving 142 patients with diabetes who had suffered 
a stroke there was no apparent link between glycaemic control as assessed by HbA1c and 
risk of recurrent stroke.99  These results may be misleading as the majority of patients in 
this cohort had well controlled diabetes and the sample size of 142 patients is small.  Tight 
glycaemic control would need to have a very large effect on the risk of recurrent stroke for 
that effect to be detectable in a cohort of 142 patients.   
Risk factors such as diabetes are often under-treated in patients who have experienced a 
stroke.100 In one large study 4.5% of patients had no treatment for their diabetes.  This 
study suggested that undertreatment of modifiable risk factors for stroke is a global 
problem. 
Treatment of risk factors does appear to be beneficial for ischaemic stroke patients who 
have diabetes.  In a subgroup analysis of the Perindopril Protection Against Recurrent 
Stroke Study (PROGRESS) outcomes for diabetic and non-diabetic patients were 
compared.101  In patients with diabetes treatment with perindopril reduced the relative risk 
of recurrent stroke by 38% (95% CI 8-58) while in non-diabetic patients there was a 
relative risk reduction of 28% (95%CI 16-39).  There was no evidence of heterogeneity 
between these results (P homogeneity = 0.5).  The reasons for this benefit are uncertain. 
1.2.10 The prevalence of diabetes in stroke patients 
The prevalence of diabetes in stroke patients may well be underestimated.  In a study 
population of stroke survivors at least 6 months after their stroke glycaemic status was 
categorised using both a fasting blood glucose sample and an oral glucose tolerance test.102  
The fasting plasma glucose level was found to have a sensitivity of only 49% for 
predicting abnormalities in the glucose tolerance test.  In this population of stroke 
survivors 77% were found to have abnormal glucose metabolism.  
1.2.11 Post mortem studies of stroke in diabetes 
Post mortem studies have shown that diabetes is associated with an increase in the 
frequency and severity of cerebral atherosclerosis in all age groups.103 Pathological studies 
from the first generation of Type 1 diabetics treated after the discovery of insulin in 1922 
showed ‘softening’ in the brains of all the patients studied.104 One paper reported 16 
patients with a duration of diabetes of between 16 and 36 years who had died before the 
age of 40.104  Fourteen of these sixteen patients had some neurological symptoms while 4 
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had clinical strokes. Evidence from post-mortems also suggests that stroke occurs much 
more frequently in diabetic patients than non-diabetic patients.105  Non-diabetics over the 
age of 85 were less likely to have evidence of stroke than diabetic patients in younger age 
groups. 
1.2.12 Type of stroke in diabetes 
The characteristics of first ever stroke in diabetic patients were examined in a study of the 
Lausanne Stroke Registry.78  This registry included 3690 ischaemic stroke patients, 
including 572 patients with diabetes mellitus.  As I have discussed in an earlier paragraph 
large artery disease was significantly more common as a cause of stroke in the diabetic 
patients.  Diabetes was also associated with a higher prevalence of subcortical infarction 
(OR 1.34, 95% CI 1.11-1.62, p=0.009) and a greater frequency of small vessel disease (OR 
1.78, 95% CI 1.31-3.82, p=0.012).  Cardioembolic strokes were not associated with 
diabetes.  The registry also includes intra-cerebral haemorrhage patients and there was 
lower relative prevalence of ICH among patients with diabetes. 
Tuttolomondo and colleagues analysed the prevalence of different stroke sub-types defined 
by the TOAST criteria in 102 diabetic and 204 non-diabetic stroke patients.95  A higher 
incidence of lacunar stroke was observed amongst diabetic patients even after adjustment 
for hypertension (adjusted OR 3.37, 95% CI 1.9-5.99, p=0.0001).  Differences in incidence 
of other TOAST subtypes were non-significant.  
Patients with diabetes appear to be at an increased risk of recurrent lacunar stroke.  In a 
prospective study of lacunar stroke quantified with MRI.  A total of 175 patients presenting 
with a first ever lacunar stroke were included in the study.  Diabetes mellitus was 
associated with the presence of multiple lacunar strokes (OR 2.43, 95% CI 1.09–5.4, 
P=0.026). 
Diabetes also seems to be associated with subclinical cerebral infarctions.106In a Japanese 
prospective observational studies 360 hypertensive patients with no history of stroke 
underwent MRI scanning.  In this population 247 silent cerebral infarcts were identified on 
MRI.  Silent cerebral infarctions were found in 82% of the diabetic patients compared to 
58% of the non-diabetic patients (p<0.001).  Multiple silent cerebral infarctions were also 
more common in the diabetic population (p<0.001). 
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Diabetes may be associated with an increased prevalence of asymptomatic intracranial 
large vessel occlusive disease.107 In a prospective study of 510 patients referred to a 
vascular imaging laboratory for carotid duplex and transcranial Doppler ultrasound 66 
patients (12.9%) were found to have asymptomatic intracranial arterial occlusions.  
Diabetes was present in 28% of these patients (p=0.021). 
1.2.13 Cerebral blood flow in diabetic stroke 
In a 1978 study Dandona and colleagues compared cerebral blood flow in diabetics and 
non-diabetics.108 A group of 59 patients with diabetes mellitus and no history of stroke was 
recruited.  Twenty-eight non-diabetics with no history of stroke were used as a control 
group.  Cerebral blood flow was measured using the 133-xenon gamma camera technique 
developed by David Wyper and colleagues at the Institute of  Neurological Sciences in 
Glasgow.109 
After challenge with carbon dioxide cerebral blood flow increased in all of the control 
patients but decreased in 26 of the diabetic patients and remained static in 10 more diabetic 
patients.  The authors conclude that these results indicate that patients with diabetes have 
impaired cerebrovascular reserve and are at an increased risk of stroke.108  A similar 2003 
paper by Kadoi and colleagues found an inverse correlation between absolute carbon 
dioxide reactivity and glycosylated haemoglobin (r = 0.69, p<0.001).110  Several 
subsequent papers have attempted to further characterise cerebrovascular reactivity in 
diabetic patients.110-117 In patients with longstanding type 2 diabetes the vasodilatatory 
ability of cerebral arterioles is diminished.116 
In a 1990 longitudinal study comparing cerebral blood flow in both diabetic and non-
diabetic stroke patients cerebral blood flow was better maintained in treated diabetics than 
in non-diabetic subjects.118 However there was a greater incidence of cognitive decline in 
the diabetic patients despite the maintenance of cerebral blood flow. 
In a 2007 paper Last and colleagues aimed to evaluate the regional effects of type 2 
diabetes on cerebral tissue volumes and cerebral blood flow (CBF) regulation.111  Diabetic 
patients and normal controls had their regional brain volumes and vasoreactivity 
determined by anatomical imaging and continuous arterial spin labelling (CASL) of blood 
flow using 3 Tesla MRI.  Diabetic patients were found to have smaller volumes of both 
gray and white matter.  Baseline cerebral blood flow was reduced in diabetic patients.  
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Higher HbA1c levels were associated with lower cerebral blood flow and greater CSF 
volumes in the temporal region.  
Mankovsky and colleagues observed impaired cerebral autoregulation in a cohort of 
diabetic patients with known cardiovascular autonomic neuropathy or orthostatic 
hypotension.113  Cerebral blood flow was assessed with transcranial Doppler ultrasound in 
both diabetic patients and normal controls.  Cerebral blood flow velocity was markedly 
reduced in patients with diabetes after one minute of standing suggesting that cerebral 
autoregulation was impaired in this group.  This could be a mechanism explaining the 
worse outcome often seen in patients with diabetes after ischaemic stroke.  If vascular 
autoregulation is impaired collateral blood supplies may be slowly recruited worsening the 
anatomical hypoperfusion and resulting in accelerated penumbral loss.  Several small 
prospective studies have suggested that impaired cerebral vasomotor reactivity was a 
predictive factor for stroke in patients with asymptomatic carotid stenosis.113, 119, 120 
Another study compared vascular reactivity in diabetic patients with normal controls.112  In 
an attempt to investigate the effect of diabetes on basal cerebrovascular endothelial 
function 14 patients with type 2 diabetes and 15 normal controls had their cerebral blood 
flow monitored during exposure to the nitric oxide synthase (NOS) inhibitor NG-
monomethyl-L-arginine (L-NMMA).  In the non-diabetic group cerebrovascular blood 
flow there was an appropriate response to the L-NMMA while cerebrovascular reactivity 
was markedly impaired in the diabetic group.   
Cardiovascular autonomic neuropathy (CAN) is associated with an increased risk of 
incident ischaemic stroke.121  Patients with known Type II diabetes mellitus were assessed 
for cardiovascular autonomic neuropathy and given a CAN score.  Patients were followed 
up over a 7 year period and data on subsequent ischaemic stroke were collected.  Patients 
with higher CAN scores were found to be at a greater risk of incident ischaemic stroke 
after Cox proportional hazard regression analysis (adjusted HR 2.7, 95% CI 1.3-5.5, 
p=0.006).  The presence of cardiovascular autonomic neuropathy may be associated with 
cerebrovascular autonomic neuropathy.  Some animal studies support this hypothesis.122, 
123
 
1.2.14 Special risk factors for stroke in Type 2 Diabetes Mellitus 
Some studies have tried to define clinical markers that may predict stroke risk in patients 
with diabetes mellitus.  In a small prospective observational study 133 patients with non-
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insulin dependent diabetes mellitus were followed up for 10 years.124  In this cohort 19 
patients had an ischaemic stroke.  Toyry and colleagues found that pre-existing 
parasympathetic neuropathy was a strong independent predictor for later ischaemic stroke 
with an odds ratio of 6.7 (95% 1.5-29.9, p=0.012) while sympathetic autonomic 
neuropathy was associated with a slightly lower risk (OR 1.2, 95% CI 1.01-1.2, p=0.042).  
Interestingly the use of beta-blockers was also strongly predictive although this was 
probably confounded by underlying cardiac disease (OR, 6.7; 95% CI, 2.1 to 21.5). 
Diabetic autonomic neuropathy also emerged as a risk factor for stroke in a prospective 
study that included 950 patients with known type 2 diabetes mellitus.125 In this population 
diabetic autonomic neuropathy conveyed an increased risk of stroke with an OR of 2.2 
after multivariate analysis (95% CI 1.1-4.44). 
Asymmetrical retinopathy may be a marker of an increased risk of stroke in diabetic 
patients.126 Theoretically, diabetic retinopathy should be symmetrical and asymmetry may 
represent localised ischaemic retinopathy due to a problem with the extraoccular blood 
supply representing an increased risk of ischaemic stroke.  Lino and colleagues performed 
a prospective study of 142 patients with diabetic mellitus, monitoring them for retinopathy 
and incident ischaemic stroke over a period of 8 years.  Ischaemic stroke occurred in 
41.7% of patients with asymmetrical retinopathy compared to only 7.7% of patients with 
symmetrical retinopathy and 7.7% of those with no retinopathy (p<0.005%).  
1.2.15 Glycosylated haemoglobin  
Glycosylated haemoglobin (HbA1c) levels indicate the exposure of a red blood cell to 
glucose over approximately 120 days.127  More recently HbA1c has suggested as a means 
of diagnosing diabetes.128  For many years it has been known that stroke or TIA is 
associated with an elevated HbA1c level even in patients with no clinical history of 
diabetes mellitus.129  In their 1982 study Riddle and Hart found that 62% of stroke/TIA 
patients had an elevated HbA1c level and when compared with various control groups the 
prevalence of an elevated HbA1c level was greater than in a healthy non-stroke community 
and similar to populations that attended diabetes clinics. 
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1.2.16 Glycosylated haemoglobin and prognosis in stroke 
It has been suggested that patients with an elevated level of glycosylated haemoglobin 
(HbA1c) have a worse prognosis after a stroke although this has not been a universal 
finding. 
In a letter to the BMJ in 1985 Oppenheimer and colleagues suggested that the relationship 
between post-stroke hyperglycaemia and poor outcome in stroke could be explained by the 
elevated HbA1c of many patients130  Oppenheimer suggested that the negative effects of 
PSH may just represent the natural history of stroke in diabetes.  The next year Cox and 
colleagues published a similar study which suggested that patients with a raised HbA1c 
and post stroke hyperglycaemia had better outcomes that those who had a normal HbA1c 
and hyperglycaemia.131   
Topic and colleagues prospectively studied the glycaemic status of 148 patients in a 1989 
paper.132  They evaluated long term glycaemic status with HbA1c levels.  Patients with an 
HbA1c of above 8.6% were assumed to be diabetic.  On this basis 16% of patients had 
unrecognised diabetes in addition to 13% who had known diabetes.  Patients with an 
elevated HbA1c had worse clinical outcomes.  Patients with normoglycemia had better 
outcomes.  Outcomes in patients with transient hyperglycemia had poor outcomes although 
these were not as bad as the diabetic subgroup. 
In the 1987 study by Gray and colleagues 86 acute stroke patients had their glycaemic 
status prospectively assessed with blood glucose and HbA1c levels.133  No significant 
correlation between HbA1c level and outcome was found in this group.    
In a 1992 prospective observational study Murros and colleagues collected data from 99 
stroke patients.134  These patients had HbA1c levels checked to establish glycaemic status 
before they had a stroke.  In this group 76 patients were classified as having a normal 
glycaemic status before the stroke (HbA1c<7) while 23 had abnormal glycaemic 
metabolism (HbA1c above 7).  There did not appear to be any relationship between HbA1c 
and mortality, severity of hemiparesis, functional outcome or infarct size.  However in 
non-diabetic patients the fasting blood glucose level correlated strongly with the severity of 
hemiparesis and predicted stroke outcome. 
In a small prospective study carried out in 1988 by Power and colleagues there was no 
significant correlation between mortality and HbA1c.135  58 patients were enrolled in this 
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study, 28 of whom died.  While there was a tendency for dead patients to have higher 
HbA1c values the confidence intervals of the two groups overlapped and the study was too 
small to produce a definitive answer. 
A cohort study published in 1994 by Moss and colleagues looked at the association 
between glycaemia and cause specific mortality in a diabetic population.136  HbA1c levels 
were checked at baseline in a population of 1780 diabetic patients who were followed up 
for a median period of 8.3 years.  In this population HbA1c was significantly associated 
with risk of mortality.  Higher HbA1c levels were associated with a hazard ratio of 1.17 for 
mortality related to stroke (95% CI 1.05 – 1.30). 
Data from the UK Prospective Diabetes Study (UKPDS) suggest that patients with a higher 
HbA1c are at a greater risk of having a fatal stroke.137  UKPDS was a prospective study 
which recruited 5102 patients with a new diagnosis of Type II diabetes mellitus.  Patients 
were followed up for a median of 7 years.  During this time 234 patients had an ischaemic 
stroke with enough available covariate data for analysis (34 further strokes occurred but 
insufficient data were available).  Forty-eight patients had a fatal stroke.  The risk of fatal 
stroke increased as HbA1c levels increased with a hazard ratio of 1.37 for every 1% 
increase in HbA1c (95% CI 1.09-1.72, P=0.0071). 
More recently in an abstract presented at the 2010 European Stroke conference Juttler and 
colleagues have suggested that HbA1c levels strongly predict the risk of haemorrhagic 
transformation after thrombolytic treatment.138  In a prospective observational study 800 
consecutive patients had various measures of glycaemic status tested.  HbA1c levels 
appeared to have the strongest predictive value for haemorrhagic transformation and 
symptomatic intracerebral haemorrhage independent of a history of diabetes or acute blood 
glucose levels. 
1.2.17 Glycosylated haemoglobin and risk of stroke 
In a large prospective observational study involving 10489 patients Myint and colleagues 
examined the relationship between HbA1c levels and risk of stroke.139 They did not find a 
linear relationship such as that between blood glucose and coronary heart disease.  Instead 
they found a threshold relationship.  In patients with an HbA1c of between 5.5% and 6.9% 
had an adjusted relative stroke risk of 0.83 (95% CI 0.54-1.27) while patients with an 
HbA1c above 7% had a adjusted relative risk of 2.83 (95% CI 1.4 – 5.74). 
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A 2004 meta-analysis conducted by Selvin and colleagues looked at the relationship 
between an increase in HbA1c level of 1% and risk of stroke.140  Data from 3 studies 
involving 5962 patients were pooled and the relative risk of stroke in a diabetic patient was 
found to increase by 1.17 for every 1% increase in HbA1c level (95% CI 1.09-1.25). 
Selvin and colleagues subsequently tried to assess the relationship between HbA1c and risk 
of stroke in diabetic and non-diabetic patients in an analysis of data from the 
Atherosclerosis Risk in Communities (ARIC) study.141 ARIC was a large cohort study 
including 15792 patients.  At the second stage of the study 10866 patients without diabetes 
and 1635 patients with diabetes had HbA1c levels checked.  After follow-up of 
approximately 10 years 89 of the diabetic patients and 167 of the non-diabetic patients had 
ischaemic strokes.  In non-diabetic patients a HbA1c level in the highest tertile conveyed a 
relative risk of stroke of 1.58 (95% CI 0.94-2.66) when compared with patients with 
HbA1c levels in the lowest tertile.  In diabetic patients a HbA1c level in the highest tertile 
conveyed a relative risk of stroke of 4.71 (95% CI 2.69-8.25) when compared with patients 
with HbA1c levels in the lowest tertile.  The paper concludes that an elevated HbA1c may 
be an independent risk factor for stroke in both diabetic and non-diabetic individuals. 
In a 2008 paper a prospectively recruited cohort of 6445 Hong Kong Chinese patients with 
type 2 diabetes mellitus were followed for a mean of 5.37 years to further establish risk 
factors for ischaemic stroke.142  In this study there appeared to be an additive risk of stroke 
in patients with both microalbuminuria and an elevated HbA1c level of above 6.2%. 
1.3 Post-stroke Hyperglycaemia 
The phenomenon of post-stroke hyperglycaemia (PSH) is common with up to 68% of 
acute stroke patients having a plasma glucose concentration >6.0mmol/L.143-147   
1.3.1 Early observations of post-stroke hyperglycemia 
Observations of abnormal glucose metabolism in stroke patients have been made for many 
years.  In a 1967 paper Jakobson performed glucose tolerance tests in a series of 52 stroke 
patients, 47 of whom had stroke disease confirmed angiographically.71  He found that 42% 
of patients with cerebrovascular disease had abnormal glucose metabolism compared to 
17% of a control group who had no evidence of stroke. 
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Another early observational study on post-stroke hyperglycemia was published by 
Melamed in 1976.148  Melamed knew that in experimental models of stroke induction of 
acute cerebral ischemia would often be followed by transient generalised metabolic 
abnormalities including marked hyperglycemia.149, 150 Melamed examined the notes of 
stroke patients (including those with intracerebral haemorrhage) admitted to a neurology 
unit over a six year period.  In a cohort of 392 patients he identified 79 (20%) who had 
known diabetes mellitus and 108 (28%) without known diabetes who had what he 
described as ‘reactive hyperglycemia’.  He also noted a 54% mortality rate in the ‘reactive 
hyperglycemia’ group, compared to 35% mortality in the diabetic group and only 17% 
mortality in the non-hyperglycemic group. 
In a 1978 paper Abu-Zeid and colleagues studied prognostic factors in 1484 stroke patients 
including 952 patients with ischaemic stroke.151  In this cohort admission blood glucose 
level was correlated with survival.  Patients with a blood glucose level of less than 
5.55mmol/L were more likely to survive in both the short term and the long term 
(p<0.005).   
1.3.2 The relationship between blood glucose level after stroke and 
outcome 
Woo and colleagues performed a prospective observational study correlating admission 
blood glucose levels with neurological outcome in 252 acute stroke patients.152  This 1988 
paper included patients with intracerebral haemorrhage as well as ischaemic strokes.  
Patients with admission hyperglycemia were more likely to be dead at 6 weeks irrespective 
of stroke subtype and diabetic status (p<0.05).  If only non-diabetic patients are considered 
mortality is significantly higher at both 1 week (p<0.05) and at 6 weeks (p<0.05).  If only 
intracerebral haemorrhage is considered the effect appears to be even more marked 
irrespective of prior diabetic status (significance levels; 1 week p<0.01, 6 weeks 0<0.005, 
3 months p<0.005). 
In a follow on study Woo and colleagues recruited a further 216 acute stroke patients 
(again including intracerebral haemorrhage).153 In this study HbA1c levels were measured 
in all patients and an oral glucose tolerance test was performed in survivors where 
possible.  Plasma glucose levels did not correlate with HbA1c levels.  There was a non-
significant trend towards surviving patients having higher HbA1c levels if known diabetic 
patients were included in the analysis.  If diabetic patients were excluded from analysis 
there was a non-significant trend towards lower HbA1c levels in survivors.  HbA1c levels 
  43 
 
did not correlate with mortality.  A relationship between admission hyperglycemia and 
mortality was only seen in intracerebral haemorrhage patients.  The authors suggest that 
hyperglycemia in the presence of a normal HbA1c may represent a ‘stress’ response and 
suggest that attempts at lowering plasma blood glucose may be unnecessary.    
A further prospective study included 304 patients, 174 of whom had an ischaemic stroke or 
lacunar infarction.154  In this study 74% of patients with stress hyperglycemia died 
compared to 23% of patients with diabetes mellitus and 24% of patients with normal 
glucose metabolism.  Patients who died had the highest mean glucose levels.  In this study 
the relationship between stress hyperglycemia and death was only significant when the 
ICH patient data were analysed with the ischaemic stroke patient data. 
In a 1992 prospective observational study Toni and colleagues recruited 327 ischaemic 
stroke patients within 12 hours of onset of first ever ischaemic stroke.155  Glucose levels 
were checked as soon as patients were admitted to hospital and before any treatments were 
started.  Patients were split into three groups; diabetic patients, non-diabetic 
hyperglycaemic patients and normoglycaemic patients.  Diabetic patients included patients 
who had persistently elevated glucose levels during admission and required anti-diabetic 
treatment.  No glycosylated haemoglobin levels were checked so it is possible that the 
diabetic group included patients with persistent post-stroke hyperglycemia but no previous 
glycaemic abnormality. 
A plain CT brain scan was performed within 12 hours of stroke onset and repeated at 21 
days.  Admission glucose levels and initial stroke severity were compared with clinical 
outcome and final stroke lesion seen on CT.  21.5% of the patients were diabetic and all of 
these patients were hyperglycaemic at admission.  A further 28.5% were hyperglycaemic at 
admission with no history of diabetes.  There was no correlation between admission 
glucose level and final infarct size.  Initial severity of neurological deficit was predictive of 
final infarct size.  Mortality at 30 days was highest in the diabetic group at 38.6% 
compared to 22.6% mortality in the hyperglycaemic non-diabetic group and 9.2% in the 
normoglycaemic group (p<0.001).155 
In 1993 De Falco and colleagues published a study of 104 patients with ischaemic stroke 
where they found a correlation between blood glucose level within 12 hours of stroke onset 
and cerebral infarct size.156  The correlation between infarct size and blood glucose level 
was highly significant.  Interestingly the relationship between glucose level and infarct size 
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was more significant in the non-diabetic patients (p=0.0373) than in the diabetic patients 
(p=0.056).  The authors felt that the effect of hyperglycemia on infarct size may be 
mediated by ‘vascular insufficiency’. 
In a paper from the North Manhattan Stroke Study published in 1994 glucose level 
predicted stroke mortality and recurrence of ischaemic stroke.157  In this prospective cohort 
study 323 patients were followed for a mean of 3.3 years.  Hyperglycemia (defined as a 
blood glucose level above 140mg/dl) was observed in 38% of patients.  An elevated blood 
glucose level in the first 48 hours after onset was an independent predictor of recurrent 
ischaemic stroke with a relative risk ratio of 1.2 per 50mg/dl (2.7mmol/L).  Hyperglycemia 
was also a significant predictor of mortality after adjustment for age with a risk ratio of 1.7 
(95% CI 1.4-2.8). 
Hyperglycaemia in acute stroke predicts a poor outcome.92, 144, 146, 147, 157-166   In an 
Australian retrospective cohort study 416 patients admitted to a tertiary referral centre were 
identified.164  Patients were divided into 4 groups; normoglycemic, normoglycemic 
diabetics, hyperglycemic diabetics and hyperglycemic non-diabetics.  Hyperglycemia was 
defined as a blood glucose of above 8mmol/L. Hyperglycemia without a history of diabetes 
was an independent predictor of in-hospital mortality in this cohort with an odds ratio of 3 
(95% CI 1.1-8.3, p=0.035).  The risk of in-hospital mortality was lowest in normoglycemic 
patients.  It is interesting to note that hyperglycemic diabetic patients had a better outcome 
than hyperglycemic patients without known diabetes.  
Another Australian prospective study looked at factors which predicted prolonged hospital 
admissions and disability.166  Diabetes was found to be a significant predictor of both 
disability and prolonged admission in this population of 257 ischaemic stroke patients.  
Unfortunately data on hyperglycemia were only available for 173 patients.  Hyperglycemia 
did appear to predict severe disability with p=0.026. 
A retrospective study published by Stead and colleagues in 2009 correlated glucose levels 
checked in the emergency department with patient outcomes.165 Data from 447 patients 
were analysed.  In this cohort hyperglycemia, defined as an admission blood glucose of 
>7.2mmol/L was associated with greater stroke severity (P=0.002) and greater functional 
impairment.  As seen in several other studies hyperglycemia without a prior history of 
diabetes was associated with the worst stroke severity (P<0.0001) and functional 
impairment (P<0.001).  There was no relationship between hyperglycemia and infarct 
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volume.  It is interesting to note that the intra-quartile range for HbA1c levels in the 
‘hyperglycemia without diabetes’ group in this paper is 5.7-6.8 suggesting that potentially 
more than a quarter of the patients in this cohort may have undiagnosed diabetes based on 
recent discussions on the use of glycosylated haemoglobin to diagnose diabetes.128 
Some studies suggest that the effect of hyperglycemia on outcome is less significant when 
other factors are considered.  In a prospective cohort of 185 acute stroke patients the 
unadjusted risk of death was significant with an odds ratio of 5 (95% CI 2.3-10.7, 
p<0.001).  However when other factors such as age, atrial fibrillation and stroke severity 
were taken into account the effect of hyperglycemia was not significant (OR 1.2, 95% CI 
0.4-3.5).167 
Post-stroke hyperglycemia may also be associated with early recurrence of ischaemic 
stroke.  In an 1989 paper Sacco and colleagues used prospectively collected data from the 
NINDS Stroke Data Bank to look for factors that may predict early recurrence of 
ischaemic stroke.168  Data from 1273 patients were used.  Hyperglycemia defined as a 
glucose level above 140mg/dl (6.66mmol/L) was present in 36% of patients and was 
associated with  a 6.36% risk of recurrent stroke compared to a risk of 2.07% in patients 
with lower blood glucose levels (p=0.001).  Multivariate logistic regression suggested that 
the risk was even greater if a patient was both hypertensive and hyperglycemic. 
In a retrospective cohort of 811 patients admitted to an acute stroke unit, admission 
glucose levels were correlated with clinical outcome at 3 months.147  This cohort included 
105 patients with haemorrhagic stroke.  Sixty-one patients with known diabetes mellitus 
were excluded from outcome analysis.  As HbA1c was not checked it is not possible to be 
sure if any patients had previous dysglycaemia.  After adjusting for other variables 
hyperglycemia (defined as a random glucose on admission of >8mmol/L) was associated 
with a relative hazard ratio for death at 3 months of 1.87 (95% CI 1.43 to 2.45, p<0.0001). 
Another retrospective study was published by Williams and colleagues in 2002.169A cohort 
of 656 acute stroke patients was identified.  Post stoke hyperglycemia, defined as a serum 
blood glucose level above 130mg/dl, was present in 40% of patients.  The mean blood 
glucose level in the hyperglycemic group was significantly higher than the mean glucose 
level of the normoglycemic group (207mg/dl vs. 105mg/dl, p<0.0001).   Mortality was 
significantly higher in hyperglycemic patients both at 30 days and at 1 year.  The mean 
length of hospital admission was 7.2 days in the hyperglycemic group and 6 days in the 
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normoglycemic group (P=0.015).  There was also a significant difference in the cost of 
hospital admissions for the two groups, with the median cost of an admission for a 
normoglycemic patient being $5262 compared to a median cost of $6611 for 
hyperglycemic patients (p<0.001).  Hyperglycemia was significantly associated with 
mortality at 1 year with a hazard ratio of 1.75 (95% CI 1.14-2.67, p=0.01). 
A large Chinese prospective study published in 2009 by Wang and colleagues fits in with 
this general trend.170  In this study glucose data were collected on 2178 patients with 
ischaemic stroke and 1760 patients with haemorrhagic stroke.  The study outcomes were 
in-hospital death or dependency.  Dependency was defined as a modified Rankin score 
above 2.171, 172  Patients were categorised by glucose levels; <6.1mmol/L, 6.1-6.9mmol/L, 
7-7.7mmol/L, 7.8-11mmol/L and >11.1mmol/L.  Normoglycemia was defined as a glucose 
level below 6.1mmol/L and multivariate adjusted odds ratios for the risk of death or 
dependency were calculated for each glycaemic category.   
In the ischaemic stroke cohort a blood glucose of 6.1-6.9mmol/L was associated with an 
odds ratio of 0.53 (95% CI 0.23-1.27, p=0.154) for unfavourable outcomes.  However a 
blood glucose level of 7-7.7mmol/L was associated with a higher risk of mortality or 
morbidity (OR 2.22, 95% CI 1.21-4.11, p=0.010).170 
Ntaios and colleagues examined the relationship between blood glucose and clinical 
outcome in a cohort of 1446 patients enrolled in the Acute Stroke Registry and Analysis in 
Lausanne (ASTRAL).173 In this cohort some patients with a plasma glucose level of above 
10mmol/L were treated with insulin.  Glucose levels were correlated with Rankin score at 
12 months and NIHSS score at 24 hours.  For both endpoints glucose appeared to have a J-
shaped relationship.  The relationship between glucose and 12 month Rankin was J-shaped 
with best outcomes related to a glucose level of approximately 5mmol/L and poorer 
outcomes observed at higher and lower glucose levels.  A similar relationship existed for 
24 hour NIHSS and glucose.  This study does not contain precise data on which patients 
were treated with insulin and individual clinical outcomes so the possibility that insulin 
may have been related to poor outcomes in some patients cannot be discounted. 
Hyperglycemia may be particularly associated with a negative outcome in elderly stroke 
patients with an altered level of conciousness.174  In a retrospective study examining data 
from 469 patients with a median age of 80 were grouped according to admission blood 
glucose level.  Mortality was greatest in the highest tertile of blood glucose (levels above 
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7.2mmol/L) with the greatest odds ratio for mortality seen in patients with hyperglycemia 
and decreased consciousness (OR 9.6, 95% CI 1.65-52.5). 
This negative association appears to continue up to 5 years.175   A correlation has also been 
noted between acute hyperglycaemia and reduced survival of MRI perfusion-diffusion 
mismatch tissue (the ischaemic penumbra), greater final infarct size and poorer final 
outcome.176  
Hyperglycemia may be associated with a reduced risk of intra-cerebral haemorrhage in a 
stroke population that has not been treated with alteplase.177  In a combined analysis of 
data from 12648 patients originally enrolled in eight original studies blood glucose levels 
above 7mmol/L were associated with a reduced risk of subsequent ICH (HR 0.33, 95% CI 
0.14-0.74). 
In Table 1.1 there is a summary of studies that reported an odds ratio for increased 
mortality with PSH. 
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Table 1-1  Odds ratio for mortality with post stroke hyperglycaemia 
Study Number 
of patients 
Glucose level 
(mmol/L) 
Odds ratio  for 
increased mortality 
Confidence 
interval 
p-
value 
Zuliani174 469 7.2 9.6   1.65 to 52.5 n/a 
Wang170 2178 7 to 7.7 2.22  1.21 to 4.11 0.010 
Ahmed178 15336 6.66 1.24 1.07 to 1.44 0.004 
Williams169 656 7.2 1.75  1.14 to2.67 0.01 
Weir147 811 8 1.87 1.43 to 2.45 <0.001 
Wong167 185 7 5 2.3 to 10.7 <0.001 
Wang164 416 8 3 1.1 to 8.3 0.035 
Sacco157 323 6.66 1.7 1.4 to 2.8 n/a 
 
1.3.3 Post-Stroke Hyperglycemia as a risk factor for a bad outcome 
after thrombolytic treatment  
In stroke thrombolysis hyperglycaemia is a risk factor for a negative outcome.144, 179-185 
Diabetes was found to be a risk factor haemorrhagic transformation after thrombolysis in 
early trials with streptokinase.34   
This effect is not always clear-cut.  In one series of 268 consecutive acute stroke patients 
treated with alteplase elevated glucose levels on arrival at hospital were not significantly 
associated with adverse clinical outcomes.186  There was a trend towards increased 
mortality in hyperglycaemic patients but this was non-significant (OR 1.71 per 100mg/dl 
increase, 95% CI 0.92 to 3.13, P=0.06).  This trend did not correlate with intra-cerebral 
haemorrhage or disability at discharge.  The authors of this paper acknowledge that the 
sample size in this paper was relatively small and that more significant results may be seen 
in a larger population. 
In one prospective observational cohort study Saposnik and colleagues looked at 216 acute 
stroke patients treated with alteplase.181  They looked for factors related to a lack of clinical 
improvement at 24 hours.  Admission glucose levels, onset to treatment time and cortical 
involvement on imaging were associated with a poor outcome.  A blood glucose level of 
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8mmol/L or greater was associated with a increased odds ratio for a poor 24 hour outcome 
of 2.89 (95% CI 1.4-5.99) after adjusting for age, sex and stroke severity.  Lack of 
improvement at 24 hours predicted a poor 3 month outcome and death. 
In an analysis of 16049 patients treated with alteplase and entered into the SITS database 
admission glucose level was recorded in 15336 patients.178  In this prospectively recruited 
cohort hyperglycemia considered as a continuous variable was independently associated 
with higher mortality (p<0.001), worse functional outcome (p<0.001) and increased risk of 
symptomatic intracerebral haemorrhage (p=0.005).  When a threshold of 120mg/dl was 
applied to use glucose as a categorical variable hyperglycemia was associated with an 
increased odds ratio for mortality (OR 1.24, 95% CI 1.07-1.44, p=0.004) and a decreased 
odds ratio for good functional outcome (OR 0.58, 95% CI 0.48-0.70, p<0.001).  
Symptomatic intracerebral haemorrhage was more likely at glucose levels of above 
180mg/dl (OR 2.86, 95% CI 1.69-4.83, p<0.001).  
In a small Norwegian study involving 127 patients treated with alteplase hyperglycemia 
after treatment was associated with an increased risk of a poor outcome (OR 1.33, 95% CI 
1.02 – 1.74, p=0.03)compared to hyperglycemia before treatment (OR 1.04, 95% CI 0.75-
1.2, p=0.8).187 
In a Swiss cohort of 325 patients treated with alteplase, hyperglycemia was again found to 
be associated with an increased risk of a poor outcome at 3 months with an odds ratio of 
1.29 (95% CI 1.07-1.55, p=0.002).184 
Prior diabetes may not be a valid reason to withhold thrombolytic therapy in acute 
stroke.188  Mishra and colleagues combined data from the SITS database with data from the 
Virtual International Stroke Trials Archive (VISTA).  Diabetic patients treated with 
alteplase were more likely to have a favourable outcome than those not treated although 
this was not statistically significant (OR 1.3, 95% CI 1.05-1.6, p=0.1). 
In the Third International Stroke Trial (IST-3) there was no significant relationship 
between glucose levels and the chances of being alive and independent at follow-up.39 
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1.3.4 Post-Stroke Hyperglycemia causing increased rates of 
intracerebral hemorrhage after thrombolysis 
Jaillard and co-authors produced a post-hoc analysis on data from the MAST-E 
(Multicentre Acute Stroke Trial) streptokinase for stroke thrombolysis study in 1999.34  In 
this analysis diabetes was predictive of haemorrhagic transformation after streptokinase but 
they did not present data on hyperglycemia. 
Hyperglycaemia increases the risk of intracerebral haemorrhage after thrombolysis.182, 189  
Some of these studies are summarised in Table 1.2.  In an Italian prospective observational 
study 1125 ischemic stroke patients were admitted to a stroke unit and 67 of these patients 
were treated with rt-PA.189  Their admission blood glucose levels were divided into three 
groups.  Patients with the highest blood glucose levels (above 8.3mmol/l) had a 
parenchymal haemorrhage rate of 6.4% compared to a rate of 2.1% in patients with glucose 
levels below 6.1mmol/L (p<0.05).  In this group the relationship between blood glucose 
level and risk of haemorrhagic transformation appeared to be linear. 
In secondary analysis of data from 748 patients treated with alteplase in the second 
European Cooperative Acute Stroke Study (ECASS II) persistent hyperglycemia at 24 
hours was associated with poor neurological recovery, poor functional outcome, increased 
90 day mortality and parenchymal haemorrhage.144  The odds ratio for mortality at 90 days 
with persistent hyperglycemia was 7.61 (95% CI 3.23 – 17.9) while the odds ratio for 
parenchymal haemorrhage was 6.64 (95% CI 2.51 – 14.1). The authors concluded that in 
addition to isolated glucose level at time of hospital admission the pattern of glucose 
change should be considered when predicting stroke outcome.144  Persistent hyperglycemia 
was more deleterious in patients who were not known to be diabetic.   Another paper has 
suggested that fluctuations in blood glucose levels post stroke may be due to regression to 
the mean, a statistical artefact.190  
In a 2002 paper Tanne and colleagues looked at data from 1205 patients treated with rt-
PA.191  In this group 72 patients had symptomatic intracranial haemorrhage while a further 
86 had asymptomatic ICH.  Glucose was associated with an increased risk of any 
intracerebral haemorrhage with the risk increasing by an odds ratio of 1.36 (95%CI 1.11-
1.67) for every increase in plasma glucose level of 2.78mmol/L.  A pre-existing diagnosis 
of diabetes mellitus was also associated with symptomatic intracranial haemorrhage. 
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Table 1-2 Risk of ICH with increasing blood glucose levels 
Study Number of 
patients 
Odds ratio for ICH Confidence 
interval 
P value 
Tanne191 1205 1.36 1.11 to 1.67 0.005 
Poppe183 1098 1.69 0.95 to 3 0.003 
Ahmed178 15336 2.86 (with glucose above 
18mg/dl) 
1.69 to 4.83 <0.001 
Yong144 748 6.64 2.51 to 14.1 <0.0001 
MacDougall192 312 1.23 (per mmol/L) 1.03 to 1.48 0.024 
 
Similar results were seen in a Canadian paper published in 2009 by Poppe and 
colleagues.183  In a prospective, observational study data from 1098 patients were 
collected.  Hyperglycemia was defined as a blood glucose level above 8mmol/L.  After 
adjusted multivariate regression hyperglycemia was associated with an increased risk of 
symptomatic intra-cranial haemorrhage (OR 1.69, 95% CI 0.95-3, p=0.03), a reduced 
chance of a good outcome (OR 0.7, 95% CI 0.5-0.9, p<0.001) and an increased risk of 
death (OR 1.5, 95% CI 1.2-1.9, p<0.001).   This study also analysed the relationship 
between glucose as a continuous measurement and outcome finding that increasing plasma 
glucose levels inversely correlated with the likelihood of a favourable outcome. 
In an abstract presented at the European Stroke Conference in 2010 Jüttler and colleagues 
looked for glycaemic parameters that predict intra-cerebral haemorrhage after 
thrombolysis.138  In a series of 800 consecutive patients treated with alteplase predictors of 
haemorrhage were identified with multivariate regression.  HbA1c levels were most 
strongly predictive of subsequent haemorrhagic transformation and symptomatic 
intracerebral haemorrhage.  These findings may indicate that long term glycaemic status 
may be the greatest predictor of outcome. 
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1.3.5 Effect of post stroke hyperglycemia in intra-arterial treatment for 
acute stroke  
In the PROACT II (PROlyse for Acute Cerebral Thromboembolism) randomised control 
trial hyperglycemia was associated with an increased risk of symptomatic intracerebral 
haemorrhage (sICH).193   In this study 36% of patients with a baseline blood glucose of 
above 200mg/dl had sICH compared to only 9% of those with lower blood glucose levels.   
The relative risk of sICH with hyperglycemia was 4.2 (95% CI 1.04 - 11.7, p=0.022).  
Hyperglycemia is also associated with a poor outcome in patients treated with multimodal 
reperfusion therapy including endovascular recanalization of acute stroke.194  In a 
retrospective observational study published by Vora and colleagues in 2007 data from 185 
patients were collected.  A heterogeneous selection of interventions was used in this cohort 
including stenting devices, angioplasty devices, snaring devices and intra-arterial 
administration of both urokinase and alteplase.  Some patients were also pre-treated with 
intravenous alteplase.  The outcome measures in this study were haemorrhagic infarction 
and parenchymal haemorrhage as defined in another paper.195  In this cohort haemorrhagic 
infarction was associated with the extent of visible changes seen on the initial plain CT 
scan while parenchymal haemorrhage was associated with associated with alteplase or 
urokinase treatment and tandem occlusions as well as hyperglycemia.  Hyperglycemia 
conveyed an increased odd ratio of 2.8 for parenchymal haemorrhage (95% CI 1.1-7.7, 
p=0.043).    
Another retrospective observational study looking at risk factors for haemorrhagic 
transformation after intra-arterial thrombolysis was published by Kidwell et al in 2002.196  
In this study mean glucose levels were higher in patients who suffered from haemorrhagic 
transformation after treatment (p=0.04) and higher still in those with symptomatic 
intracerebral haemorrhage (p=0.02).  In a multivariate model there was no significant 
association between hyperglycemia and haemorrhagic transformation. 
1.3.6 Effect of post-stroke hyperglycemia on recanalization rates after 
treatment with alteplase 
Hyperglycaemia appears to be more harmful if present before blood vessel recanalization 
post-thrombolysis.180, 197-199 In a Spanish study recanalization rates after thrombolysis were 
evaluated in a prospectively recruited series of 139 acute stroke patients.200  Complete 
Recanalization was observed in 32% of patients.  Patients who recanalized had lower 
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admission glucose levels (127 vs146 mg/dl, p=0.039) although HbA1c levels were the 
same.  An admission glucose level of above 158 mg/dl (8.7mmol/L) was an independent 
predictor of no recanalization with an odds ratio of 7.3 (95% CI 1.3 to 42.3, p=0.027).  
Other less powerful independent predictors included platelet count above 219 000/ml and 
proximal MCA occlusion.  The authors suggest that acute hyperglycemia has more of an 
effect that chronic hyperglycemia on recanalization rates although causality cannot really 
be established in this study.   They also state that there was no apparent graded response to 
glucose level but an apparent threshold effect for reduced recanalization at levels of 
approximately 160mg/dl (8.9mmol/L).  Ribo and colleagues hypothesise that at this level 
an anti-fibrinolytic effect may be triggered by glycation of key proteins in the fibrinolysis 
chain.   
Similar findings were seen in another small prospective observational study that recruited 
27 patients.201  In this cohort of patients treated with alteplase trans-cranial Doppler 
ultrasound was used to assess recanalization at 2 hours and 24 hours.  The group of 
patients that did not recanalize had higher glucose levels (mean glucose 8.16mmol/L vs. 
6.25mmol/L, P=0.5). 
1.3.7 Relationship between post-stroke hyperglycemia and arterial 
patency 
In a later study the Barcelona group recruited 47 patients in an attempt to evaluate the 
effect of glucose burden on MRI DWI lesion growth in relation to the duration of ischemia. 
197
 All of the patients were treated with t-PA and had serial TCD recordings to monitor for 
recanalization and define total occlusion time.  They had continuous glucose monitoring 
via a subcutaneous probe which recorded a glucose level every 5 minutes.  It is important 
to note that these patients were subjected to a fast-acting insulin sliding scale which aimed 
to maintain blood glucose below 140mg/dl (7.7mmol/L).  Patients had MRI on admission 
(MR angiography, perfusion weighted imaging and diffusion weighted imaging) followed 
with a second MRI-DWI scan at between 24 and 36 hours.  Lesion growth was the 
difference in size between the first and second DWI lesions.   
In this study a poor clinical outcome was defined as an improvement of less than 50% in 
NIHSS.  Hyperglycemia during arterial occlusion was found to be the only independent 
predictor of a poor outcome with an odds ratio of 20.3 (95% CI 3.77 to 108.8, P < 0.001).   
DWI lesion growth correlated with total occlusion time (p=0.007) and hyperglycemia 
(p=0.01).   
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The discussion in this paper notes that: 
‘…after adjusting for total time of ischemia, those patients with suboptimal glucose control 
despite tight insulin treatment experienced a worse clinical outcome…’. 
It is impossible to firmly conclude that hyperglycemia and not insulin exposure is 
responsible for the poor clinical outcome in these patients.  Despite the clear problems with 
causality in this paper the authors then state;  
‘A tight subcutaneous insulin sliding scale showed to be insufficient to maintain 
normoglycemia in as high as 51% of all patients, therefore more intense glucose control 
measures, such as intravenous insulin, should be considered in future studies.’ 
This paper does suggest that hyperglycemia during arterial occlusion is associated with 
poor clinical outcomes and DWI lesion growth but the use of insulin reduces the validity of 
the authors’ conclusions. 
1.3.8 Hyperglycemia may attenuate the effects of alteplase on 
reducing infarct growth 
The EPITHET (Echoplanar Imaging Thrombolytic Evaluation Trial) authors suggest that 
diabetes and hyperglycemia may attenuate the effects of rt-PA on infarct evolution.202, 203 
EPITHET was a small randomised control trial which allocated patients to alteplase or 
placebo between 3-6 hours after stroke onset.  A total of 101 patients were enrolled in the 
trial, 22 of whom were known to be diabetic.  There were no significant differences in 
baseline DWI and PWI lesion size between diabetic and non-diabetic patients. 
Fifty-two patients were randomised to alteplase treatment while 48 received placebo.  
Eleven diabetics were allocated to each group.  In the active treatment group there was 
evidence of infarct attenuation in the non-diabetics who had a median relative infarct 
growth of 0.96 (IQR 0.58-1.74) compared to diabetics who exhibited greater median 
infarct growth (1.27, IQR 0.51-6.78).  The difference in infarct growth between these 
groups was significant (p=0.007).  In the placebo group there was no significant difference 
in infarct growth between diabetics and non-diabetics.  Alteplase significantly attenuated 
infarct growth in non-diabetics (p=0.012) but had no significant effect in diabetics (p=1). 
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EPITHET was a small study and is only powered to produce statistically significant results 
when large differences between groups exist.  No differences in reperfusion or 
recanalization rates were apparent between diabetics and non-diabetics.  The authors 
hypothesise that recanalization and reperfusion may occur at a slower rate in diabetics 
explaining the greater relative mean infarct growth.    
The interaction between hyperglycemia and poor outcomes from thrombolysis may be 
mediated by impaired collateral circulation in diabetics. 
The EPITHET authors hypothesise that alteplase failed to attenuate infarct growth due to a 
lack of collateral circulation in diabetic patients.203 They suggest that diabetes may impair 
the development of collateral circulation.  These ideas echo the earlier work of Toni et al 
that I will discuss in a later section.204 
1.3.9 Could blood glucose be controlled before administering 
thrombolytic therapy? 
In one prospective observational study two hyperglycaemic patients were treated with 
insulin by their family doctor before being given t-PA.  These patients had better clinical 
and radiological outcomes than similar hyperglycaemic patients.205 While these 
observational data are interesting we do not know enough about the underlying 
pathophysiological reasons for the poor alteplase response seen in diabetic and 
hyperglycemic patients.  There is currently no clinical evidence to support the routine use 
of insulin in acute ischaemic stroke as I discuss in my systematic review of the evidence in 
Chapter 4.  The animal evidence for the use of insulin is also of limited value and cannot 
justify clinical trials at present (see Chapter 3).206   
1.3.10 Different effects of hyperglycemia in stroke and TIA 
Two papers have suggested that hyperglycemia may have less of a deleterious effect on 
patients who suffer a transient ischaemic attack.175, 207  
Both studies were fairly small and may not have enough statistical power to conclusively 
state that hyperglycemia has no effect on mortality after TIA.  Previous studies have 
suggested that patients with known diabetes who present to an emergency department with 
symptoms of TIA are at an increased risk of subsequent stroke within 90 days (OR 2, 95% 
CI 1.4-2.9, p<0.001).208 
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In a 2010 paper Thuy and colleagues retrospectively looked at 194 patients who had 
presented with TIA.207  In this cohort 27.8% of patients were hyperglycemic (defined as 
blood glucose levels above 7mmol/L) and 22% were diabetic.  In this cohort acute 
hyperglycemia was not associated with mortality after TIA.  Thuy and colleagues 
acknowledge that there was a low death rate in this group which may make the result less 
statistically valid. 
In another retrospective cohort study Kostulas and colleagues examined data from 509 
patients presenting to Karolinska University Hospital in Sweden.175  This cohort included 
114 (22%) patients with TIA.  Hyperglycemia was observed in 28% of patients with 
ischaemic stroke and 18% of patients with TIA.  Mean admission blood glucose level was 
lower in patients with TIA (P=0.0002).  Admission hyperglycemia did not appear to have 
any effect on mortality rates in TIA patients. 
It has also been suggested that stroke may be more common than TIA in diabetic 
patients.209, 210 This observation was reported by Weinberger and colleagues in 1983 when 
they studied factors contributing to stroke in patients with carotid atherosclerosis.209  In a 
cohort of patients attending a vascular laboratory for arterial assessment they noted that the 
incidence of stroke as opposed to TIA was twice as high in patients with diabetes.  
In a secondary analysis of data from the Dutch TIA study diabetes was found to be an 
independent predictor of major stroke after TIA or minor stroke.211 In these data 
hyperglycemia did not predict stroke in multivariate analysis although diabetes continued 
to be predictive even after CT and ECG findings were taken into account.  After an initial 
TIA diabetes is associated with a hazard ratio of 2.1 for subsequent stroke (95% CI 1.5-
2.9). 
In a 1988 paper published by Lithner and colleagues 428 consecutive unselected patients 
presenting to a stroke unit were prospectively studied.210  These patients were divided into 
a diabetic group of 75 and a non-diabetic group of 353.  Transient cerebral ischemia was 
observed in 4% of the diabetics compared to 14% of the non-diabetics (p<0.01).  Cerebral 
embolism was observed in 32% of the diabetics compared to 22% of non-diabetics 
(p<0.05).  Stroke was more common in diabetic patients than non-diabetic patients while 
TIA was more common in non-diabetic patients than in diabetic patients.  Several 
possibilities could explain this difference.  Patients with diabetes may be more susceptible 
to cerebral ischaemia and may therefore be more likely to develop a stroke when cerebral 
  57 
 
blood flow is compromised.  It is also possible that TIA symptoms are misdiagnosed in 
diabetic patients (for example as the effects of transient hypoglycaemia). 
This issue was also considered by Fritz and colleagues in a 1987 paper.212  This paper 
examined the hypothesis that diabetes mellitus predisposes the brain to irreversible 
ischaemic damage as opposed to reversible transient ischaemic symptoms.  In a 
prospectively collected observational series of 525 patients presenting with TIA or minor 
stroke, 54 had diabetes.  In this group 388 patients had a TIA but only 6.7% of TIA 
patients had diabetes.  However 28/54 patients with diabetes had strokes compared to only 
109/471 patients without diabetes.  Patients with diabetes were more likely to present with 
a stroke (p<0.0001) 
Interestingly in a prospective observational study published by Matz and colleagues in 
2006 it appears that diabetic patients have more severe NIHSS scores than non-diabetic 
patients.158  The Matz study was a prospective observational study that carefully defined 
the dysglycaemia of stroke patients.  Patients were classified as having diabetes, impaired 
glucose tolerance, transient hyperglycemia and normoglycemia.  The median NIHSS on 
admission in the diabetic group was 7.2+/-6.6 compared to 4.6 +/- 3.1 for patients with 
impaired glucose tolerance, 4.2 +/- 4.4 for patients with transient hyperglycemia and 3.7 
+/- 3.6 for patients who were always normoglycemic (p<0.001).   
1.3.11 Measuring blood glucose after stroke 
The accurate assessment of glucose levels and glycaemic status after a stroke can be 
difficult.  Plasma glucose is a constantly changing physiological variable that will alter 
with many internal and external factors.  The majority of papers that discuss post-stroke 
hyperglycemia deal with admission blood glucose level and can only provide a point 
estimate of glucose exposure. 
Several studies use repeated capillary blood glucose measurements and this may give a 
better estimate of average glucose exposure.161, 213  Other studies have used constant 
glucose monitoring which gives an accurate glucose profile but is invasive and costly.214, 
215
  Glycosylated haemoglobin levels can give a historical picture of glycaemic status but 
they are insensitive to acute changes. 
One paper, published in 2002 by Bhalla and colleagues evaluated Glycated Serum Proteins 
for predicting outcome after acute stroke.216 Glycated Serum Proteins (GSP) reflect plasma 
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glucose levels over the preceding two weeks.  Albumin is one protein that may be used as a 
GSP.  In a prospective study 167 patients had their GSP levels checked within 24 hours of 
admission.  GSP levels were subsequently rechecked 14 days later.  For patients whose 
GSP levels increased, every 1% increase in GSP levels increased the odds ratio of death by 
3 months by 1.28 (95% CI 1.1 to 1.62, p=0.04).  This ratio was obtained after multiple 
logistic regression analysis and was independent of admission plasma glucose, age, stroke 
severity, stroke subtype and serum albumin change 
1.4  Hypotheses on the pathophysiology of post-stroke 
hyperglycaemia 
While post-stroke hyperglycaemia has been recognised for some time its pathological basis 
has been unclear.148 It is also possible that an individual patients’ glucose metabolism may 
alter over time after a stroke.217 
1.4.1 Post-Stroke Hyperglycemia as a stress response 
Several hypotheses on the origin of PSH have been advanced.  PSH may be a stress 
response which reflects a severe stroke.218, 219 This idea was put forward by Woo and 
colleagues in a 1988 paper that noted a lack of correlation between HbA1c levels and 
plasma glucose levels after an acute stroke.153 This disparity was also observed by Gray 
and colleagues in their 1987 paper.133 
In a small 1991 study of 23 patients, only 15 of whom had complete data, O’Neill and 
colleagues prospectively collected a series of blood samples for glucose, insulin, c-peptide, 
catecholamine, cortisol, glucagons and lactate levels.218 In this small sample of 15 patients 
glucose levels varied with insulin, cortisol and glucagon levels leading the authors to 
conclude that post stroke hyperglycemia probably reflects the intensity of a stress hormone 
response.  The authors admit that their population is too small to establish any significant 
statistical associations between hormonal levels, glucose and stroke outcomes.  The 
conclusions of the O’Neill paper on a link between stress and glucose levels are probably 
premature as PSH is seen in all types of stroke and does not appear to correlate with stroke 
severity.147   
Tracey and colleagues carried out a similar study in 1993.220  They analysed data on blood 
glucose, HbA1c and cortisol levels from 66 prospectively recruited acute stroke patients.  
Patients were followed up at 3 months with a plain CT scan.  Plasma glucose levels were 
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higher in patients who died during the study (p=0.025).  Mean cortisol levels were also 
higher in patients who died.  After multivariate analysis only age and cortisol levels were 
significantly associated with mortality.  Infarct size correlated more strongly with cortisol 
levels than with glucose levels or insulin levels although all of these relationships were 
significant. 
Another study published by van Kooten and colleagues in 1993 found that catecholamine 
levels were not associated with hyperglycaemia.   This study prospectively recruited 91 
stroke patients presenting within 24 hours of stroke onset.  All patients had catecholamine 
levels checked.  Norepinephrine levels were associated with severity of stroke and 
hypertension.221   No significant association was found between catecholamine levels and 
blood glucose levels or glycosylated haemoglobin levels.  In a 2001 study by Sander and 
colleagues that included 112 acute stroke patients there was no significant difference in 
average plasma glucose levels of patients who had Norepinephrine levels below 300pg/mL 
compared with those who had levels above 300pg/mL.222  In their 1997 paper Weir and 
colleagues argue that post-stroke hyperglycemia cannot be a pure stress response as it still 
predicts final outcome in a statistical model that takes other prognostic factors into 
account.147 
More recently copeptin has been proposed as a prognostic biomarker in acute illness.223  
Copeptin has recently been shown to predict recurrent ischaemic events after TIA while 
cortisol does not.224  It may be interesting to look for a relationship between copeptin and 
post stroke hyperglycemia in the future.  
It has also been noted that pre-operative hyperglycemia is associated with an elevated risk 
of stroke in patients undergoing carotid endartectomy as described in a paper by McGirt 
and colleagues that I have already discussed.46 As this group of patients had pre-existent 
hyperglycemia it suggests that in at least some cases post-stroke hyperglycemia is not 
related to a stress response.  This relationship between pre-operative hyperglycemia and 
stroke was also independent of the presence of diabetes. 
1.4.2 Post-stroke hyperglycemia due to a specific neuroanatomical 
lesion 
Another possibility is that specific neuroanatomical lesions cause acute stress 
hyperglycaemia although this has not been confirmed by later studies.225, 226  This concept 
was partly based on earlier observations on the effects of specific neuroanatomical lesions 
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on the glucose metabolism of animals.227, 228  In a classical experiment in 1854 Claude 
Bernard noticed that damage to the floor of the fourth ventricle would produce 
glycosuria.227 In a study including 31 patients who had acute MRI diffusion weighted 
imaging within 24 hours of stroke onset Allport and colleagues found that patients with 
insular cortex ischemia had a higher mean glucose that patients who had no insular cortex 
damage.225  Moreton and colleagues tried to correlate insular cortex hypoperfusion on CT 
perfusion imaging in a retrospective study looking at 35 patients.226  They found no 
relationship between hyperglycemia and insular cortex hypoperfusion.   
A retrospective analysis of data from 966 patients in the Canadian Activase for Stroke 
Effectiveness Study (CASES) found that insular cortex damage was not an independent 
predictor of hyperglycemia or hypertension.229  
Post-stroke hyperglycemia may reflect a hyperglycaemic state immediately before stroke 
1.4.3 Post-Stroke Hyperglycemia as undiagnosed Type 2 Diabetes 
Mellitus 
Post-stroke hyperglycaemia may represent undiagnosed type 2 diabetes mellitus.230  In 
1985 Oppenheimer and colleagues carried out a prospective observational study comparing 
glycosylated haemoglobin levels with outcome and plasma glucose.130  They found that a 
highly significant correlation existed between plasma glucose levels and HbA1c levels.  
They also observed a significant relationship between diabetes mellitus and early death 
after stroke.  They concluded that pre-stroke abnormal glucose metabolism may be a major 
determinant of post-stroke hyperglycemia.  They hypothesised that the poor outcomes for 
hyperglycemic stroke patients may reflect the clinical course of stroke in diabetes mellitus. 
Studies suggest that up to one third of acute stroke patients have diabetes mellitus but that 
in patients with post stroke hyperglycaemia only two-thirds of survivors have impaired 
glucose tolerance or diabetes mellitus diagnosed at 12 weeks.231  Certainly in non-stroke 
populations the prevalence of undetected type 2 diabetes mellitus is significant.232 
Retrospective studies have suggested that many clinicians do not screen acute stroke 
patients for unrecognised Type II DM.233 
A 1989 study by Topic and colleagues which prospectively observed glucose metabolism 
in acute stroke patients found that while 41% of patients were hyperglycemic after an acute 
stroke only 29% had diabetes as defined by an elevated glycosylated haemoglobin level.132  
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Insulin resistance may be a mechanism for post-stroke hyperglycemia in cases where 
patients do not have clinically overt diabetes mellitus.  A 2002 review paper found six 
methodologically sound papers that supported the hypothesis that insulin resistance may be 
a prevalent risk factor for stroke.234  This review was followed by a prospective 
observational study aiming to establish the prevalence of insulin resistance in a cohort of 
non-diabetic patients presenting with TIA or non-disabling stroke.48  Of the 72 participants 
in this study 36 (50%, 95% C.I 38% to 62%) had evidence of insulin resistance.  However 
subgroup analysis of an 18 year follow up study in Japan suggests that diabetes is a risk 
factor for stroke while insulin resistance is not.235 
In a prospective observational study published in 2005 Vancheri and colleagues formally 
assessed glucose metabolism in a cohort of 106 acute stroke patients.236  Patients with 
known diabetes were excluded as were patients on medications such as beta-blockers or 
diuretics which may interfere with glucose metabolism.  Patients had a glucose tolerance 
test at discharge from their acute admission.  Insulin and HbA1c levels were also measured 
and insulin resistance was assessed using HOMA.  These tests were repeated at 3 months 
after discharge. 
At discharge based upon the results of the oral glucose tolerance test 45.8% of patients had 
diabetes mellitus, 38.5% had impaired glucose tolerance and 15.6% had normal 
metabolism.  In the same group of patients at 3 months 36% had diabetes mellitus, 26% 
had impaired glucose tolerance and 35% had normal metabolism.  Among the patients with 
abnormal glucose metabolism at 3 month follow up 43.5% had a normal HbA1c (below 
5.7%) at baseline.  These results suggest that there is a high prevalence of unrecognised 
diabetes mellitus in acute stroke populations and that the glycaemic status of patients may 
change over time. 
A Japanese study assessed glucose metabolism in 427 ischaemic stroke patients.  An 
existing diagnosis of diabetes mellitus was present in 155 patients (36%).  Oral glucose 
tolerance testing was performed in 113 patients.  The remaining patients were unable to 
undertake a glucose tolerance test.  Previously undiagnosed diabetes was discovered in 
28% of patients suggesting that the overall prevalence of diabetes mellitus in this cohort is 
at least 42%.  A further 39 patients had impaired glucose tolerance.  The prevalence of 
both diabetes and impaired glucose tolerance are likely to be higher in this cohort if 
patients who were unable to be tested were included.  Patients with previously undiagnosed 
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diabetes were more likely to have had an atherothrombotic stroke (64.3%) than a lacunar 
stroke (32.1%) or a cardioembolic stroke (3.6%). 
In a similar study published by Dave and colleagues in 2010 a prospective observational 
study attempted to evaluate the prevalence and predictors of persistent hyperglycemia in 
non-diabetic patients with stroke.237  Patients were prospectively assessed with an oral 
glucose tolerance test within 5 days of admission.  In this study 107 patients were initially 
recruited.  Abnormal glucose function was apparent in 65 patients (61%), 24% of whom 
had diabetes mellitus while 37% had impaired glucose tolerance.  After 3 months 44 of the 
dysglycaemic patients were re-investigated with either an OGTT or with HbA1c if on 
hypoglycaemic treatment.  At this point 26 patients (59%) had normal glucose tolerance, 6 
(14%) had diabetes and 12 (27%) had impaired glucose tolerance. 
Interestingly 23% of the patients who had diabetes based on the acute OGTT had normal 
glucose tolerance at follow-up.  One patient who had impaired glucose tolerance acutely 
developed clinical diabetes.  These results reflect the possibility that the glycaemic status 
of a stroke patient may change between the acute period and convalescence. 
A causal relationship between glycaemic status and stroke outcome has been considered.   
It has been observed that hyperglycaemic patients without a history of diabetes mellitus 
appear to have larger infarcts on CT imaging and that there is a correlation between 
admission glucose concentration and poor stroke outcome.238   MRI studies support this 
observation.176 
1.5 The definition of post-stroke hyperglycaemia 
It is not known if there is a clear cut-off level at which blood glucose becomes pathogenic 
and we do not know the best way to measure blood glucose level to accurately predict 
prognosis.  Many different levels of blood glucose have been suggested for 
hyperglycaemia as can be seen in Table 1.3. 
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Table 1-3 Blood Glucose levels used to Define Post-Stroke Hyperglycaemia 
Author Year PSH level 
mmol/L 
PSH level 
mg/dl 
Number of 
patients 
Percentage 
with PSH 
Percentage 
with DM 
Abu-Zeid151 1978 5.55 100 1484 51 n/a 
Scott239 1999 6 108 303 50 n/a 
Gray240 2004 6 108 452 n/a 15.3 
Gray231 2004 6 108 582 n/a 14 
Lindsberg241 2004 6 108 n/a n/a n/a 
Gray242 2007 6 108 933  16.5 
Wong190 2008 6 108 124 n/a 0 
Mazighi243 2009 6 108 477 n/a 88 
Cazzato244 1991 6.1 110 76 71 22.4 
Capes 146 2001 6.1 110 n/a n/a n/a 
Bang245 2005 6.1 110 512 40 n/a 
Johnston 246 2009 6.1 110 74 n/a 59 
Paciaron189 2009 6.1 110 1125 42.4 20.7 
Wang170 2009 6.1 110 2178 40.1 11.3 
Dziedzic247 2010 6.1 110 302 36.4 0 
Benedetti248 1993 6.4 115 94 50.5 17.2 
Jorgensen249 2001 6.5 117 396 n/a n/a 
Pulsinelli92 1983 6.6 120 107 + 31 n/a n/a 
Levy250 1985 6.6 120 214 56 n/a 
Toni155 1992 6.6 120 327 28.5 21.5 
Toni204 1994 6.6 120 82 n/a n/a 
Lavy251 1973 6.66 120 1522 n/a 20 
Chalela252 2004 6.66 120 27 66.6 n/a 
Melamed148 1976 6.7 120 392 48% 20 
Matcher253 1992 6.7 120 146 n/a 23 
de Falco156, 254 1993 6.7 120 104 51.9 33.6 
Bell255 1994 6.7 120 n/a n/a n/a 
Ahmed178 2010 6.7 120 16049 44 17.3 
Topic132 1989 7 126 148 59 29 
Dutch TIA trial 
study group211 
1993 7 126 302 n/a n/a 
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Sulter256 1998 7 126 41 36.5 n/a 
Scott143 1999 7 126 53 100 15.1 
Milionis257 2005 7 126 163 7 28 
Stollberger258 2005 7 126 992 n/a 30 
Wong167 2005 7 126 186 37.8 19 
Allport214 2006 7 126 59 81 36 
Walters259 2006 7 126 25 100 n/a 
Moreton226  2007 7 126 35 51.4 11.4 
Ortega-
Casarrubios96 
2007 7 126 2213 n/a 29.9 
Uyttenboogaart260 2007 7 126 1375 51.1 20.9 
Kruyt261 2008 7 126 113 38 30 
Dziedzic262 2009 7 126 689 13.6 22.2 
Gunarathne263 2009 7 126 60 n/a 46.5 
Kruyt264 2009 7 126 10 100 20 
Scott265 2010 7 126 224 45 25 
Staszewski266 2010 7 126 50 100 0 
Thuy207 2010 7 126 194 27.8 22 
Muir267 2011 7 126 2649 53.7 14 
Lindegard268 1987 7.2 130 1379 78.5 32 
Williams169 2002 7.2 130 656 40 52 
Gentile269  2006 7.2 130 960 38.9 36.4 
Zuliani174 2006 7.2 130 469 n/a 25.8 
Stead174 2009 7.2 130 447 34.2 25.7 
Folsom58 1999 6.655  191   
Sacco168 1989 7.7 140 1273 36 26 
Hier270 1991 7.7 140 1273 27.9 26.1 
Sacco157  1994 7.7 140 323 38.1 28.5 
Alvarez-Sabín180  2003 7.7 140 73 42.5 23 
Bravata233 2003 7.7 140 90 33  
Alvarez-Sabin271 2004 7.7 140 138 37.3 20.3 
Dora272 2004 7.7 140 46 43.4 15.2 
Yong144 2008 7.7 140 748 32.8 21.5 
Kim273 2009 7.7 139 115 50 40.9 
Mankovsky274 1996 7.77 140 41 0 53.7 
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Martini 275 2006 7.77 140 117 27.7 22.2 
Ribo197 2007 7.77 140 47 51 19 
Woo154 1990 7.8 140 174 31.6 27 
Kiers 238 1992 7.8 140 176 34 28.4 
Milia276 2010 7.9 143  n/a n/a 
Cox131 1986 8 144 81 16  
Gray133 1987 8 144 86 22 8 
Gray277 1989 8 144 200 22.8 8.5 
Van Kooten221 1993 8 144 91 43 24.2 
Counsell278 1997 8 144  n/a 0 
Weir147 1997 8 144 645 25.1 8.8 
Wang164 2001 8 144 416 26 20 
Wang279 2001 8 144 440 n/a n/a 
Parsons176 2002 8 144 63 34.9 28.6 
Spratt166 2003 8 144 257 43 27 
Saposnik181 2004 8 144 216 n/a 23.1 
Diener280 2008 8 144 4946 23.6 22.1 
Kostulas175 2009 8 144 509 26 18 
Poppe183 2009 8 144 1098 27 15.1 
Putaala281 2010 8 144 851 43.6 13.3 
Berger 282 1986 8.3 150 39 30.7 35.9 
Leigh198 2004 8.3 150 201 n/a 23 
Bruno283 2008 8.3 150 46 100 91 
Fuentes161 2009 8.6 155 476 37.2 25 
Fuentes213 2010 8.6 155 476 n/a n/a 
Ribo200 2005 8.7 158 139 n/a 38 
Bruno284 2004 9.4 170 24 n/a 100 
Els205 2002 9.9 178.2 31 45.2 0 
Woo152 1988 11 198 252 7.9 12.3 
Di Bontio285 2003 11 198 286 n/a 49.6 
Kase193 2001 11.1 200 110 10 14.5 
Mcgirt46 2006 11.1 200 1201 10.7 27 
Al-Himyar286 2007 11.1 200 50 12 n/a 
Vora194 2007 11.1 200 185 23.2 22.7 
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As the table demonstrates, plasma glucose values ranging from 5.55 to 11.1mmol/L have 
been used to define post stroke hyperglycaemia.  This variation in definition leads to the 
differing incidences that are proposed for PSH. 
More methodical attempts have been made to define PSH.  Fuentes and colleagues took an 
alternative approach in another prospective observational study involving 476 patients.161  
In an attempt to establish the capillary glucose level that best predicts poor outcome 
capillary blood glucose was measured 3 times daily for 48 hours.  They calculated that a 
glucose value of 155 mg/dl (8.6mmol/l) or above at any time during the first 48 hours was 
associated with a 2.7 times increase in the risk of a poor outcome (95% CI 1.79 – 8.1). 
In a similar study presented as an abstract at the European Stroke Conference Milia and 
colleagues attempted to establish a threshold value that best predicts short term mortality 
after stroke.276 Data from 851 patients were included and an admission blood glucose level 
of 143mg/dl was found to be most predictive with a sensitivity and specificity of 72%. 
A consensus statement on the definition of post stroke hyperglycaemia may be valuable.  
Future research would be more cohesive if researchers were using the same definition. 
1.6 Uncertainties regarding post stroke hyperglycaemia 
There are several interesting issues around post stroke hyperglycaemia that may merit 
further investigation in the future.   
1.6.1 Could the effects of post-stroke hyperglycemia be mediated by 
collateral blood supply? 
Toni and colleagues attempted to look for a relationship between glycaemic status,  
collateral cerebral blood flow and clinical outcome.204  They prospectively recruited 82 
patients all of whom underwent cerebral angiography within 4 hours of stroke onset.  The 
patients were divided into 3 groups by glycaemic status; diabetics, patients with transient 
hyperglycemia and patients who were normoglycemic at all times.  The ‘diabetic’ group 
had slightly ambiguous inclusion criteria as previously seen in the 1992 paper by this 
group.155  
Using the cerebral angiogram the site of the arterial occlusion was defined and collateral 
blood flow was assessed.  Patients with no arterial occlusion, carotid disease only or 
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complete carotid occlusion were excluded from the study.  Patients were followed up with 
a repeat CT scan and clinical assessment at day 30. 
Nine patients were classified as diabetic, 40 were classified as hyperglycemic and 33 were 
classified as normoglycemic.  In the diabetic group the main serum blood glucose was 
15mmol/L, in the hyperglycemic group the mean glucose was 7.84 and in the 
normoglycemic group the mean was 5.5.  At day 30 89% of the diabetic patients were 
dead, 72% of the hyperglycemic patients were dead and 54% of the normoglycemic 
patients had died (P<0.05).  Collateral blood supply was present in 33% of diabetic 
patients, 55% of hyperglycemic patients and 66% of normoglycemic patients.  Patients 
with good collateral blood supply had smaller than expected infarcts at 30 day follow-up.  
However smaller infarcts were more likely to be seen in normoglycemic patients (82%) 
than hyperglycemic patients (64%).  No diabetic patients had smaller than expected 
infarcts.  In patients without a collateral blood supply infarcts were usually of the expected 
size and no significant differences were observed between glycaemic groups. 
The authors hypothesise that diabetes may reduce the effectiveness of the collateral blood 
supply.  This could be due to a functional problem, with reduced autonomic recruitment of 
collateral blood vessels, or due to an anatomical shortage of blood vessels due to diabetic 
arteriopathy.   This hypothesis is similar to the stated hypothesis of De Silva and the 
EPITHET investigators that I have discussed in an earlier section.203 
1.6.2  Gender Differences in relation to Post-Stroke Hyperglycemia 
One study suggested that admission hyperglycemia may only be associated with brain 
infarction and higher 5 year mortality in females.243 This study is part of a larger French 
stroke genetics study which excluded anyone with non-Caucasian parents.  Patients could 
be enrolled in the study within one week of stroke.  The quantification of hyperglycemia 
was based on one fasting blood glucose sample.  Glycosylated haemoglobin values were 
not checked in this study.    
1.6.3  Post-Stroke Hyperglycemia as a protective mechanism 
It has also been suggested that post-stroke hyperglycaemia may be a protective mechanism 
although the current weight of evidence does not support this idea.287  In a 2007 letter to 
Brain Metso and Murros highlighted the argument that the association between 
hyperglycemia and poor outcome does prove causality.  They highlight that our knowledge 
  68 
 
of the pre-stroke glycaemic status of a patient is often incomplete and that it may be 
dangerous to assume that hyperglycemia in itself is detrimental.  They cite the results of 
the GIST-UK study, where patients with the greatest reduction in serum glucose levels 
during the acute phase of stroke died, as evidence for this hypothesis.  They also express 
concern at contemporary guidelines that advocated treatment of hyperglycemia and 
espouse the principle of primum non nocere.  First do no harm. 
1.6.4 Post-Stroke hyperglycemia may have different effects on 
different stroke sub-types 
In a secondary analysis of data collected prospectively for two clinical trials of luceluzole 
in acute stroke Uyttenboogaart and colleagues found a dichotomous relationship between 
hyperglycemia and clinical outcome when lacunar strokes were compared to non-lacunar 
strokes.260  Data from 168 lacunar stroke patients and 1207 non-lacunar patients were 
available.  Hyperglycemia defined as a blood glucose above 8mmol/L was associated with 
a lower chance of a good outcome (mRs<2) at 3 months in non-lacunar stroke (OR for 
good outcome 0.60; 95% CI 0.41–0.88, P=0.009).  However in lacunar patients 
hyperglycemia was associated with a good outcome (OR 2.70, 95% CI 1.01- 7.13, 
P=0.048). 
1.6.5  Associations between post-stroke hyperglycemia and cerebral 
oedema 
In a 1986 paper Berger and Hakim retrospectively reviewed the cases of 39 patients to 
study the effect of serum glucose levels on clinical and radiological progression after 
stroke.282 All patients had at least two CT scans during their admission and an average 
glucose level over the first 30 days of the admission was calculated.    Patients were 
divided into tertiles of mean glucose level.  In this cohort there was a significant trend in 
the association between rising mean glucose levels and the proportion of scans showing 
midline shift or ventricular compression.  When the diabetic and non-diabetic patients were 
separated the trend for worse clinical outcome and death was not significant in the diabetic 
patients but continued to be significant in the non-diabetic patients (p<0.005).  Younger 
patients were also more likely to have bad outcomes with higher average glucose levels 
(p<0.001). 
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1.6.6 Markers of neuronal damage and PSH 
Neuron specific enolase (NSE) is a marker of brain injury that is released into the 
peripheral blood and the cerebro-spinal fluid.  It has been suggested that elevated NSE 
levels may be a biomarker for on-going neuronal damage in stroke patients.  One small 
prospective observational study recruited 41 patients who had their NSE levels checked 
within 24 hours of stroke onset.256  There appeared to be a correlation between higher NSE 
levels and higher blood glucose levels.  The authors suggest that this correlation lends 
further weight to the hypothesis that hyperglycemia promotes neuronal necrosis during the 
acute stage of ischemic stroke. 
1.6.7 Could post-stroke hyperglycaemia be a hypercatabolic state 
associated with acute starvation? 
Acute stroke can be associated with acute starvation if swallowing is impaired.  When food 
or other exogenous energy sources are not available the body has to mobilise endogenous 
stores via gluconeogenesis and glucose sparing to maintain blood glucose at an adequate 
level to nourish the brain.  Synthesis of protein and fat is curtailed during fasting. 
In a 1985 paper Bjorkman and Eriksson demonstrated that insulin resistance had increased 
after 60 hours of fasting in normal subjects.288  Euglycemic 1-mU insulin and 
hyperglycemic glucose clamp studies were undertaken on subjects after overnight fasting 
and prolonged (60 hour) fasting.  A greater degree of insulin resistance was apparent after 
a longer period of fasting.  
A study similar to this would be difficult to perform in unstable acute stroke patients.  The 
subjects enrolled in the Bjorkman and Eriksson study were healthy and non-obese making 
them not directly comparable to the average stroke patient.  However it is possible that 
acute insulin resistance will develop in some stroke patients if they are undernourished for 
the first few days of their hospital admission. 
Acute stroke is a hypercatabolic state.  In a 2004 paper Chalela and colleagues reported a 
prospective observational study that aimed to assess nitrogen balance in acute stroke 
patients.252 In patients with an acute illness who require tube feeding the Harris-Benedict 
Equation is used to measure Resting Energy Expenditure.  Adjustments for clinical 
conditions that elevate energy expenditure are made with ‘stress factors’.  There is no 
‘stress factor’ available for acute stroke.  Chalela and colleagues wanted to validate the 
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Harris-Benedict Equation in stroke patients who required enteral nutrition by analysing 
their nitrogen balance.  Twenty seven patients were prospectively recruited.  Post stroke 
hyperglycemia was seen in 66% of these patients.  A negative nitrogen balance was seen in 
44% of patients suggesting that they were catabolic.  No evidence of catabolism or 
anabolism was seen in 16% of patients while the remaining 40% showed evidence of 
anabolism. 
Enteral feeding determined by the Harris-Benedict Equation underestimates the 
requirements of acute stroke patients in a significant proportion of patients as anabolism 
was only achieved in 40% of patients.  Stroke patients requiring enteral support were being 
underfed.  This was a small group and there was no significant correlation between 
glycaemic status and catabolism.   
Johanssen and colleagues attempted to assess the relationships between circulating levels 
of pro-inflammatory cytokines, adrenocortical hormones and leptin in the acute stroke 
period.289 Multiple blood samples collected over the first 7 days post-stroke were collected 
in 12 patients and compared with 10 healthy controls.  A significant correlation was 
observed between IL-6 and cortisol in the first two days after stroke (P<0.05).  The diurnal 
rhythm of leptin levels was abnormal in half of the patients by the end of the week.  Leptin 
is thought to be a key factor in neuroendocrine balance with reciprocal connections to 
several hormone systems.  Leptin is also thought to be involved in the neuroendocrine 
response to fasting.290 
Catabolism is associated with loss of lean body mass.  Carlotti and colleagues have 
suggested that an increase in the rate of creatinine excretion may be a marker of the onset 
of catabolism.291   
1.6.8  ‘Glucose Kinetics’ - which pattern of post-stroke hyperglycemia 
is most harmful? 
As the majority of patients are hyperglycemic at some point after a stroke it may be 
important to consider ‘glucose kinetics’ or the pattern of blood glucose levels that is most 
harmful. 
In a prospective observational study Dziedzic and colleagues looked at the pattern of blood 
glucose levels in a cohort of non-diabetic patients who had experienced their first ever 
stroke.247 A total of 302 patients had fasting blood glucose levels checked on days 1, 2, 3, 5 
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and 7 after admission.  The patients were then divided into 4 groups – patients that were 
normoglycaemic at all times, patients who were initially normoglycaemic and then became 
hyperglycemic, patients who were initially hyperglycemic before becoming 
normoglycemic and patients who were hyperglycemic at all times.  After multivariable 
adjustment post-admission hyperglycemia was associated with a higher risk of death 
regardless of admission glucose level (HR 1.80, 95% CI 1.39-2.86, P<0.01).  
Hyperglycemia at all times was associated with the greatest risk of death (HR 4.83, 95% 
CI 1.93-12.06, P<0.01) and late onset hyperglycemia after admission normoglycemia was 
also associated with an increased risk of death (HR 1.64, 95% CI 1.06- 2.54, p=0.04).   
Patients who became normoglycemic after admission hyperglycemia had a lower risk of 
death than those who were persistently hyperglycemic (HR 0.21 95%CI 0.08-0.52).  
Spontaneous normalisation of blood glucose appears to be associated with better clinical 
outcomes.  The authors conclude that hyperglycemia has a causative role in the poor 
outcomes associated with post stroke hyperglycemia and that patients should be given 
glucose lowering treatment for extended periods in future clinical trials. 
Wong and colleagues put forward a different hypothesis on glucose kinetics in a 2008 
paper published in Neurology.190  In a prospectively recruited cohort of 124 non-diabetic 
patients they checked capillary blood glucose levels at a frequency of at least every 4 hours 
for the first 48 hours after admission.  No thrombolytic therapy was given to any patient in 
the study.  After statistical analysis the authors concluded that observed variation in 
capillary blood glucose levels in non-diabetic stroke patients was due to regression to the 
mean.  Regression to the mean is a statistical phenomenon where random values above and 
below a mean value will gradually drift back to an average value over time.  Regression to 
the mean occurs when repeated measurements are made of the same subject or unit of 
observation.292 Observed values have a random error which produces non-systematic 
fluctuations in observed values of a measurement (such as glucose levels) which vary 
around a true mean.  Mean glucose levels of individual patients appeared to be static for 
the duration of the study.   
Regression to the mean may give the impression that glucose levels are normalising when 
all that is being witnessed is actually just a statistical phenomenon.  The authors believe 
that the mean glucose level is more important than actual glucose levels at any one time.  
They also noted that serial glucose measurements are higher in patients with more severe 
stroke. 
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The hypothesis put forward by Wong et al is interesting but it is important to note that they 
excluded patients with known diabetes from their study and they did not attempt to define 
glycaemic status in study participants.  The study size of 124 is also relatively small. 
 
1.6.9  How should we treat post-stroke hyperglycemia? 
There is no consensus on the treatment of post-stroke hyperglycemia.  The academic 
community are not really sure that any treatment is indicated.  Clinical guidelines make 
various suggestions for the initiation of hypoglycaemic treatment but these guidelines are 
not evidence based.293, 294 
In a 2008 paper Casaubon and colleagues surveyed 278 physicians involved in the clinical 
care of stroke patients.295  The results of the survey reflected the therapeutic uncertainty of 
clinicians with a great deal of variability in clinical practice.  Intensive care physicians 
treat hyperglycemia in stroke patients most aggressively while emergency care physicians 
were the most conservative group. 
Insulin treatment has inherent risks.  In a letter to the journal Critical Care Medicine in 
2005 Strong and colleagues suggest that lowering blood glucose with insulin may be 
associated with an increased risk of brain injury.  They observed the ‘complete 
disappearance’ of glucose in the brain dialsyate in a traumatic brain injury patient treated 
with insulin.  Strong et al suggest that this evidence, in conjunction with evidence that 
spontaneous depolarization events are related to low extracellular glucose levels and poor 
outcomes, should encourage clinicians to avoid hypoglycaemia in acute stroke and brain 
injury patients.296, 297  A safe ‘lower limit’ for blood glucose in acute stroke patients may 
exist. 
One retrospective observational study of 960 patients with thromboembolic stroke 
suggested that post stroke hyperglycemia (glucose >7.2mmol/L) was associated with a 
higher mortality rate than normoglycemia (OR 3.15, 95%CI 1.45 to 6.85; p = 0.004).269  In 
this cohort persistent PSH over 48 hours had an even higher risk of death (OR = 6.54; 95% 
CI = 2.41 to 17.87; p < 0.001).  Patients with initial hyperglycemia that was later 
normalised had lower mortality than those with persistent PSH (OR = 0.22; 95% CI = 0.05 
to 0.96; p < 0.05).  These results suggest that there may be some benefit in normalising 
blood glucose levels after stroke. 
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A recent randomised control study on the use of glucose, potassium and insulin infusions 
to control post-stroke hyperglycaemia was negative.  This may be because the mean onset 
of therapy was 12 hours post stroke.144  Further pilot studies of the use of intensive insulin 
therapy for post-stroke hyperglycemia have been completed and larger randomised control 
trials may be carried out in the future.259, 283, 298 
In a post-hoc analysis of the GLIAS observational study Fuentes and colleagues assessed 
the treatment of persistent post-stroke hyperglycemia.213 In this cohort of 476 patients, 291 
received treatment for hyperglycemia while 117 were identified as having persistent post 
stroke hyperglycemia defined as 2 or more blood glucose readings above 155mg/dl.  In 
114 patients hyperglycemia persisted despite treatment. 
Persistent hyperglycemia was an independent predictor of poor outcome in this study but 
given the high level of treatment for hyperglycemia it is possible that the intervention may 
have had some negative effects on the patients.  In this study up to 97.5% of patients with 
persistent post-stroke hyperglycemia were treated with no clear benefit.  The authors 
conclude that better protocols are required for the management of PSH but as yet there is 
no good evidence that lowering blood glucose is beneficial.  Indeed if the data from the 
ASTRAL study are correct hypoglycaemia may be as harmful as hyperglycemia.173 
Data from the retrospective study by Gentile and colleagues did suggest that treatment for 
PSH resulted in lower rates of mortality but evidence from published clinical trials does 
not currently support this.246, 269, 299   
Intensive insulin protocols have been used in several clinical environments with variable 
results.300-304  Patients on these protocols appear to be more likely to become 
hypoglycaemic according to the results of meta-analyses.305, 306  At least one trial has been 
stopped early due to safety concerns about hypoglycaemia.307 
Other, less acute studies such as the Insulin Resistance Intervention After Stroke (IRIS) 
trial are ongoing.  IRIS is a randomised control trial treating patients with pioglitazone or 
placebo if they have biochemical evidence of insulin resistance.  Pioglitazone is a 
thiaziolidnedione or ‘insulin sensitizer’ which is used in the treatment of Type II Diabetes 
Mellitus.  Pioglitazone reduces blood glucose and insulin levels while increasing HDL-
cholesterol.  The PROactive (PROspective pioglitAzone Clinical Trial In macroVascular 
Events) study identified an apparent reduction in recurrent strokes in patients with Type II 
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DM who were treated with pioglitazone.308, 309  The IRIS trial hopes to replicate this 
beneficial effect in patients with insulin resistance many of whom may demonstrate post-
stroke hyperglycaemia.  As I have discussed earlier, insulin resistance has been reported in 
up to 50% of patients in a preliminary observational study by some of the IRIS 
investigators.48  Further information on the IRIS trial can be found at the study website 
(http://iristrial.org/index.html). 
Several animal models of post-stroke hyperglycemia have used insulin to reduce the size of 
experimentally induced infarcts.  Unfortunately these studies are highly heterogeneous 
with varying results.310-312 I discuss the limitations of the available evidence in chapter 3. 
1.7 Pre-clinical science and post-stroke hyperglycaemia 
1.7.1  Animal models of post-stroke hyperglycemia 
Many of our theories about the pathophysiology of post-stroke hyperglycemia and 
potential treatments for PSH are based on animal models.  Animal models of ischaemic 
stroke are useful because smaller observational human studies cannot easily control for the 
severity of the initial stroke. 
While many studies suggest that hyperglycemia increases infarct growth in animal models 
of stroke others suggest that high blood glucose may be beneficial.313-319   
Heterogeneity is a major problem in the use of animal models for PSH.  These studies 
involve different strains and species of animal model.  The method of induction of 
hyperglycemia may also be problematic as many experiments use streptozotocin which 
produces a model of type 1 diabetes mellitus that may no be relevant to most human cases 
of PSH. 
I have conducted a systematic review of models of focal cerebral ischemia and 
hyperglycemia and this is included in Chapter 3. 
1.7.2 Glucose metabolism in the normal brain 
In a healthy individual the brain consumes 20-25% of total body glucose.  The brain relies 
on a constant supply of blood glucose to function normally.  Brain tissue requires 5mg of 
glucose per 100mg per minute to function normally.  This works out as a requirement of 
approximately 140g of glucose per day.  Glucose requirements are higher in more 
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metabolically active areas of the brain such as the grey matter.320  In hypoglycaemic 
conditions the brain can function with glycogen.321 Glycogen is converted into lactate 
which is then used as energy by the brain.     
 
1.7.3 ‘The ‘glucose paradox’ of cerebral ischaemia’ - Why does 
hyperglycemia worsen cerebral ischemia? 
Glucose is thought to be the main source of energy for the brain.  It had been suggested 
that no other substrate could enter the brain in large enough levels to meet cerebral energy 
requirements.322  More recently it has been observed that the healthy brain can also use 
lactate for energy.323   
The ‘glucose paradox’ of cerebral ischaemia refers to the observed phenomenon that pre-
ischaemic hyperglycaemia aggravates post-ischaemic outcome.324  This was initially 
described in 1977 by Myers and Yamaguchi who noticed that administration of glucose 
immediately before cardiac arrest results in more widespread neurological injury.325 
The mechanism of this glucose related neurological injury is uncertain.  Lactic acidosis has 
been suggested as one probable mechanism.  Other hypotheses include an increased release 
of glucocorticoids, beta-amyloid precursor proteins or increased superoxide and nitric 
oxide production.326 
1.7.4 Lactic acidosis 
The lactic acidosis hypothesis is that pre-ischaemic hyperglycaemia results in elevated 
lactic acid levels during ischaemia and increases ischaemic brain damage.  This situation is 
described as a paradox because the brain requires glucose to function normally.  Why 
should glucose, the normal fuel of brain cells, cause damage under ischaemic 
circumstances? 
Ischaemic or anaerobic energy metabolism is less energy efficient and produces lactate and 
acidic free hydrogen ions.  Under anaerobic conditions, such as cerebral ischemia, 
glycolysis is the only process capable of producing enough adenosine triphosphate (ATP) 
to meet the energy requirements of the brain. Unless glucose is available in large quantities 
glycolysis could not last for more than a few minutes. As glucose is the sole substrate of 
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the glycolytic pathway, higher glucose levels mean that glycolytic ATP is produced for a 
longer period. Lactate is the main product of glycolysis.  Persistent anaerobic metabolism 
results in intracellular acidosis.  
At the end of an ischemic episode, and upon reperfusion/re-oxygenation, aerobic 
conditions (and often a shortage of glucose) exist.  Under these circumstances lactate can 
easily enter the tricarboxylic acid cycle via pyruvate to maintain ATP production as 
efficiently as glucose.  The `Pasteur Effect' phenomenon, the significant increase in 
glucose consumption that occurs upon the exhaustion of oxygen supplies is the regulatory 
mechanism responsible for lactate production. This process, which supplies ATP to 
oxygen-deprived tissue, has been thought to cause the demise of that very tissue under 
ischemic conditions. 
It has been assumed that lactic acidosis is harmful to neurons although this had not been 
conclusively proven.327  Schurr and colleagues noted that there is some discordance 
between in vivo and in vitro models of hyperglycemic cerebral ischemia.324, 327   
For some time researchers using in vitro models were unable to reproduce the aggravation 
of cerebral ischemia by pre-ischaemic hyperglycemia (hyperglycemia actually appears to 
be neuroprotective in some models)328-330.  These in vitro studies model global cerebral 
ischemia (i.e. cardiac arrest) suggesting that the neurotoxic effects of lactic acidosis may 
be mediated by the cerebrovascular blood supply 
However one in vitro study suggests that glucose in combination with acidosis is harmful 
to neuronal cells while lactate does not have the same effect.331  Cronberg and colleagues 
used a murine hippocampal slice model of in vitro ischemia.   The synergistic mechanism 
by which glucose and acidosis combine to cause neuronal damage is still unknown. 
In a 2009 paper Berthet and colleagues suggested that lactate may actually be 
neuroprotective after focal cerebral ischemia.332  In an in vitro experiment they found that 
lactate protected against neuronal death when cells were deprived of oxygen and glucose.  
A subsequent in vivo experiment found that an injection of lactate into the cerebral 
ventricles at the time of reperfusion after middle cerebral artery occlusion resulted in a 
significant decrease in infarct size.  When lactate was given 1 hour after reperfusion it did 
not reduce infarct size but neurological outcomes improved. 
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In animal experiments it has been observed that during focal cerebral ischaemia that the 
ischaemic penumbra exhibits heterogeneous development of intracellular cortical acidosis.  
In a 1999 paper Anderson and colleagues attempted to test two hypotheses; firstly they 
wanted to confirm that this acidosis was due to glucose utilization and secondly they 
wanted to confirm that intracellular acidosis leads to infarction of potentially salvageable 
tissue.333  Experimental ischaemia was induced in rabbits using a 3-vessel occlusion model 
and hyperglycemia was produced using an intravenous dextrose solution.  In vivo 
fluorescent imaging was used to assess brain pH, regional cortical blood flow and NADH.  
Final infarct volume was measured pathologically.   
Anderson et al observed that pre-ischaemic hyperglycemia resulted in more pronounced 
intracellular acidosis and reduced NADH regeneration.  They conclude that hyperglycemia 
worsens intracellular brain acidosis and mitochondrial function in the ischaemic penumbra 
supporting the hypothesis that the evolution of acidosis in the penumbra is related to 
glucose metabolism.  
1.7.5 Other mechanisms by which hyperglycemia may exacerbate 
ischaemic brain damage  
If lactate metabolism is beneficial it has been suggested that the harmful effects of 
hyperglycaemia may be mediated by steroids.324   It has been hypothesised that 
hyperglycemia (or glucose loading) results in a transient increase in the release of 
glucocorticoids resulting in a worse outcome.  In a rat model of global cerebral ischemia 
Schurr and colleagues used metyrapone, a corticosterone synthesis inhibitor, to reduce 
steroid levels.  A significantly lower level of delayed neuronal damage was seen in these 
animals. 
In a global ischemia model hyperglycemia has been seen to induce early intraneuronal 
expression of β-amyloid precursor protein.  Rats that were exposed to dextrose at the time 
of ischemia had very widespread β-amyloid precursor immunoreactivity while 
normoglycemic rats only had very weak staining.  It has been suggested that β-amyloid 
precursor protein or its metabolites may be involved in the process of ischaemic brain 
injury.334 
In a rat model of focal cerebral ischemia Ste-Marie and colleagues found that 
hyperglycemia at the time of ischemia resulted in an early rise in superoxide and nitric 
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oxide production.  This may in turn lead to an increase in production of hydroxyl radical 
formation leading to neuronal cell damage.335 
1.7.6 Imaging biomarkers for brain metabolism 
While data from animal models may suggest possible mechanisms by which 
hyperglycemia may exacerbate the ischemic brain damage of human stroke such studies 
will never give us definitive answers.  Human studies will never give us tissue for 
histological data so imaging biomarkers of brain metabolism have been used in an attempt 
to elucidate the situation. 
The 2003 paper by Smith et al examined cerebral metabolism using FDG-PET 
(18fluorodeoxyglucose positron emission tomography) scanning and suggested that lactate 
may be a preferred substrate in the healthy human brain.323   In healthy human subjects 
who were infused with lactate whilst undergoing the FDG-PET scan.  Whole brain glucose 
uptake was significantly reduced by approximately 17% during lactate infusion suggesting 
that the euglycaemic brain may preferentially metabolise lactate if available. 
In a 2002 paper Parsons and colleagues used magnetic resonance spectroscopy to explore 
the relationship between hyperglycemia, lactic acidosis and clinical outcome in human 
acute stroke patients.176  MR spectroscopy was used in 33 patients to assess the 
relationship between acute blood glucose levels and lactate production in ischaemic areas 
of brain.  All of the patients initially had MRI assessment of perfusion-diffusion mismatch 
to estimate penumbral volume.  Higher acute blood glucose levels in patients with 
perfusion-diffusion mismatch were associated with greater sub-acute lactate production 
and reduced salvage of mismatch tissue.  In patients with no evidence of mismatch there 
was no correlation of blood glucose with outcome measures and no evidence of lactate 
production.  The authors concluded that acute hyperglycemia increases brain lactate 
production and facilitates the infarction of penumbral tissue.   
McCormick and colleagues subsequently undertook a randomised placebo controlled trial 
of a GKI (glucose, potassium and insulin) infusion to control blood glucose levels in acute 
stroke patients.336  Infarct growth was assessed between admission and the seventh day 
after the stroke.  MR spectroscopy was used to assess lactate production.  The use of the 
GKI infusion was found to reduce blood glucose levels and brain lactate levels but had no 
effect on infarct growth.   
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The work of McCormick and colleagues suggests that while hyperglycemia may be related 
to lactate levels, increased lactate levels are not the only factor that contributes to infarct 
growth.  These results may correlate with the results of Cronbergs’ in vitro work.331 
It may be interesting to use MR spectroscopy to monitor pH changes in relation to 
hyperglycemia in acute stroke patients although this would be a complex imaging process. 
There are limitations to MR spectroscopy techniques that should be considered.  MR 
spectroscopy does not directly quantify lactate levels and instead expresses a 
lactate:creatine or lactate:choline ratio.337  It is of course possible that all of the brain 
metabolites used for MR spectroscopy are altered during stroke possibly skewing results.  
For practical reasons the MR spectroscopy voxel was placed in the DWI (‘core’) lesion as 
opposed to the mismatch (‘penumbral’) region in both studies.  It is possible that lactate 
may have behaved differently in the mismatch region.   
At present there is no conclusive solution to the ‘Glucose paradox’. 
1.7.7 Positron Emission Tomography studies on PSH 
In a 1990 paper Kushner and colleagues used positron emission tomography (PET) 
scanning to look at the relationship between hyperglycemia within 12 hours of stroke 
onset, structural brain damage assessed using CT and brain metabolic disruption.338  They 
were able to study 39 patients who had an appropriate blood glucose measurement.  
Patients had PET imaging within 7 days of stroke onset.  In this study hyperglycemia was 
defined as a blood glucose level of above 6.7mmol.  For the PET scanning 18F-
fluorodeoxyglucose (FDG) was used to delineate cerebral metabolism. 
In patients with low initial blood glucose levels PET imaging was normal or only slightly 
abnormal.  In patients with high blood glucose levels a greater degree of metabolic 
abnormality was observed.  In both qualitative and quantitative analysis of PET images 
hyperglycemia was associated with either lobar or multi-lobar hypometabolism.  There was 
no statistically significant relationship between diabetes and abnormal metabolism. 
In a 1993 study Heiss and colleagues looked the relationship between cerebral glucose 
metabolism as assessed by PET scanning and functional outcome.339  Patients with 
diabetes were excluded from this study as diabetes may have a confounding effect on 
cerebral glucose transport and metabolism.  Sixty-six patients were prospectively recruited 
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and scanned at an average of 9.2 days after stroke.  Patients were followed up for an 
average of 50.5 months to assess final functional outcome.  Good global, ipsilateral and 
contralateral glucose metabolism were significantly related to better final functional 
outcomes (P= 0.001).  Multiple regression analysis revealed that cerebral glucose 
metabolism correlated more with functional outcome in hypertensive patients (P=0.016). 
1.7.8 The effect of hyperglycemia on haemostasis 
It has been suggested that hyperglycemia may have a pathological effect on haemostasis.  
Fibrinogen is associated with primary haemostasis and increased fibrinogen levels are 
associated with atherosclerosis and incident vascular events.340-343  Permeability of the 
fibrin clot may be reduced in hyperglycaemic or diabetic patients.344-346  Fibrin clots 
formed by diabetic patients have a denser, less porous structure than those of control 
subjects.  Similar changes are seen in vitro and may explain the reduced efficacy of tissue 
plasminogen activator in hyperglycaemic patients.347, 348  These structural changes may be 
related to poor glycaemic control and exposure to high levels of blood glucose.349  
Improving glycaemic control may reduce the cardiovascular risk associated with 
fibrinogen.350 
Ozkul and colleagues looked at the interaction between insulin resistance and coagulation 
in the acute phase of ischaemic stroke.351  Patients were prospectively identified after first 
ischaemic stroke. Patients with diabetes or other pre-existing conditions that may interfere 
with coagulation were excluded.  They found that Protein C and Protein S levels were 
significantly lower in insulin resistant patients and that levels of these anticoagulants 
correlated with HOMA levels.  A negative correlation was observed between NIHSS and 
Protein S levels.  The authors suggest that the significant associations between insulin 
resistance and haemostatic markers may worsen stroke severity by creating a procoagulant 
state. 
Lindahl et al reported an association between insulin resistance and low fibrinolytic 
activity in a sub-study of patients enrolled in the Swedish MONICA (MONItoring of 
trends and determinants in CArdiovascular diseases) study.352  They investigated 756 
patients by checking fasting insulin and glucose levels as well as PAI-1 activity and tPA 
activity.  Subjects within the highest tertile of insulin resistance had higher PAI-1 activity 
and lower tPA activity.  
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Evidence of a relationship between insulin resistance and impaired haemostasis has also 
been seen in the Framingham Offspring Cohort.353 Insulin levels and haemostatic factors 
were measured in 2962 study participants.  Mean levels of haemostatic factors were 
observed to increase with insulin levels.  Levels of both PAI-1 and tPA antigens were 
significantly higher in patients with highest insulin levels.  The authors suggest that 
patients with insulin resistance may be at an increased risk of acute thrombotic disease. 
1.7.9 Vascular effects of hyperglycemia 
Martini and Kent reviewed the vascular effects of hyperglycemia in 2007 and concluded 
that hyperglycemia results in a pro-vasoconstrictive, pro-thrombotic and pro-inflammatory 
phenotype which may make the cerebral vasculature vulnerable to reperfusion injury.354 
Martini and Kent believe that the vascular injury that results from hyperglycemia is one of 
the main factors that limits the utility of other interventions that aim to provide 
neuroprotection 
Hyperglycemia is known to induce various biochemical changes within endothelial 
cells.355  The GLUT-1 transporter moves glucose from the blood stream into cells.356  In 
vitro studies suggest that the GLUT-1 transporter in vascular endothelial cells is not insulin 
sensitive so hyperglycemia in the blood stream results in intracellular hyperglycemia.357  
Intracellular hyperglycemia is thought to result in many of the biological abnormalities 
seen in diabetes.  Several biochemical pathways are activated by intracellular 
hyperglycemia.358 Hyperglycemia seems to produce an increase in reactive oxygen species 
(ROS).  Reactive oxygen species cause DNA damage resulting in poly(ADP-ribose) 
polymerase (PARP) activation which in turn decreases the activity of the key glycolytic 
enzyme glyceraldehyde-3 phosphate dehydrogenase (GAPDH).  Inhibition of GAPDH 
activates 4 pathways that damage cells.355, 358 
Hyperglycemia does not appear to be the major determinant of macrovascular disease in 
diabetes mellitus.358  Macrovascular disease may be more linked to other features of 
diabetes such as insulin resistance and subsequent free fatty acid deposition in endothelial 
cells. 
1.7.10  Effect of blood glucose on fibrinolysis 
Type 2 diabetes mellitus is thought to be associated with abnormalities of haemostatic 
factors in the circulation.  The fibrinolysis inhibitor plasminogen activator inhibitor-1 
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(PAI-1) appears to be closely related to insulin resistance.359-361 Mansfield and colleagues 
attempted to investigate the relationship between PAI-1 levels and stroke in diabetic and 
non-diabetic patients.362  Mansfield et al performed a case control study where 4 cohorts of 
patients were recruited:  40 diabetic patients with stroke, 80 diabetic patients without 
stroke, 80 stroke patients without diabetes and 40 controls without stroke or diabetes.  In 
this population PAI-1 levels were highest in diabetic patients without stroke.  In this 
subgroup levels were significantly higher than in either stroke patients without diabetes or 
normal controls (P<0.0005).  Circulation tissue plasminogen antigen activator levels were 
also checked.  Levels of t-PA antigen were lower in patients with diabetes who had 
experienced a stroke when compared with diabetic controls without a stroke.  The authors 
conclude that these results do not support a hypothesised relationship between impaired 
fibrinolytic function and incident ischaemic stroke in patients with type 2 diabetes mellitus.  
This conclusion may be wrong if antigen levels change acutely after stroke although at 
least one study suggests this is not the case.363  The authors admit that patients with the 
highest PAI-1 levels may be under-represented in this study if they die soon after stroke. 
In 1993 Nordt and colleagues reported in vitro studies where they attempted to determine if 
PAI-1 secretion is dependent on glucose levels.364  A significant increase in the secretion 
of PAI-1 was observed as plasma glucose levels increased.  This effect of glucose on the 
synthesis of PAI-1 by endothelial cells may contribute to reduced local fibrinolysis.   
In human studies patients with type 2 diabetes have been found to have significantly higher 
t-PA antigen and PAI-1 levels than normal controls.365 Correlations have been found 
between PAI-1 levels, insulin levels, body mass index and apolipoprotein B although only 
the correlation between PAI-1 and insulin remained after adjustment.361  Similar 
correlations have been observed in obese patients.359  A small study compared tissue 
specimens from the mammary arteries of diabetic and non-diabetic patients who were 
undergoing coronary artery bypass grafting.366  PAI-1 immunofluoresence was increased in 
the arterial wall of diabetic patients.  An animal study published by the same group 
suggests that acute hyperglycemia and acute hyperinsulinaemia decrease plasma 
fibrinolytic activity and increase PAI-1 activity.367 
Historically reduced reperfusion rates have been seen in diabetic patients who have been 
thrombolysed for myocardial infarction.368  Abnormal platelet aggregation in diabetes may 
also partially explain poorer outcomes from thrombolysis in these patients.369-371 
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1.8 Imaging techniques in acute stroke 
Brain imaging is very important in the clinical diagnosis and management of patients with 
stroke.  Brain imaging is also very important in stroke research.  There has been some 
debate about the best form of imaging in acute stroke patients.372 Clinical scoring systems 
to predict the cause of a stroke are unreliable.373 
1.8.1 Plain CT 
Non-contrast computerised tomography (NCCT/’plain’ CT) was first used by 
neuroradiologists over 35 years ago.374  CT was soon used in the diagnosis of stroke.375  
CT imaging was correlated with post-mortem data.376 
All suspected stroke patients should have a CT brain as soon as possible after admission.377  
Haemorrhage is instantly visible on CT.378 
Early changes can be seen on CT in ischaemic stroke very soon after presentation.379-382 
There has been some debate about the value of these changes but they do appear to be 
clinically useful.383  Scoring systems such as the ASPECTS score are available to help 
clinicians predict clinical outcome based on early CT appearances.384  It is also possible in 
some cases to see a ‘hyperdense’ middle cerebral artery on a plain CT scan which can 
represent arterial occlusion.385, 386 
As time progresses an infarct becomes more clearly demarcated and hypoattenuated on CT 
after a few days.387  Visible infarction on CT is associated with a poor functional 
outcome.388 
1.8.2 CT angiography 
CT angiography (CTA) has been used to evaluate intracranial arterial anatomy and has 
been compared with conventional angiography and MR angiography.389  CTA can add 
useful information to non-contrast CT in acute ischaemic stroke.  It can reveal the location 
and size of an occluded arterial segment as well as allowing evaluation of collateral blood 
flow.390 
In the era of cerebral revascularisation it is important to be able to clearly define the degree 
of revascularisation in research studies.  There are two distinct aspects to revascularisation 
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– recanalization and reperfusion.  Recanalization implies that the primary arterial occlusive 
lesion (AOL) has been destroyed opening the original artery.  In recanalization it is still 
possible that clot fragments have embolised to distal arteries causing further occlusion.  
Reperfusion implies that distal arteries are patent.  It is possible for distal arteries to be 
reperfused while the proximal occlusive lesion has only been partially removed. 
Various scoring methods have been developed to define the degree of recanalization and 
reperfusion after revascularization.  The AOL recanalization score has been developed in 
interventional neuroradiology stroke trials.391 The AOL score is detailed in table 1.4.  This 
score was initially defined using conventional cerebral angiography but it can be applied to 
CT cerebral angiography. 
Table 1-4 The AOL recanalization score 
Score AOL Recanalization 
0 No recanalization of the primary 
occlusive lesion 
I Incomplete or partial recanalization of the 
primary occlusive lesion with no distal 
flow 
II Incomplete or partial recanalization of the 
primary occlusive lesion with any distal 
flow 
III Complete recanalization of the primary 
occlusion with any distal flow 
Reperfusion has been described in interventional stroke trials using the TIMI (thrombolysis 
in myocardial infarction) score.392  The TIMI score is detailed in Table 1.5.  The TIMI 
score was developed using conventional angiography and is not intended for use with CT 
angiography.  
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Table 1-5 The TIMI (Thrombolysis in Myocardial Infarction) score 
Score TIMI reperfusion 
0 No perfusion 
1 Perfusion past the initial occlusion but no 
distal branch filling 
2 Perfusion with incomplete or slow distal 
branch filling 
3 Full perfusion with filling of all distal 
branches including M3, 4 
 
CT angiography requires administration of intravenous contrast which has been associated 
with worsening renal failure.  Current Royal College of Radiologists guidelines advise 
caution in the use of IV contrast although there has been some debate as to the real level of 
risk involved.393  This relative contraindication can limit use of CT angiography and 
perfusion CT in some patients. 
There has been some concern that iodinated contrast may inhibit fibrinolysis in acute 
stroke however a recent systematic review does not suggest that this is a serious 
problem.394  
 
1.8.3 Perfusion CT 
Imaging techniques that allow us to quantify cerebral blood flow may be valuable 
clinically.  Such techniques could define the infarcted core tissue of a stroke and the 
ischaemic penumbra.  This knowledge may make thrombolysis decisions easier.  
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Imaging methods such as positron emission tomography (PET), single photon emission 
computed tomography (SPECT), magnetic resonance (MR) imaging and stable xenon CT 
have been used to measure cerebral blood flow (CBF) and cerebral blood volume (CBV) 
for research purposes.  These techniques are expensive and often not practical for many 
clinical uses.  
Previous research has shown that stable xenon CT gives a quantitative and accurate map of 
cerebral blood flow.395  Perfusion CT studies and xenon CT studies have been shown to 
provide similar estimates of regional cerebral blood flow allowing some validation of 
perfusion CT techniques.396  Earlier research had validated the use of CT perfusion for the 
assessment of cerebral blood flow in animals.397  Perfusion CT has also been found to have 
the potential to provide similar perfusion maps to PET in some studies.398 
Perfusion CT uses contrast dye as an intravascular tracer with the CT scanner detecting 
brain blood flow.  Tracking the contrast bolus allows measurement of CBF and CBV as 
well as meant transit time (MTT) and time to peak (TTP) of contrast.  The change in signal 
intensity in Hounsfield units is proportional to the concentration of the dye in the pixel 
imaged.  Repeated scanning allows the creation of pixel concentration against time curves 
which can be used to generate the different perfusion maps.396, 399  It is thought that a 
prolonged MTT suggests penumbral tissue while a reduced CBV represents core infarcted 
tissue.400  
Clinically, CT perfusion has been found to be more accurate at predicting final outcome 
than plain CT when using the ASPECTS score.401  An example of CT perfusion imaging 
can be seen in Figure 3
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Figure 3 - CT perfusion images from the POSH study
  
 
1.8.4 Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is another commonly used imaging modality for 
stroke.  An MRI machine consists of a magnet, magnetic gradient coils, a radio frequency 
transmitter and receiver, and a computer that controls the acquisition of signals and 
computes the MR images.   
MRI produces images by utilizing the properties of atomic nuclei, principally those of 
hydrogen in water molecules.  A high intensity magnetic field forces the nuclei to align 
before a radio-frequency pulse displaces the nuclei from their position.  When the pulse 
stops the nuclei return to their original state, releasing energy in the form of a radio 
frequency signal.  A computer then analysis this ‘resonance’ signal and converts it into a 
grey scale image.402  Imaging can be weighted in different ways to better visualise different 
tissue types. 
MRI lets us examine the response of magnetised tissue to a radio frequency pulse and 
abnormal tissue will return abnormal signals.   
MRI will produce good quality brain imaging but scanning times are longer than for CT 
and many patients cannot enter the scanner due to metal implants or pacemakers.  
Monitoring critically ill patients can be difficult in an MRI scanner and CT is often quicker 
and safer.1 
1.8.5 MRI Diffusion Weighted Imaging 
Acute ischaemic stroke results in cytotoxic oedema.  Diffusion weighted imaging looks at 
the rate if diffusion of water through tissue   Healthy cells will only let water diffuse in 
certain ways.  Cytotoxic oedema will alter the diffusion of water through the cell.  This 
will result in a high diffusion weighted signal that will make even very small strokes easy 
today in the first 5-10 days after onset.403 
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1.8.6 Transcranial Doppler Ultrasound 
Transcranial Doppler (TCD) ultrasound is a non-invasive, portable tool that can be used to 
evaluate blood flow in cerebral blood vessels.  Studies have shown that transcranial 
Doppler findings predict angiographic findings.404  The TIBI score has been developed to 
grade flow in cerebral blood vessels.405  The technique is operator dependant and requires 
training and experience to perform and interpret results. 
TCD has been validated against CT angiography with a sensitivity of 79.1% and a 
specificity of 94.3%.  TCD can also give useful information about embolisation and 
arterial blood flow that is unavailable from CT anfiography.406 Power Motion Doppler 
(PMD) TCD was also compared to CT angiography in another prospective observational 
study of 100 patients within 24 hours of acute stroke.407  PMD-TCD had 95.6% sensitivity 
and 94.5% specificity for middle cerebral artery occlusion when compared with CT 
angiography as a gold standard. 
TCD is commonly used to screen children with sickle cell disease for stroke risk.  It is also 
used after spontaneous subarachnoid haemorrhage to monitor for angiographic vasospasm.  
TCD can be used for perioperative monitoring during carotid endartectomy and coronary 
artery bypass grafting.408  TCD is also very reliable when used in the detection of patent 
foramen ovale (PFO).409 
Some studies have looked at the use of TCD for sonothrombolysis to augment alteplase410, 
411
.  The initial CLOTBUST (Combined Lysis of Thrombus in Brain Ischemia Using 
Transcranial Ultrasound and Systemic t-PA) trial suggested a non-significant trend towards 
increased arterial recanalization with continuous TCD exposure.  There was also a non-
significant trend towards an increased rate of recovery with TCD compared with placebo. 
The subsequent TUCSON (Transcranial Ultrasound in Clinical SONothrombolysis) trial 
looked at the use of intravenous microspheres to augment TCD sonothrombolysis and 
improve recanalization rates.  The trial was a randomised, single blinded dose escalation 
study aiming to find a safe dose of microspheres.  Unfortunately the study was stopped 
prematurely due to an excess of intracerebral haemorrhage with the first microsphere dose 
increase.412  The trial was stopped at a very early stage by the sponsor and the numbers 
recruited were very small.  Three of 11 patients in the higher dose group had symptomatic 
intracerebral haemorrhage but in such a small cohort such numbers could be entirely due to 
chance.413 
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1.8.7 Arterial patency in acute stroke and early neurological 
deterioration after thrombolysis  
As described above arterial patency can be assessed in acute stroke using CTA and TCD.  
There is interest in investigating the patency of blood vessels after stroke thrombolysis as it 
is possible that some arteries may re-occlude.   
In the initial NINDS stroke thrombolysis trial 13% of patients showed an early clinical 
deterioration after initial improvement.414  This group of patients has a poorer long term 
prognosis. 
A proportion of the patients who had early neurological deterioration (END) would have 
had intracerebral haemorrhage.  Some patients may have malignant cerebral infarction 
which can be treated with decompressive craniotomy.415-417  Other patients may have early 
neurological deterioration due to haemodynamic factors.418  Some patients appear to have a 
further ischaemic stroke in a different arterial territory due to atrial fibrillation.419   . 
Arterial reocclusion after initial recanalization has been observed using TCD.420  In one 
observational study of a consecutive series of 60 patients treated with t-PA were monitored 
using TCD.  Forty-seven patients were seen to recanalize after thrombolytic therapy.  
Sixteen patients (34%) were seen to reocclude after initial recanalization.  Mortality was 
higher in the group of patients with reocclusion (33%) than in the group with stable 
recanalization (8%).  This difference was significant with a p value of <0.05. 
As mentioned previously, there appears to be a relationship between early recanalization in 
the presence of hyperglycaemia and a poor clinical outcome.180, 197, 198, 271 
In one prospective observational study looking at acute deterioration after recanalization 
(with IV t-PA or an intra-arterial procedure) there was a strong correlation between 
hyperglycaemia and a poor outcome.198  Acute deterioration was defined as an increase in 
NIHSS of 4 or more points at 24 hours.  Of 201 patients treated within 6 hours of symptom 
onset 13% worsened, 39% improved and 48% were unchanged at 24 hours.  
Hyperglycaemia, defined as blood glucose above 150mg/dl (8.3mmol/l), was more severe 
in patients who deteriorated even if an occluded vessel recanalized.  Hyperglycaemia was 
associated with an odds ratio of 6.47 for a poor outcome (P= 0.004). 
Similar results were seen in a series of papers from a Spanish centre.180, 197, 271 
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1.9 Clinical assessment scales and stroke research  
In both clinical practice and research clinical assessment scales are useful to record 
neurological functional deficits.  Such scales allow clinicians to communicate stroke 
severity and help guide clinical decision making.  In research these scales can be used to 
gauge homogeneity of a study population and to assess patient outcomes.  It is important 
that scales should be valid, reliable and easy to use421.  A valid test accurately describes a 
phenomenon or disease.  A reliable scale is reproducible between users and consistent for 
scale items.422  A good scale should be reliable on an interobserver and intraobserver basis. 
There are three main types of stroke assessment scale.  Global outcome scales assign 
patients to broad categories.  They are simple and easy to use but often not reproducible.  
They may be insensitive.422  The modified Rankin Scale is an example171, 423.  Physical 
deficit scales describe stroke related deficit based on neurological examination.  The 
National Institute of Health Stroke Scale is a physical deficit scale.422, 424  Activities of 
daily living (ADL) scales measure function needed for independent living.  They score 
basic biological functions such as continence and more complex tasks like food 
preparation.422  The Barthel Index is an ADL scale.425 
1.9.1 The National Institute of Health Stroke Scale 
The National Institute of Health Stroke Scale (NIHSS) is used both clinically and for 
research purposes.  It is used to guide stroke thrombolysis decisions.35  It was initially 
published in 1989 to clinically measure the severity of an acute stroke for therapeutic trials.  
It was based on three earlier scales424 The NIHSS initially had a good positive predictive 
value for imaging outcomes and final outcomes.426  When independent observers compared 
it with other neurological scoring scales it was found to have the best predictive value.427  
The initial scale had moderate to substantial interobserver agreement.428  
The NIHSS scale was later modified  to simplify its use while improving reliability and 
sensitivity.429  Training in the use of the NIHSS is straightforward and can be done using 
various audiovisual materials, some of which are available on the internet.430  The NIHSS 
scale is now used in most acute stroke trials.  
  
2 Materials and methods 
2.1 Introduction 
This chapter provides a detailed description of the patients and general methods used in the 
clinical studies presented in this thesis.  Methodology and endpoints that are only relevant 
to a single chapter are described in that chapter. 
The main study was entitled Post Stroke Hyperglycemia and Brain Arterial Patency.  The 
study was referred to by the acronym POSH which I will use later in the text. 
2.2 Patient recruitment 
Study participants were prospectively recruited from patients referred to the Acute Stroke 
Service at the Southern General Hospital in Glasgow between the 1st of January 2009 and 
the 31st of December 2011.  All patients who presented to the unit within six hours of an 
acute stroke were considered for the study.  While the majority of patients included in the 
study were domiciled in the immediate Glasgow area some patients were referred from the 
wider West of Scotland region. 
The study was designed to prospectively recruit 100 acute stroke patients within 6 hours of 
stroke onset.  We aimed to define the interaction of early and delayed hyperglycaemia with 
arterial patency and brain perfusion in these patients.   
2.3 Exclusion Criteria 
Exclusion criteria included a non-stroke diagnosis (e.g. primary intracerebral haemorrhage, 
tumour, subarachnoid haemorrhage or epilepsy), known sensitivity to iodinated contrast 
materials (previous contrast reactions or severe asthma), an inability to lie flat for the 
duration of additional imaging (e.g. severe cardiac failure, desaturation on lying flat, high 
risk of aspiration) and any intercurrent illness that was likely to limit survival to less than 
30 days.  Patients with severe renal failure were excluded as they could not have iodinated 
contrast material.  Pregnant women were not approached for the study to avoid radiation 
exposure. 
Patients enrolled in the study were treated with alteplase if appropriate.  In some cases 
patients were enrolled in a concurrent clinical trial of thrombolytic therapy and randomised 
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for treatment with desmotoplase or placebo. Age, stroke severity and past history of 
dysglycaemia are not exclusion criteria for this study. 
Informed consent for the study was sought where possible.  If a patient was unable to 
consent due to their neurological condition informed assent was obtained from the next-of-
kin. 
Patient data were collected on admission using a specifically designed case report form.  
This form was designed to record information regarding the past medical history of the 
patient and to prospectively record clinical data during the study period.   
2.4 Ethical approval 
Ethical approval was granted for this study by the appropriate NHS Research Ethics 
Committee. 
2.5 Timetable of Study Procedures 
Before the trial began a timetable of the study protocol was established.  Many of the data 
recorded were generated by routine clinical practice.  The additional procedures that were 
study specific are detailed in Table 2.1.  A flowchart of the study is included in Figure 4. 
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Table 2-1 Timetable of POSH study procedures 
Procedure Baseline (<6h) 6-24h 24-
48h 
72h Day 
7 
Day 
30 
Informed consent or assent 
from next of kin 
 
     
Non-contrast CT brain  
 *    
CT Perfusion *      
CT Angiography  
 
 
   
NIHSS  
 *    
Blood Sample – biomarkers  
     
Blood sample – HbA1c, 
glucose 
 
     
Blood sample – U&Es  
 *    
Capillary Blood Glucose    
   
Modified Rankin Scale 
     
 
Oral glucose tolerance test 
     
 
 denotes study-specific procedure 
 denotes clinically routine procedure, data captured for study 
* denotes procedure clinically routine in some patients 
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Acute Ischaemic Stroke <6h 
after onset
>18 years of age
Exclusions:
1. Known non-stroke diagnosis (eg
PICH, tumour, SAH, epilepsy)
2. Known sensitivity to iodinated contrast 
media (including previous contrast 
reactions or severe asthma)
3. Inability to lie in a recumbent position 
for the duration of additional imaging (eg
severe cardiac failure, desaturation on 
lying flat, high risk of aspiration)
4. Intercurrent illness likely to limit 
survival to less than 30 days
Consent or Assent
Brain Imaging with CT, CTA, CTP (8 
slice)
Blood Samples for Biomarkers, HbA1c, 
U&Es
NIH stroke scale
Capillary blood glucose 4 hourly for 48h
NIH stroke scale at 24h
48-72h
Repeat Brain Imaging with CT, limited intracranial CTA
Blood for U&Es
Day 7
NIH stroke scale
Day 30
Modified Rankin Scale Structured Interview
Glucose tolerance test
Pathophysiology of acute post-stroke hyperglycaemia in 
relation to brain perfusion and arterial patency
 
Figure 4 - POSH study procedures flowchart 
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2.6 Clinical assessment 
All patients were clinically assessed by the clinical medical team.  Severity of stroke was 
graded using the National Institute of Health Stroke Scale (NIHSS).424, 429  The NIHSS was 
repeated at 24 hours in all patients and if possible 72 hours and 7 days to assess clinical 
change in stroke severity.  At day 30 patients were invited to return to the hospital for 
clinical assessment and an oral glucose tolerance test (if not known to be diabetic).  
Clinical outcome was assessed using the modified Rankin Scale and the NIHSS.  If a 
patient was unable to return to the hospital on day 30 their clinical condition was assessed 
by a research nurse (AW) using the modified Rankin Scale structured interview (mRS-SI) 
during a telephone call.172, 431  If a patient was uncontactable their clinical status was 
established from doctors involved in their care or medical notes.  
2.7 Blood samples 
Blood samples were taken on admission for glucose, glycosylated haemoglobin (HbA1c) 
and renal function.  Additional blood was stored for later analysis. 
2.8 Blood capillary glucose monitoring 
Capillary blood glucose levels are checked as a matter of routine every four hours in the 
Acute Stroke Unit.  These data were recorded in the study proforma.  Where possible, the 
initial ambulance capillary glucose level was recorded. 
Serial capillary blood glucose concentrations were used to define groups: admission 
hyperglycaemia (blood glucose >7mmol/l within 6h of stroke onset), delayed 
hyperglycaemia (blood glucose >7mmol/l 6-48h after stroke onset), and normoglycaemia 
(blood glucose always below 7mmol/l). 
2.9 Imaging protocol 
Multimodal CT examination was obtained using a Multidetector Scanner (Philips 
Brilliance 64 Slice). Whole brain non-contrast CT was acquired first (5 mm slice thickness 
FOV 218 x 218 mm,120kv, 171 mA or 0.9 mm slice thickness, FOV 250x250mm, 120 kV, 
404 mA).   
This was followed by CT perfusion with 40mm slab coverage (8x5mm slices, FOV 25cm, 
80kVp, 476 mAs, 2 second cycle time, 30 cycles) using a 50 ml contrast bolus 
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administered at 5mls/second (350 Xenetix) via a large-gauge venous cannula, usually 
placed in the antecubital fossa.  
Finally a CT angiogram was performed from aortic arch to the top of the lateral ventricles 
(0.67 mm slice thickness, 120 kV, 475 mA) using bolus tracking to enable correct timing 
of image acquisition. 
Follow up imaging consisted of whole brain non-contrast CT followed by intracranial CTA 
from base of skull to the top of the lateral ventricles. If the initial occlusion was 
extracranial, the subacute CTA was extended using the same protocol as the admission 
CTA.  Follow-up CTA was only performed in patients with an arterial occlusion on initial 
CTA. 
2.10  Image Analysis 
CTP was processed using commercially available software (MIStar, Apollo Medical 
Imaging Technology, Melbourne, Australia) providing 4 perfusion parameters for analysis, 
Cerebral Blood Flow (CBF), Cerebral Blood Volume (CBV), Mean transit time (MTT) and 
Delay (DT). Motion correction was automatically applied after loading the CTP dataset. 
Arterial input function (AIF) and venous output functions (VOF) were selected semi-
automatically after placing a region of interest (ROI) in the anterior cerebral artery and 
superior saggital sinus respectively. 
Core volumes and penumbra volumes were measured on the 8 processed perfusion slices.  
This measurement was partially automated.  The CT perfusion thresholds used came from 
the Parsons group in Australia.  Core tissue was defined as having a delay time of > or = to 
2 seconds and a cerebral blood flow (CBF) of <40%.  Penumbral tissue was defined by a 
delay time of > or = to 2 seconds with a CBF of more than 40%.432 
Final infarct volume was measured on non-contrast CT images.  The non-contrast CT 
images were co-registered with the CTP images using the 3D fusion tool in the MIStar 
software.  The infarct volume was initially measured in the co-registered slices.  The total 
infarct volume visible in all CT slices was then measured. 
All scan volumes were measured by two observers (NM and XH). For final analysis mean 
volumes were used. 
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Inter-rater and intra-rater reliability was assessed using an anonymised set of CTP scans.  
This set included scans from the POSH cohort as well as scans from two other prospective 
studies.  Two observers (NM and XH) blinded to the preparation of this set measured core 
and penumbra volumes on these scans. Inter-rater reliability was assessed using both intra-
class correlation coefficients and weighted Cohen’s Kappa in Stats Direct. 
 
2.10.1 Reliability Results in test population 
For perfusion core the intra-class correlation co-efficient was 0.89 with 95% limits of 
agreement being -6.6 to 19.8.  These results suggest that one observer thought core volume 
was larger than the other in several cases. 
Agreement Plot (95% limits of agreement)
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Figure 5 Agreement plot of inter-observer perfusion core volume 
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For penumbra the intra-class correlation co-efficient was 0.89 with 95% limits of 
agreement -24.3 to 15.7.   
Agreement Plot (95% limits of agreement)
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Figure 6 Agreement plot for inter-observer perfusion penumbra volume 
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For co-registered 24-48h infarct volume the intra-class correlation co-efficient was 0.67 
with 95% limits of agreement being -88.3 to 99.4.   
Agreement Plot (95% limits of agreement)
0 40 80 120 160
-120
-70
-20
30
80
130
mean
difference
 
Figure 7 Agreement plot for inter-observer co-registered 24-48h infarct volume 
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For final infarct volume looking at all slices the intra-class correlation co-efficient was 
0.92 with 95% limits of agreement being -80.8 to 69.6.   
Agreement Plot (95% limits of agreement)
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Figure 8 Agreement plot for inter-observer total 24-48h infarct volume 
For arterial patency weighted Kappa was 0.689 (95% CI 0.52 to 0.859). 
2.10.2 Inter-observer agreement for POSH scans 
Inter-observer agreement was reassessed in the POSH cohort.  For perfusion core the intra-
class correlation co-efficient was 0.93 with 95% limits of agreement -20.5 to 13.8. 
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Figure 9 – Agreement plot of inter-observer perfusion core volume in POSH cohort 
For penumbra volume on perfusion imaging the intra-class correlation co-efficient was 
0.84 with 95% limits of agreement -23.7 to 30.1. 
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Figure 10 Agreement plot of inter-observer perfusion penumbra volume in POSH cohort 
For co-registered 24-48h infarct volume the intra-class correlation co-efficient was 0.91 
with 95% limits of agreement being -49.3 to 45.9. 
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Figure 11 - Agreement plot of inter-observer co-registered 24-48h infarct volume in POSH 
cohort 
For final infarct volume looking at all slices the intra-class correlation co-efficient was 
0.94 with 95% limits of agreement being -70.8 to 48.9 
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Figure 12 Agreement plot for inter-observer total 24-48h infarct volume in POSH cohort 
For the presence of arterial occlusion in the POSH cohort the weighted Kappa for 
agreement was 0.782 (p<0.001, 95% CI 0.61 to 0.96).  For recanalization the weighted 
Kappa was 0.777 (p<0.001, 95% CI 0.59 to 0.97). 
 
2.11 Statistical analysis 
Details of statistical analysis will be given in individual chapters.  Clinical data were 
prospectively entered into a spreadsheet by one person (NM).  Statistical analysis was 
mainly performed using PASW IBM SPSS statistics (SPSS Chicago, Illinois, USA, v 16-
19).  Where other packages have been used I have noted this in the text. 
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3 Animal models of post stroke hyperglycaemia 
3.1 Introduction 
3.1.1 The rationale for animal models of stroke 
Animal models of human disease are often used to gain pathophysiological information 
that cannot be obtained from human experiments and to develop new therapeutic 
strategies.   
In animal models we can control the severity, duration, location and cause of cerebral 
ischaemia.  We can also control for variations in cerebral anatomy and co-morbid diseases 
in a way that is impossible in clinical research. It is also possible to manipulate 
physiological variables to ensure that experimental strokes can be reproduced if 
necessary.433 
3.1.2 Problems with translational research in stroke 
Preclinical evaluation of any new potential therapy is important.  It is essential to know 
about any potential for toxicity before a new compound is used in humans.  It is also 
important to have evidence that any new compound may have some therapeutic value.   
A drug will usually be tested in animals before it is used in a clinical trial. While this has 
not always been the case historically new compounds that have never been used in humans 
are routinely tested in animals first. Animal studies may indicate potential human 
therapeutic efficacy.  Unfortunately there have been many cases of a failure to translate the 
positive results of animal studies into successful clinical trials.434   
The 1999 Stroke Therapy Academic Industry Roundtable (STAIR) guidelines were created 
to help with the translation of positive experimental neuroprotective trials into useful 
clinical treatments.435   They have subsequently been updated after several failed major 
stroke trials.436  These recommendations were as follows -  
1. Define the dose-response curve 
2. Define the time window in a well-characterized model 
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3. Blinded, physiologically controlled reproducible studies 
4. Histological and functional outcomes assessed acutely and long-term1 
5. Initial rodent studies, then consider gyrencephalic species 
6. Permanent occlusion then transient in most cases 
In the years since the initial STAIR guidelines were published no successful new 
treatments for acute ischaemic stroke have emerged and the guidelines are as yet 
unvalidated. The compound NXY-059 was thought to fulfil all the STAIR criteria but still 
failed to be clinically useful.437   
Pre-clinical research that has failed to translate into workable clinical treatments has been 
re-examined.  Systematic review and meta-analysis of basic research has suggested that 
publication bias exists and that pre-clinical research may have flawed methodology in 
some cases.438, 439 
It is possible that experimental studies have not included enough animals to have 
statistically significant results.  Historically sample size calculations have not always been 
included in basic scientific research papers and it has been suggested that many studies 
have just not been large enough to ensure that positive results have evolved from anything 
other than chance.440 
More recently several journals have decided to only consider basic research papers for 
publication if there are clear descriptions of sample size calculations, inclusion and 
exclusion criteria, randomization, allocation concealment, reporting of animals excluded 
from analysis, blinded assessment of outcome and reporting of potential conflicts of 
interest and study funding.441-443  While more basic studies containing observational, pilot 
or hypothesis generating data should still be published it should be made clear that these 
are only preliminary studies.   
There may also be an issue with the choice of animals used for individual studies.  Most 
experiments use young, male animals with no other co-morbidities.  As the majority of 
                                                 
1
 For stroke recovery drugs an appropriate time window for histological studies may be several 
days or weeks after ischaemia to allow the drug to take effect.  Behavioural studies should be 
carried out in the same time frame, 
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acute ischaemic strokes occur in older humans with various risk factors who are more 
likely to develop complications than young fit rats.  An update of the STAIR 
recommendations suggests that studies should be repeated in older animals with co-morbid 
disease to better mimic the target human population.  Efficacy studies should also be 
carried out in female animals.436 Infarcts may be influenced by a multitude of factors 
including anaesthetic agents and all of these issues should be considered.444 
3.1.3 Models of ischaemia 
Stroke is a heterogeneous human disease so a variety of animal models are viable in basic 
research.   
A variety of different types of models of cerebral ischemia exist.  Ischaemia can be global 
(as in a cardiac arrest), hemispheric (as if a common carotid artery has been occluded) or 
focal (which may mimic a stroke in the vascular territory of the middle cerebral artery).445  
Focal ischaemic models are most appropriate for human ischaemic stroke.   It is probably 
sensible to chose different models for lacunar stroke as opposed to cortical stroke.446 
3.1.4 MCAO models 
Several models of ischaemic middle cerebral artery (MCA) stroke exist.   Some models 
have been in use since the 1930s447.  The most widely used models involve unilateral 
middle cerebral artery occlusion (MCAO) in rats, mice or cats.  These models can involve 
permanent occlusion of the MCA (pMCAO) or transient occlusion (tMCAO).  Arterial 
occlusion can be induced by surgical ligation or cauterization of the MCA, intraluminal 
passage of a nylon suture or injection of an autologous thrombus into the common carotid 
artery. 
The surgical method of MCA occlusion developed by Tamura et al in 1981 has also been 
widely used.448  This technique involves a subtemporal approach to the MCA with 
diathermy to occlude the blood vessel.   This method also allows access to more proximal 
regions of the MCA and creates infarctions that are similar to those produced by 
intraluminal suture.  Infarctions are usually seen within 4 hours of vessel occlusion.  The 
technique has been refined to identify anatomical sites in the MCA that will produce 
consistent infarcts when occluded.449 
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The intraluminal suture MCAO method is probably the most frequently used model of 
experimental ischaemic stoke450, 451.  This technique is minimally invasive and can be used 
to induce both permanent and transient ischaemia in a controlled manner.  The model 
involves inserting a monofilament into the internal carotid artery until blood flow is 
occluded in the MCA.  Various technical modifications have been developed to improve 
the model.452  Filament size is known to influence infarct size.453  Problems with this 
technique include the risk of blood vessel rupture, hyperthermia and inadequate vascular 
occlusion. 
In cats a transorbital approach can be used454, 455.  This technique minimises manipulation 
and disturbance of the brain.   
Experimental infarct volumes need to be consistent.  The size of an infarct varies with the 
duration of ischaemia.  For infarcts to be of a reproducible model at least 60 to 90 minutes 
of ischaemia are required.   
Other models of MCA occlusion include photothrombosis models where a cortical infarct 
is induced by the systemic injection of a photoactive dye before irradiation with a light 
beam of a specific wavelength.456  As the infarct is created quickly it is unlikely that any 
ischaemic penumbra exists in this model.457  Endothelin-1 can be used to vasoconstrict the 
MCA causing cerebral infarction but this method allows less control than surgical 
techniques.458   
There are several other surgical models which allow occlusion of the MCA.  These models 
are often invasive and require craniotomy.  They can be used in a variety of species.459-464 
Table 3-1 Examples of benefits and drawbacks of animal models of MCA occlusion 
Animal Model Benefits Drawbacks465 
Squirrel 
Monkey459 
Transorbital approach 
to occlude MCA 
Anatomy similar to 
human 
Reproducible infarct 
size 
Gyrencephalic brain 
Ethical concerns 
Expensive 
Requires transorbital 
surgery 
Anaesthetics may have 
impact on infarct 
growth 
Miniature 
Pig460 
Focal cerebral ischemia Reproducible 
Cheaper than primates 
Less ethical concerns 
Larger and more 
expensive than rats 
Cat461 Retro-orbital extradural Easier physiological Ethical concerns 
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approach for occluding 
MCA 
monitoring  Requires orbital 
surgery 
Dog463 Occlusion of 
intracranial trunk 
arteries 
Good control of infarct 
development is 
possible 
Consistent results 
Extensive collateral 
cerebral circulation 
Ethical concerns 
Expensive 
Larger than rats 
Requires craniectomy 
 
3.1.5 Embolic models 
Embolic stroke models exist.466 Human and homologous rat emboli have been used 
although infarct size may be variable.467, 468  Human atherosclerotic plaques have been 
used to create emboli that are subsequently injected into rats.469A thoracotomy is often 
required to inject emboli.470  Artificial embolic materials have been used although these 
may be less relevant to human stroke than clot based emboli.471, 472 Multiple infarcts may 
be formed which makes precise reproducibility of lesions difficult.473, 474  Not all animals 
will develop infarction even in more modern models.470  When microspheres are used the 
evolution of infarcts appears to be prolonged.475  These models are often in non-rodent 
species.476-478 
3.1.6 Choice of species 
The rat is often used as an animal model of stroke for several reasons.  The cerebrovascular 
anatomy and physiology of the rat is similar to man.433  The vascular anatomy of the gerbil, 
the cat and the dog are less similar to man.  Table 3.1 summarises a few benefits and 
drawbacks of different models.  Different strains of rat are fairly homogenous within a 
strain making reproducible studies possible.  There is not as yet a standardised rat model.  
Intra-arterial suture occlusion models result in massive hemispheric infarction with short 
animal survival times.435 In stroke recovery trials a more focal surgical technique such as 
the Tamura method may be better.448  While the rat is a useful model species it is not 
perfect.   
There are arguments that a distinct role exists for primate models of stroke recovery.435  
There are differences between the human brain and the rodent brain that may lead to a 
different response to a similar ischaemic insult.  These differences are less apparent when 
the human brain is compared to the non-human primate brain.  It would be easier to 
estimate human drug doses based on primate data than it is using rodent data.  However 
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there are no standardised well recognised primate models of stroke recovery (as with 
rodents) and there are significant ethical concerns regarding the use of primates in medical 
research in western cultures.479  
3.1.7 Models of hyperglycaemia - Streptozotocin 
Streptozotocin is a broad spectrum antibiotic which was initially identified as an agent to 
create a model of type 1 diabetes mellitus in 1963.480-482  Streptozotocin causes pancreatic 
islet cell destruction resulting in an insulin deficiency which mimics human type 1 DM.  
The severity of the diabetes is dose dependent.483   
3.1.8 Models of hyperglycaemia - Dextrose infusions 
Hyperglycaemia can also be induced by the infusion or injection of a dextrose solution.  
Animals can be infused with variable strengths of dextrose ranging from 5% to 50%.  This 
will produce well controlled levels of hyperglycaemia although it may not precisely mimic 
a natural pathophysiological state. 
Neither the streptozotocin model, nor the dextrose infusion model is likely to accurately 
reflect the pathophysiology of post-stroke hyperglycaemia. 
3.1.9 Models of insulin resistance and Type II Diabetes Mellitus 
It is possible that models of insulin resistance or Type II Diabetes may be more relevant in 
the experimental observation of post-stroke hyperglycaemia.  The majority of human 
patients with PSH do not have type 1 diabetes mellitus and are not infused with highly 
concentrated dextrose solutions.  Models have been developed for the ‘metabolic 
syndrome’ which may be more useful 
The Zucker rat has been used as a model of metabolic syndrome.  Normally rats do not 
develop atherosclerosis meaning that in the past they were considered to be poor models of 
cardiovascular disease.  More recently genetic rat models of cardiovascular disease have 
been developed.   
The fatty Zucker rat was first described in 1961484.  The Zucker rat strain has a 
spontaneous mutant gene (fa or fatty) that affects the action of the adipocyte peptide 
hormone leptin.  Leptin is a key element in the regulation of food intake through the 
inhibition of the release of hypothalamic neuropeptide Y.  The Zucker also has a degree of 
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glucose intolerance, variable hyperglycaemia, hyperinsulinaemia, insulin resistance and a 
tendency to obesity.485, 486  These features are only seen in the homozygous fa/fa animals 
and are not seen the heterozygous Fa/fa or the homozygous Fa/Fa.487  The heterozygote 
and homozygous Fa/Fa Zucker rats are lean and metabolically normal.  
The Zucker rat may be more representative of the average human stroke patient and may 
be a better model for post-stroke hyperglycaemia than animals treated with streptozotocin 
or dextrose infusions. 
3.1.10 The need to re-examine the basic scientific evidence for 
post-stroke hyperglycemia 
The rationale for the UK Glucose Insulin Stroke Trial (GIST-UK) was at least partially 
based on animal models143, 313, 315, 488. Since the publication of GIST-UK, a number of 
studies in other clinical groups have raised concerns about the safety of insulin treatment in 
acutely hyperglycaemic patients242, 259, 283, 284, 298.  As GIST-UK was negative with a 
significantly worse outcome in patients whose blood glucose fell by more than 2mmol/l 
there is a need to reconsider some of the original basic experimental studies.242 
We elected to explore the data on pathophysiology of hyperglycaemia in acute stroke, and 
undertook a systematic review of the literature and meta-analysis of studies in 
hyperglycaemia in animal models of focal ischaemia induced by middle cerebral occlusion 
(MCAO). 
3.1.11 Assessment of quality of papers in basic scientific 
research 
Several checklists have been proposed to help assess the quality of papers in basic 
scientific reseach.440  Ideally a paper should make it clear exactly what a researcher has 
done to the extent that a reader could reproduce the original experiment.   
3.2 Methods 
3.2.1 Systematic review 
Studies of hyperglycemia in animal models of MCAO were identified from OVID medline 
(1950- March 2009) and EMBASE (1980-March 2009).  The search strategy is specified in 
appendix 1. 
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Titles were screened for relevance and abstracts for all potentially relevant papers were 
read by one investigator.  We also performed hand searches of abstracts of scientific 
meetings including the 2008 World Stroke Conference, the 1981 - 2009 International 
Stroke Conferences, the 2005-2009 Brain meetings, the 1992 - 2009 European Stroke 
Conference and Marburg Conferences from 1994-98, and screened reference lists of 
identified publications. 
3.2.2 Inclusion criteria 
We included models of focal ischaemia induced by middle cerebral artery occlusion 
(MCAO) where data were presented on infarct volume, defined either histologically or on 
brain imaging. The subset of papers that included data on the use of insulin, while meeting 
other inclusion criteria, was identified for additional analysis.  We excluded models of 
global or forebrain ischemia, and studies whose data did not include volumetric data. 
3.2.3 Data extraction 
We extracted data from the included papers on species, strain, gender and weight of 
animals; model and timing of ischemia; presence or absence of reperfusion; number of 
animals and experimental groups; experimental interventions; method of induction and 
timing of hyperglycemia; level of hyperglycemia; insulin use: timing of outcomes; method 
of measuring infarct and mean final infarct size and standard deviation.  
Studies that clearly reported method of inducing hyperglycemia and volume of final 
infarction with standard deviation were included in further analyses. 
If published data were incomplete, we contacted authors to obtain further information 489-
495
.   
3.2.4 Meta-analysis 
Data on infarct volume were recorded. To allow for different species in studies, the effect 
size was normalised to the mean of the control group (assumed 100%) before analysis in 
Review Manager 5.0.2 (Cochrane Collaboration) and StatsDirect, version 2.7.3 
(StatsDirect Ltd, Cheshire, UK) by means of a DerSimonian-Laird random effects model 
that expresses the difference between groups as a weighted mean difference (WMD) for 
effect size, and 95% confidence interval. The significance of difference between groups 
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was assessed by partitioning heterogeneity and using the chi-squared distribution with n-1 
degrees of freedom where n equals the number of groups.  
Several stratified analyses were planned.  We looked for a differential effect due to either 
streptozotocin or dextrose.  The insulin studies were stratified by control group 
(normoglycaemic or hyperglycemic). We also compared permanent and transient MCAO 
models. In order to allow for multiple comparisons we adjusted the significance level using 
the Bonferroni method to p<0.02. 
3.2.5 Study Quality 
We assessed the quality of the individual papers analysed in this study using a modified 
version of the CAMARADES (Collaborative Approach to Meta-Analysis and Review of 
Animal Data in Experimental Stroke) score 438, 440, omitting a score for neuroprotective 
properties of anaesthetic agents used, and therefore giving a maximum score of 10 points. 
3.2.6 Assessment of bias 
Funnel plots comparing standard error of the mean treatment effect against effect size for 
each study were obtained and analysed by Egger’s method to identify possible publication 
bias 496. 
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3.3 Results 
3.3.1 Identification of papers 
The initial search produced 1482 titles that were screened to identify 178 abstracts that 
were read in detail.  From these abstracts, 57 papers were initially identified for data 
extraction.  A further 15 papers were identified by hand searches.   
Twenty-two papers reported data in a format suitable for meta-analysis 312, 313, 316, 319, 488, 497-
512
.  One further paper was included when an author kindly contacted us with additional 
data for analysis 491. Six papers had insufficient data to include in the meta-analysis (see 
Table 3.1).  The remaining papers did not report infarct size, but included measurement of 
cerebral blood flow 513-515, brain biochemistry  analysis 516, blood brain barrier function 517, 
genetic analysis, evaluation of tissue energy states 314, 518, 519,  behavioural tests 520 and 
immunohistochemical analysis. 
From the 23 papers included, a total of 36 different comparisons of infarct size between 
hyperglycemia and normoglycemic controls after MCAO were described (see Table 3.2).  
These experiments used a total of 664 animals.   In two cases 2 comparisons used the same 
control group. This is noted below table 2. Hyperglycemia was induced with dextrose 
infusion or injection in seven cat and one rabbit experiments. In rats, streptozotocin was 
used in 18 comparisons while dextrose infusion was used in 10.  One study had useable 
data on infarct size but was excluded from analysis as it used a photosensitising model to 
induce local infarction instead of MCAO 313. 
Streptozotocin was given 48 hours before the experiment in 8 papers.  In other studies 
streptozotocin was administered at earlier times (72 hours earlier in 2 studies; 4 days 
earlier in 1 study; 7 days earlier in 1 study; 5-6 weeks earlier in 3 studies and i 4 months 
earlier in 1 study: note that these numbers do not add up to 18 as some studies included 
more than one comparison group). 
Dextrose infusions were started between 15 and 120 minutes (median time 30 minutes) 
before MCA occlusion in the comparisons where hyperglycemia was induced before 
occlusion. Dextrose infusion concentration varied from 10% to 50%.  In the comparisons 
where hyperglycemia was induced after MCAO this was done with an injection of 50% 
dextrose 5 to 20 minutes post ictus. 
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In 9 papers the frequency of monitoring of blood glucose was unclear. Glucose 
concentration was reported at the time of arterial occlusion and at an unstated time after 
occlusion in the remaining papers. Peak blood glucose values ranged from 18.4 to 
31.2mmol/l in hyperglycaemic groups, and from 4.6 to 11.1mmol/l in control groups.  In 
the hyperglycaemic groups the mean blood glucose was 23.9 mmol/l (95%CI 22.4-25.3).  
In the control groups the mean glucose was 8mmol/l (95%CI 7.3-8.7) 
3.3.2 Study Quality 
Study quality was generally low based on the modified CAMARADES score (median 
3/10, range 1-6 points).  All papers were published in peer reviewed journals.  Blood 
pressure monitoring was documented in 20/24 papers while temperature monitoring was 
documented in 22/24.  Random allocation of animals to experimental groups was 
documented in only 6/24 papers, while blinded assessment of outcome was only detailed in 
7/24.  No papers documented blinded induction of ischemia, sample size calculations or a 
clear conflict of interest statement. The complete quality score table is included as 
Appendix 2. 
3.3.3 Assessment of Bias   
Funnel plots (Figure 13, graphs A-C) suggested possible publication bias, with paucity of 
small, negative studies (particularly using the streptozotocin model), but formal statistical 
analysis was not significant (Egger’s bias test 2.88 (95% CI = -1.53 to 7.29, p = 0.1925) 
496
.   
  116 
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Figure 13 - Bias Assessment Plot for Effect of Hyperglycaemia on Infarct Size 
 
3.3.4 Measurement of effect size 
Infarct size was quantified by tissue staining (2,3,5-Triphenyltetrazolium Chloride [TTC] 
in 9 studies, cresyl violet in 4 studies, and hematoxylin and eosin in 11 studies) or 
magnetic resonance imaging (MRI). Two histology studies used both cresyl violet and 
hematoxylin and eosin staining.  One study reported only MRI measurement, and three 
others undertook both MRI and histology.   Where both techniques were used, we included 
MRI data as reported by the original authors.  Infarct volume was measured at times 
ranging from 3 hours after arterial occlusion up to 2 weeks.  
3.3.5 Streptozotocin Model and Dextrose Infusion Models  
Hyperglycaemic animals had significantly larger infarcts (effect size 94, 95% confidence 
interval 69.1 - 118.9, p<0.00001), but streptozotocin was associated with greater 
exacerbation of infarct volume compared to dextrose alone (effect size 140.3, CI 104.8-
175.9, p<0.00001 versus 48.3, CI 14.8-81.9, p=0.005).  There was significant statistical 
heterogeneity between studies with chi-squared equal to 1208.7 with 32 degrees of 
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freedom (p<0.00001). There was also statistical difference between sub-groups (chi-
squared =186.3, df =1, p<0.00001).  See Figure 14 below. 
Study or Subgroup
1.1.1 Streptozoticin Treated animals
Bomont 1995b
Duverger 1988a
Duverger 1988b
Huang 1996a
Huang 1996b
Kittaka 1996a
Li 2004
Nedergaard 1986a
Nedergaard 1986b
Nedergaard 1986c
Nedergaard 1987a
Nedergaard 1987b
Quast 1997a
Quast 1997b
Slivka 1991b
Wei 1997
Wei 1998
Subtotal (95% CI)
Heterogeneity: Tau² = 1030.33; Chi² = 419.29, df = 15 (P < 0.00001); I² = 96%
Test for overall effect: Z = 6.08 (P < 0.00001)
1.1.2 Dextrose treated animals
Araki 1992
Berger 1989
Bomont 1995a
Combs 1990a
de Courten-Myer 1988
de Courten-Myer 1989a
de Courten-Myer 1989b
de Courten-Myer 1994a
de Courten-Myer 1994b
Kittaka 1996b
Kraft 1990
Liu 2007a
Liu 2007b
Martin 2006
Nedergaard 1987c
Slivka 1991a
Wei 2003
Zasslow 1989
Subtotal (95% CI)
Heterogeneity: Tau² = 160.06; Chi² = 480.96, df = 14 (P < 0.00001); I² = 97%
Test for overall effect: Z = 3.17 (P = 0.002)
Total (95% CI)
Heterogeneity: Tau² = 260.55; Chi² = 1236.00, df = 30 (P < 0.00001); I² = 98%
Test for overall effect: Z = 9.07 (P < 0.00001)
Test for subgroup differences: Chi² = 335.75, df = 1 (P < 0.00001), I² = 99.7%
Mean
185
145.2
87.2
155.6
179.3
99.5
27
29.9
63
9
61
91
44
67.2
213
218.7
203.3
29.8
10.8
161
30.5
29.5
0.2
41
44.1
4.6
77.3
33.1
27.7
46.8
294.51
67
129
406.89
12
SD
19
12.8
13.1
35.3
32
31.6
3.2
9
20
10
45
22
33.5
27.5
38
47.4
61.2
10.8
2.4
18
7.6
6.5
0.1
9
28.7
6.3
18.9
2.8
5.32
11.98
97
27
37
112.17
2
Total
10
10
6
8
8
12
8
4
5
4
21
11
8
13
12
12
5
157
7
7
10
5
11
17
20
13
13
12
12
12
12
12
5
13
9
10
200
357
Mean
110
106.6
62.2
57.5
24.5
70.6
15.1
4
23
4
58
0
23.5
20.1
214
41
73.12
33.9
12
110
33.8
10.2
1.2
14
13.6
13
0
34
0
0
144.49
12.5
141
140.95
28
SD
23
4.5
10.9
15.4
9.7
10.5
1.5
4
12
3
35
0
17.3
15.7
36
12.7
32.64
12.8
22
9
2.8
3.4
0.4
4
12.9
7
0
4.6
0
0
54.73
4
18
65.49
5
Total
10
7
8
8
8
12
8
4
5
4
17
0
10
10
11
12
5
139
8
6
10
5
8
20
20
13
13
0
12
0
0
12
14
12
5
10
168
307
Weight
3.2%
4.0%
3.7%
2.5%
2.8%
3.2%
4.3%
4.0%
3.1%
3.9%
2.6%
2.6%
3.3%
2.3%
2.5%
0.9%
49.0%
3.8%
3.3%
3.8%
4.1%
4.3%
4.3%
4.3%
3.4%
4.2%
4.3%
0.9%
2.8%
2.9%
0.4%
4.3%
51.0%
100.0%
IV, Random, 95% CI
75.00 [56.51, 93.49]
38.60 [29.99, 47.21]
25.00 [12.08, 37.92]
98.10 [71.41, 124.79]
154.80 [131.63, 177.97]
28.90 [10.06, 47.74]
11.90 [9.45, 14.35]
25.90 [16.25, 35.55]
40.00 [19.56, 60.44]
5.00 [-5.23, 15.23]
3.00 [-22.44, 28.44]
Not estimable
20.50 [-5.07, 46.07]
47.10 [29.26, 64.94]
-1.00 [-31.25, 29.25]
177.70 [149.94, 205.46]
130.18 [69.38, 190.98]
51.80 [35.09, 68.52]
-4.10 [-16.04, 7.84]
-1.20 [-18.89, 16.49]
51.00 [38.53, 63.47]
-3.30 [-10.40, 3.80]
19.30 [14.79, 23.81]
-1.00 [-1.18, -0.82]
27.00 [22.68, 31.32]
30.50 [13.40, 47.60]
-8.40 [-13.52, -3.28]
Not estimable
-0.90 [-3.95, 2.15]
Not estimable
Not estimable
150.02 [87.00, 213.04]
54.50 [30.74, 78.26]
-12.00 [-34.54, 10.54]
265.94 [172.85, 359.03]
-16.00 [-19.34, -12.66]
12.08 [4.61, 19.56]
30.49 [23.90, 37.08]
Hyperglycemic Normoglycemic Mean Difference Mean Difference
IV, Random, 95% CI
-50 -25 0 25 50
Favours experimental Favours control
 
Figure 14 Meta-analysis of effect of hyperglycaemia on infarct size 
3.3.6 Permanent versus Transient MCAO 
The streptozotocin model was associated with larger infarcts in both transient and 
permanent MCAO. In 9 comparisons involving 190 streptozotocin-treated animals with 
permanent MCAO, the effect estimate for infarct size was 55.2 (95% CI 31.2 to 79.1, 
p<0.0001).  There was statistically significant heterogeneity between studies (chi-squared 
=99.3, df=8, p<0.00001).  In 8 comparisons involving 115 streptozotocin treated animals 
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with transient MCAO the effect estimate for infarct size was 319.1 (95% CI 191 to 447, 
p<0.000001). There was statistically significant heterogeneity between studies (chi-
squared =116.6, df=7, p<0.00001)   
In 10 comparisons involving 227 dextrose-treated animals with permanent MCAO the 
effect size was less than for STZ at 43.1 (95% CI -0.05 to 86.2, p=0.05) with statistically 
significant inter-study heterogeneity (chi-squared = 509, df=9, p<0.00001), and in 6 
comparisons involving 140 animals with dextrose-induced hyperglycaemia and transient 
MCAO there was no significant effect on infarct size (effect size 19.2, 95% CI.-42.9 to 
81.2, p = 0.54).  There was statistically significant heterogeneity between studies (chi-
squared = 149.8, df = 5, p<0.00001)   
 
3.3.7 Effects of Insulin Treatment 
In comparing insulin treatment with either hyperglycaemic or normoglycaemic control 
groups, infarct volume was smaller with insulin, but not significantly so.  
Insulin did not significantly reduce infarct size (10 comparisons, n=194, effect size -13.4, 
95% CI -41 to -5, p = 0.01) and results were heterogeneous in a statistically significant 
manner (chi-squared = 54.8, df=7, p<0.00001).  (See Table 3.3 and figure 15) 
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Study or Subgroup
3.3.1 Insulin vs Hyperglycemia with pMCAO
Bomont 1995c
Combs 1990b
de Courten-Myer 1994c
Subtotal (95% CI)
Heterogeneity: Tau² = 1202.88; Chi² = 47.09, df = 2 (P < 0.00001); I² = 96%
Test for overall effect: Z = 1.00 (P = 0.32)
3.3.2 Insulin Vs hyperglycemia and rMCAO
de Courten-Myer 1994d
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 3.57 (P = 0.0004)
3.3.3 Insulin Vs normoglycemia and pMCAO
Izumi 1992
Nedergaard 1987d
Subtotal (95% CI)
Heterogeneity: Tau² = 25.17; Chi² = 1.43, df = 1 (P = 0.23); I² = 30%
Test for overall effect: Z = 8.41 (P < 0.00001)
3.3.4 Insulin Vs normoglycemia and rMCAO
Hamilton 1995a
Hamilton 1995b
Zhu 2004a
Zhu 2004b
Subtotal (95% CI)
Heterogeneity: Tau² = 126.95; Chi² = 4.44, df = 1 (P = 0.04); I² = 78%
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI)
Heterogeneity: Tau² = 895.43; Chi² = 161.47, df = 7 (P < 0.00001); I² = 96%
Test for overall effect: Z = 1.60 (P = 0.11)
Mean
131
38.3
25.2
32.3
60
19.9
96.5
51.9
27
26
SD
14
8.4
18.8
23.7
10
19
12.5
7.7
12
8
Total
10
5
10
25
10
10
14
14
28
10
10
12
12
44
107
Mean
185
30.5
41.1
4.6
111
58
113.6
0
26
0
SD
19
7.6
28.7
6.3
12
35
17.8
0
12
0
Total
10
5
12
27
10
10
13
17
30
10
0
10
0
20
87
Weight
12.5%
12.9%
11.9%
37.2%
12.4%
12.4%
13.0%
11.9%
24.9%
12.6%
12.9%
25.4%
100.0%
IV, Random, 95% CI
-54.00 [-68.63, -39.37]
7.80 [-2.13, 17.73]
-15.90 [-35.89, 4.09]
-20.53 [-60.75, 19.70]
27.70 [12.50, 42.90]
27.70 [12.50, 42.90]
-51.00 [-59.37, -42.63]
-38.10 [-57.49, -18.71]
-47.64 [-58.74, -36.54]
-17.10 [-30.58, -3.62]
Not estimable
1.00 [-9.07, 11.07]
Not estimable
-7.47 [-25.17, 10.23]
-17.37 [-38.72, 3.97]
Insulin No Insulin Mean Difference Mean Difference
IV, Random, 95% CI
-100 -50 0 50 100
Favours experimental Favours control
 
Figure 15 Meta-analysis of effect of insulin on infarct growth 
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3.4 Discussion 
Whilst a large body of clinical observational evidence indicates that hyperglycaemia in the 
acute phase of stroke is associated with poorer outcomes 146, typically defined by death or 
dependence 90 days after the event, few clinical studies have addressed the mechanism by 
which this may occur 176, 336. Many mechanistic proposals are based on inferences drawn 
from animal models of focal ischaemia. In particular, the rationale for acute intervention to 
lower blood glucose (usually by administration of insulin) is based on an assumption that 
the adverse effect of hyperglycaemia relates predominantly to exacerbation of acute infarct 
evolution. However, insulin treatment carries significant risks, particularly hypoglycaemia 
(Finfer and Heritier 2009; Griesdale et al 2009) and the clinical evidence supporting an 
acute effect of hyperglycaemia is mainly observational and open to alternative 
interpretations. Data relating hyperglycaemia to early infarct volume can alternatively be 
explained by “stress” hyperglycaemia resulting from more severe infarcts, for example. 
Recent observations that hyperglycaemia carries a higher risk of symptomatic intracerebral 
haemorrhage in patients treated with intravenous alteplase may be confounded by a similar 
effect 179, 182. An association of glucose concentration with lactate concentration in the 
infarct core, and with infarct growth in a small observational study using MRI (Parsons et 
al 2002) is mechanistically plausible, but without an intervention arm, could not discount 
the possibility that the relationship with blood glucose is not causal. In addition, the 
assumption that lactate itself is toxic in the ischaemic brain is not necessarily correct, with 
other evidence suggesting that lactate is instead produced as an alternative metabolic 
substrate and is beneficial 176, 332. Only one small clinical trial has attempted to address 
these mechanistic hypotheses using advanced imaging, and found that insulin treatment 
reduced blood glucose and lactate concentration in brain, but had no effect on infarct 
growth 336.  
Our systematic review yields findings that suggest that existing animal model data have 
limited relevance to the clinical situation, and that further studies may therefore be required 
in order to inform clinical study design.  
First, while hyperglycaemia at the time of focal ischaemia onset increases infarct size, this 
is predominantly due to its large effect in the streptozotocin rat model, which simulates 
Type 1 Diabetes Mellitus 480. Hyperglycaemia induced by dextrose infusion has a much 
smaller effect on infarct size, although still significant. Significant heterogeneity of effect 
size was present among both STZ and dextrose models. While the animal data may be 
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informative with respect to a biological effect of hyperglycaemia on acute infarct volume, 
the clinical inferences that can be drawn are very limited. Dextrose infusion models 
typically administered hypertonic solution (20-50% dextrose) to give blood glucose 
exceeding 20mmol/l, a level considerably greater than is typically encountered in clinical 
practice (fewer than 2% of subjects in one study), and so the clinical relevance of findings 
in this model system is unclear. While only a minority of stroke patients have established 
diabetes mellitus (overwhelmingly type 2 diabetes), a high proportion of patients with 
acute hyperglycaemia after stroke are found to have unrecognised insulin resistance when 
followed (impaired glucose tolerance, metabolic syndrome, or undiagnosed type 2 
diabetes) 231, 521. No study of infarct volume used animals that model the insulin resistant 
phenotype typical of patient populations. 
The underlying mechanism for the difference in final infarct size between dextrose models 
and STZ models is uncertain.  In models of global ischemia the anatomical distribution and 
severity of brain damage in the STZ model is similar to that seen in animals acutely 
infused with dextrose 522.  It has been suggested that STZ may increase the rate of 
apoptosis in models of focal cerebral ischemia 523.  The diabetic state induced by STZ may 
damage the microvasculature of the rat brain or impair the compensatory mechanisms that 
would normally protect from ischemia. The difference in effect size raises a central 
question of whether the adverse effect arises from high glucose, or from lack of insulin.  
The effect of insulin was non-significant, although the effect size estimate is consistent 
with reduction in infarct volume. However, as insulin may reduce infarct volume when 
compared with normoglycaemic control groups, it is possible that insulin does not act via 
reducing blood glucose in these model systems, and we cannot infer that reducing blood 
glucose (as opposed to administering insulin) represents an effective intervention.  As the 
results of these studies are heterogeneous a degree of caution is necessary when 
interpreting them. 
To allow for comparisons involving different species and models we used weighted mean 
differences in infarct volume normalised to the mean volume of the control group 524, 525. 
Given the small group sizes, and the possible exclusion of animals that either died or 
exhibited no evidence of infarction from group mean infarct volume measurements - 
commented on in only a handful of studies – the magnitude of the effect size can be 
regarded only as an approximation.  
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Methodological quality of animal experiments is a significant concern as several reviews 
suggest that studies that do not report items such as blinding of outcomes and 
randomisation are more prone to bias than more rigorous studies 440. Quality scores have 
been based on criteria developed for pre-clinical evaluation of therapeutic interventions 
(e.g. the STAIR criteria) which have gone through several iterations over time, rather than 
physiological studies such as those predominantly reported here. The median quality score 
using a slightly modified system used by the CAMARADES group 438 was only 3 (out of a 
possible 10), and only two papers scored 6, which likely reflects a predominance of older 
papers and different standards of documentation for physiological studies (e.g. items such 
as conflict of interest statements are not likely to be perceived as necessary, in contrast to 
drug treatment studies). The feasibility of blinding in some circumstances – such as 
streptozotocin pre-treated animals, and dextrose infusions in animals monitored by regular 
blood sampling – is also unclear. 
We did not identify significant publication bias by a conventional analysis, but a recent 
publication highlights alternative methods such as ‘trim-and-fill’ analysis 526 to estimate 
the effect of publication bias on efficacy outcomes in systematic reviews and meta-analysis 
of animal models of stroke 527. This method estimates the number of unpublished studies 
that may exist based upon the estimated proportion of unpublished data from the Egger 
Regression. While this approach suggested that up to one sixth of studies were unpublished 
(with effect sizes potentially altered by one third) the relevance of publication bias to 
physiological studies rather than therapeutic agents is not clearly established. Even with an 
effect of this magnitude on overall estimates, hyperglycaemia would have a highly 
significant adverse effect on infarct volume.  
In summary, while animal focal ischaemia models indicate exacerbation of infarct volume 
by acute hyperglycaemia, this effect reflects a particularly detrimental effect in a model of 
type I (insulin deficient) diabetes, with both a smaller effect size and considerable 
heterogeneity in acute hyperglycaemia induced by dextrose infusion, which may represent 
a situation analogous to “stress hyperglycaemia”. No study has reported the effects of 
hyperglycaemia in an insulin resistant model, which is potentially the most clinically 
relevant scenario. Few studies have investigated the effect of insulin on infarct  volume, 
and since the concentrations of blood glucose induced in the model systems have generally 
greatly exceeded those relevant to clinical practice, we have no adequate data to support 
current clinical guidelines suggesting intervention at concentrations of >140mg/dl 
(7.7mmol/l) or greater.294  
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Whilst a large body of clinical observational evidence indicates that hyperglycaemia in the 
acute phase of stroke is associated with poorer outcomes, typically defined by death or 
dependence 90 days after the event, few studies have addressed the mechanism by which 
this may occur. Many mechanistic proposals are based on inferences drawn from animal 
models of focal ischaemia. In particular, the rationale for acute intervention to lower blood 
glucose (usually by administration of insulin) is based on an assumption that the adverse 
effect of hyperglycaemia relates predominantly to exacerbation of acute infarct evolution. 
However, insulin treatment carries significant risks, and the clinical evidence supporting an 
acute effect of hyperglycaemia is predominantly observational and open to alternative 
interpretations.  
Data relating hyperglycaemia to early infarct volume can alternatively be explained by 
“stress” hyperglycaemia resulting from more severe infarcts, for example. Recent 
observations that hyperglycaemia carries a higher risk of symptomatic intracerebral 
haemorrhage in patients treated with intravenous alteplase may be confounded by a similar 
effect. An association of glucose concentration with lactate concentration in the infarct 
core, and with infarct growth in a small observational study using MRI is mechanistically 
plausible, but without an intervention arm, could not discount the possibility that the 
relationship with blood glucose is not causal. In addition, the assumption that lactate itself 
is toxic in the ischaemic brain is not necessarily correct, with other evidence suggesting 
that lactate is instead produced as an alternative metabolic substrate and is beneficial.176, 332 
Only one small clinical trial has attempted to address these mechanistic hypotheses using 
advanced imaging, and found that insulin treatment reduced blood glucose and lactate 
concentration in brain, but had no effect on infarct growth.528 
Our systematic review yields findings that suggest that existing animal model data have 
limited relevance to the clinical situation, and that further studies may therefore be required 
in order to inform clinical study design.  
First, while hyperglycaemia at the time of focal ischaemia onset increases infarct size, this 
is predominantly due to its large effect in the streptozotocin rat model, which simulates 
Type 1 Diabetes Mellitus.480 Hyperglycaemia induced by dextrose infusion has a much 
smaller effect on infarct size, although still significant. Significant heterogeneity of effect 
size was present among both STZ and dextrose models. The dextrose infusion models 
typically administered hypertonic solution (20-50% dextrose) to give blood glucose 
exceeding 20mmol/l, a level considerably greater than is typically encountered in clinical 
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practice (fewer than 2% of subjects in one study), and so the clinical relevance of findings 
in this model system is unclear. While only a minority of stroke patients have established 
diabetes mellitus (overwhelmingly type 2 diabetes), a high proportion of patients with 
acute hyperglycaemia after stroke are found to have unrecognised insulin resistance when 
followed (impaired glucose tolerance, metabolic syndrome, or undiagnosed type 2 
diabetes).231, 521 No study of infarct volume used animals that model the insulin resistant 
phenotype typical of patient populations.  
The effect of insulin was non-significant, although the effect size estimate is consistent 
with reduction in infarct volume. However, as insulin may reduce infarct volume when 
compared with normoglycaemic control groups, it is possible that insulin does not act via 
reducing blood glucose in these model systems, and we cannot infer that reducing blood 
glucose (as opposed to administering insulin) represents an effective intervention.  As the 
results of these studies are heterogeneous a degree of caution is necessary when 
interpreting them. 
In summary, while animal focal ischaemia models indicate exacerbation of infarct volume 
by acute hyperglycaemia, this effect reflects a particularly detrimental effect in a model of 
type I (insulin deficient) diabetes, with both a smaller effect size and considerable 
heterogeneity in acute hyperglycaemia induced by dextrose infusion, which may represent 
a situation analogous to “stress hyperglycaemia”. No study has reported the effects of 
hyperglycaemia in an insulin resistant model, which is potentially the most clinically 
relevant scenario. Few studies have investigated the effect of insulin on infarct  volume, 
and since the concentrations of blood glucose induced in the model systems have generally 
greatly exceeded those relevant to clinical practice, we have no adequate data to support 
current clinical guidelines suggesting intervention at concentrations of >140mg/dl 
(7.7mmol/l) or greater.294  
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Table 3-2 Summary of excluded studies 
Study Hyperglycemic 
agent 
No. 
Animals 
Normal 
Glucose 
Size 
Infarct 
Normal 
Glucose 
No. Animals 
Hyperglycemia 
Size infarct 
Hyperglycemia 
Reason 
for 
exclusion 
Kamada 
2007489 
STZ 6 100 
graph 
6 300 graph Incomplete 
data on 
infarct size 
Rizk 
2006490  
STZ 6 3.02 +/- 
2.4 
6 Approx 10x 
greater 
No report 
of infarct 
size 
Gisselsson 
1999493 
DEX Unclear 115 
graph 
Unclear 125 graph Incomplete 
data on 
animal 
numbers 
and infarct 
size 
Li 1998a529 DEX None None ?6 50 Incomplete 
data on 
animal 
numbers 
and infarct 
size 
Quast 
1995492  
STZ 7 60 graph 7 400 graph Incomplete 
data on 
infarct size 
Zhang 
2003494 
STZ 6 100 
graph 
6 500 graph Incomplete 
data on 
infarct size 
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Table 3-3 Characteristics of studies included in the study 
Comparison Hyperglycemic 
agent 
Permanent 
or 
reversible 
MCAO 
Species Strain 
 
 
Time of 
induction of 
hyperglycemia 
with dextrose 
Experimental 
glucose level 
(mmol/l) 
Control 
glucose 
level 
(mmol/l) 
Araki 1992 Dextrose Reversible Cat  After Above 27 Below 8.9 
Berger 1989 Dextrose Permanent Rat  Before 19.2   8.2 
Bomont 1995a Dextrose Permanent Rat  Before 30.8  Below11.1 
Bomont 1995b Streptozotocin Permanent Rat   30.1  Below11.1 
Combs 1990 Dextrose Permanent Cat  Before 25.5 12 
De Courten-
Myer 1989a 
Dextrose Reversible Cat  Before 22  6 
De Courten-
Myer 1989b 
Dextrose Permanent Cat  Before 22  6 
De Courten-
Myer 1994a 
Dextrose Permanent Cat  Before 12.9 – 24.7  elow 9.2 
De Courten-
Myer 1988 
Dextrose Permanent Cat  Before 20  6.5 
De Courten-
Myer 1994b 
Dextrose  Reversible Rat  Before 18.2-22.5  Below 9.4 
Duverger 
1988a 
Streptozotocin Permanent Rat Fischer  25.3 8.3 
Duverger 
1988b 
Streptozotocin Permanent Rat Wistar  30.6  8.8 
Huang 1996a Streptozotocin Permanent Rat   25 8.1 
Huang 1996b Streptozotocin Reversible Rat   25.8  8 
Kraft 1990 Dextrose Permanent Rabbit  Before Above 22.8 Below 9.2 
Li 2004 Streptozotocin Permanent Rat   24.3 6.1 
Liu 2007a Dextrose Permanent Rat  Unclear 22.4  4.8 
Liu 2007b Dextrose Reversible Rat  Unclear 22.7  4.8 
Nedergaard 
1986a 
Streptozotocin Reversible 
(10min) 
Rat   Above 20  Below 9.2 
Nedergaard 
1986b 
Streptozotocin Reversible 
(15min) 
Rat   Above 20  Below 9.5 
Nedergaard 
1986c 
Streptozotocin Reversible 
(5min) 
Rat   Above 20   Below 9.5 
Nedergaard 
1987a 
Streptozotocin 
(2 days) 
Permanent Rat   25  7.3 
Nedergaard 
1987b 
Streptozotocin 
(4 months) 
Permanent Rat   28 7.3 
Nedergaard 
1987c 
Dextrose Permanent Rat  After 32 7.3 
Quast 1997a Streptozotocin Permanent Rat   26.5  9 
Quast 1997b` Streptozotocin Reversible Rat   26.5  9 
Slivka 1991a Dextrose Permanent Rat SHR Before 22.2 7 
Slivka 1991b Streptozotocin Permanent Rat SHR  26.4  8.8 
Wei 1997 Streptozotocin Reversible Rat   20.9  6.1 
Wei 1998 Streptozotocin Reversible Rat   25.6  7.2 
Wei 2003 Dextrose Reversible Rat  Before 19.6  4.5 
Zasslow 1989 Dextrose Permanent Cat  Before 31.2  11.6 
Martin 2006 Dextrose Reversible Rat  Before 18.4  8.6 
Kittaka1996a Streptozotocin Reversible Rat   15.5 4.3 
Kittaka1996b Dextrose Reversible Rat  Before 14.8 4.3
2
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Table 3-4 Details of insulin Studies 
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4 A Systematic review of therapeutic 
interventions for Post-Stroke Hyperglycemia 
in Humans 
4.1 Introduction 
Although clear causality between post stroke hyperglycemia and poor clinical 
outcome has not been established there have been various attempts to control blood 
glucose levels with the intention of improving clinical outcome. 
The majority of these attempts have relied upon an intravenous infusion of insulin 
running at a rate that varies in proportion to the level of blood glucose as measured 
using a capillary blood glucose monitoring machine.  While this approach may appear 
to be mechanistically sensible in some ways there are several problems with this 
system, some that are universal to all patients and some that are specific to patients 
who have suffered from a stroke 
These include 
Dysphagia – many stroke patients are unable to swallow and cannot have a normal 
diet.  This can result in malnutrition and an increased risk of hypoglycaemia when 
exposed to insulin.  If feeding is instituted via a nasogastric tube the patient may 
become hyperglycaemic again. 
Inability to speak – Stroke may cause aphasia or dysarthria making it difficult for 
patients to express themselves.  A patient with communication problems may be 
unable to tell clinical staff of symptoms of hypoglycaemia that may require alteration 
of an insulin infusion rate. 
Reduced level of consciousness – in a severe stroke a patient may have a reduced 
level of consciousness.  In a drowsy patient the symptoms of hypoglycaemia may be 
masked by the effects of stroke.  This situation may be analogous to the risk of 
nocturnal hypoglycaemia in insulin treated diabetes mellitus. 
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These stroke related problems may increase the risk of a patient becoming 
hypoglycaemic without any overt physical symptoms or signs. 
4.1.1 Definition of hypoglycaemia 
Hypoglycaemia is considered present when blood glucose level is below 2.8mmol/L 
(50 mg/dl). Although 3.3 or 3.9mmol/L (60 or 70 mg/dl) is commonly cited as the 
lower limit of normal glucose, different values (typically below 40, 50, 60, or 
70 mg/dL) have been defined as low for different populations, clinical purposes, or 
circumstances. A normal healthy person can occasionally have a glucose level in the 
hypoglycemic range without symptoms or disease.  
Most cases of hypoglycaemia are due to exogenous insulin administration although it 
can be seen in fasting, severe liver disease and insulinoma.  Many prescription drugs 
can cause hypoglycaemia as a side effect. 
4.1.2 Risk and consequences of hypoglycaemia 
The use of intravenous insulin puts a patient at risk of hypoglycaemia with resultant 
neurological injury and other complications.    Hypoglycaemia can quickly cause 
coma, cardiac dysrhthymia and death.  Neurological symptoms can include altered 
mental function, seizures, visual disturbance, speech disturbance, ataxia and focal 
motor deficits.  Indeed acute stroke patients should always be checked for 
hypoglycaemia before a diagnosis of stroke is made. 
A small functional magnetic resonance imaging study involving 6 patients showed a 
generally decreased level of activity in motor areas when plasma blood glucose level 
was experimentally lowered to 2.5mmol/l for approximately 40 minutes.530 
4.1.3 The use of intensive insulin regimes in other patient groups 
The vogue for the use of intensive insulin regimes in critically ill patients was kick-
started in 2001 with the publication of a study by Van den Berghe and colleagues in 
the New England Journal of Medicine.303  This study involved mechanically 
ventilated patients admitted to a surgical intensive care unit (ICU) and was performed 
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on a prospective, randomised controlled basis.  A total of 1548 patients were enrolled 
into this study before being randomly allocated to either intensive therapy (target 
blood glucose 80-110mg/dl) or conventional therapy (insulin infusion only starting if 
blood glucose exceeded 215mg/dl with a target of 180-200mg/dl). 
Van den Berghe et al found that mortality dropped from 8% in the conventional care 
group to 4.6% in the intensive insulin group (p<0.04). The paper concluded that 
intensive insulin therapy improved outcomes in a surgical intensive care unit.  This 
paper is highly cited (2553 times by 2/2/2010) and has had a visible impact on the 
medical literature and clinical practice as seen in Figure 16. 
 
Figure 16 Graphical representation of citation map for Van Den Berghe et al 2001 from 
ISI Web of Science (accessed 2/2/2010) 
More recently a meta-analysis performed by Griesdale and co-authors was published 
in 2009.531  This meta-analysis included 26 trials involving a total of 13 567 patients.  
The pooled relative risk (RR) of death with intensive insulin therapy compared with 
conventional therapy was 0.93 (95% confidence interval [CI] 0.83–1.04).  Only 14 
trials reported hypoglycaemia and among these trials the pooled RR with intensive 
insulin therapy was 6.0 (95% CI 4.5–8.0).  Different targets of intensive insulin 
therapy (glucose level ≤ 6.1 mmol/L v. ≤ 8.3 mmol/L) did not influence either 
mortality or risk of hypoglycaemia.  The paper concludes that intensive insulin 
therapy significantly increases the risk of hypoglycaemia with no overall mortality 
benefit for critically ill patients. 
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Another recent meta-analysis looked at 29 randomised control trials including 3 of the 
trials discussed later in this chapter.  A total of 8432 patients were included in these 
trials.  There was no difference in hospital mortality between tight glucose control and 
usual care (21.6% vs. 23.3%; RR, 0.93; 95% confidence interval 0.85-1.03).  Tight 
glucose control was associated with a significantly increased risk of hypoglycaemia 
(glucose < 40mg/dL; 13.7% vs. 2.5%; RR, 5.13; 95% CI 4.09-6.43).306     
A post-hoc analysis of the DIGAMI data suggested that hypoglycaemia during initial 
hospitalisation after myocardial infarction was not a risk factor for mortality or 
morbidity in patients with type II Diabetes Mellitus although hypoglycaemic episodes 
were more prevalent in patients who were at risk for other reasons.532 
In a retrospective cohort study of 2582 patients with Type II DM treated on general 
medical wards hypoglycaemia was observed in 7.7% of admissions.533  Multivariate 
analysis of this cohort suggested that each additional day on which a hypoglycaemic 
event occurred increased the odds of inpatient death by 85.3% (p=0.009) and the risk 
of death within a year by 65.8% (p=0.0003).  Inpatient death was more likely with 
lower levels of hypoglycaemia with risk of death increasing threefold for every 
10mg/dl drop in lowest blood glucose level 
In a series of papers published in Critical Care Medicine in 2006 Vriesendorp and 
colleagues looked at the consequences of and risk factors for hypoglycaemia in an 
intensive care unit.534, 535  The hypoglycaemic population of 156 studied was too small 
to clearly identify a causal link between hypoglycaemia and poor outcome although 
there were 3 cases where a causal link was likely.  Risk factors for hypoglycaemia 
were found to include continuous intravenous haemofiltration, decrease in nutrition 
without adjustment of insulin dose, diabetes mellitus, insulin use, sepsis and inotropic 
support were associated with hypoglycaemia. 
Another study attempted to identify risk factors for hypoglycaemia in 
medical/surgical intensive care unit (ICU) patients and to assess the association 
between hypoglycaemia and mortality in this group536.  In this paper hypoglycaemia 
was defined as a blood glucose level below 2.2mmol/l.  The 523 patients in the study 
had been enrolled in a randomised control trial where patients with an admission 
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blood glucose of above 6.1mmol/L and assigned to either intensive or conventional 
insulin therapy.  
Hypoglycaemia was observed in 16% of patients and was more common in the 
intensive insulin group (adjusted odds ratio, 50.65; 95% confidence interval, 17.36 –
147.78; p < 0.0001).  After adjustment for potential confounding factors 
hypoglycaemia was not significantly associated with increased mortality (adjusted 
hazard ratio, 1.31; 95% CI, 0.70 –2.46; p=0.40) although patients with an admission 
glucose of below 10mmol/L had an increased mortality with hypoglycaemia (adjusted 
hazard ratio, 4.43; 95% CI, 1.36–14.44; p =0.01).  There was also a non-significant 
trend towards increased mortality with blood glucose below 1.2mmol/L (adjusted 
hazard ratio, 2.56; 95% CI, .85–7.70; p= 0.10). 
A 2006 combined analysis by Van den Berghe and colleagues used the pooled data set 
from both the original 2001 New England Journal of Medicine paper and from a later 
2006 paper in the same journal.303, 304, 537   This combined analysis supported their 
original findings.  As these positive results are not supported by later meta-analysis 
and these randomised control trials have been staged in a single centre it is possible to 
hypothesise that the host intensive care unit may be of particularly high quality and 
may be undertaking additional procedures that are not carried out elsewhere.  All 
patients were given 200-300g of intravenous glucose from admission to ICU and 
additional nutrition (enteral or parenteral) was started as soon as possible.  
From the evidence that is currently available I do not believe that intensive insulin 
therapy should be used routinely in intensive care unit due to an uncertain clinical 
benefit and an increased risk of hypoglycaemia.  The concerns that I have over the use 
of such treatment regimes in ICU are also applicable to stroke units. 
In 2011 new guidelines were published by the American College of Physicians 
making recommendations for the use of intensive insulin therapy for the management 
of glycaemic control in hospitalized patients.538  The first recommendation was that 
intensive insulin therapy should not be used in non-surgical ICU/medical ICU patients 
with or without diabetes mellitus.  This was a strong recommendation based on 
moderate quality evidence.  The second recommendation was that intensive insulin 
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therapy should not be used to normalise blood glucose levels in surgical or medical 
ICU patients with or without diabetes mellitus.  The final recommendation was that if 
insulin therapy is used in these patients a target blood glucose level of 7.8 to 
11.1mmol/L would be appropriate. 
 
Figure 17 – The American College of Physicians guidelines on the use of intensive 
insulin therapy for glycaemic control in hospitalized patients 
4.1.4 Insulin and the insulin receptor 
Insulin is a hormone of metabolic homeostasis that is essential for human life.  Insulin 
promotes the uptake of blood glucose into liver, muscle and fat cells.  Glucose is 
stored as glycogen in the liver and the muscles.  If insulin is not present the body uses 
fat for energy and glucose levels in the blood stream rise.  In Type I diabetes mellitus 
there is a deficiency of endogenous insulin while in Type II diabetes mellitus insulin 
may be present at a normal or increased level but the target tissues are insensitive to 
insulin. 
Insulin is a small protein containing 51 amino acids and has a molecular weight of 
5808 Da.539  Insulin is a polypeptide hormone that is synthesised in the B cells of the 
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islets of Langerhans (located in the pancreas).  Initially proinsulin is produced before 
it is cleaved into mature insulin and C-peptide.  Insulin secretion is principally 
regulated by glucose although insulin release can also be stimulated by some amino 
acids and inhibited by epinephrine. 
Insulin binds to a receptor on the cell surface.  The insulin receptor is a tyrosine 
kinase receptor which phosphorylates other proteins within the cell.540  One such 
protein is the ‘insulin receptor substrate 1’ (IRS-1) protein which increases the 
number of high affinity glucose transporter (GLUT4) molecules on the outer 
membrane of insulin responsive tissues.541  GLUT4 is transported from intracellular 
vesicles to the cell surface of muscle or adipose tissue cells where it potentiates the 
uptake of glucose from the blood into these cells.542 
4.1.5 Vascular effects of insulin 
Insulin is thought to have certain vascular effects on both the vascular endothelium 
and the vascular smooth muscle cells (VSMCs).  Insulin has vasodilatory effects and 
may inhibit apoptosis of vascular endothelium.  Excess insulin may have damaging 
effects on large arteries.  Insulin may cause VSMCs to contract in the short term.  
Over longer periods of time hyperinsulinaemia may sensitise VSMCs promoting 
hypertension and atherogenesis.543 
4.1.6 Central nervous system effects of insulin 
Historically it was thought that insulin had no direct effect on the brain and only 
impacted on central nervous system (CNS) function by producing peripheral 
hypoglycaemia.  This view was challenged in 1978 when Havrankova and colleagues 
identified insulin receptors in the brain.544   
A positron emission tomography study used 18-flurodeoxyglucose to examine the 
effects of  basal insulin levels on global and regional brain glucose uptake in 8 healthy 
men.545  Endogenous insulin production was suppressed with somatostatin and 
subjects were given an insulin infusion followed by a saline infusion.  Insulin 
appeared to regulate human brain glucose uptake, most prominently in the cortical 
areas. 
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It is now thought that insulin may have CNS effects which influence both glucose and 
energy homeostasis and it has been suggested that an abnormal CNS response to 
insulin may have a key role in the relationship between Type II Diabetes Mellitus and 
obesity.546   Indeed, a link between the brain and diabetes was initially hypothesised in 
1854 when the renowned French physiologist Claude Bernard observed that diabetes 
(glucosuria) could be induced in animals by puncturing the floor of the fourth 
ventricle.227  Supporters of this idea argue that unless brain tissue is spared from the 
tissue insulin insensitivity features of Type II DM the action of insulin on the CNS 
must be abnormal.547  Figures 17 and 18 illustrate the role that the brain is thought to 
play in the regulation of blood glucose. 
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Figure 18 – The role of the brain in the regulation of glucose levels (Schwartz et al 
2005) 
 
Figure 19 - Possible role of the brain in the relationship between glucose, insulin, Type 
II diabetes and obesity (Schwartz et al 2005) 548 
As well as having a prominent role in metabolic homeostasis insulin may also have a 
role in the regulation of neuronal survival, learning and memory.549  Both Type 1 and 
Type 2 diabetes mellitus are associated with cognitive changes.  Type 2 DM is clearly 
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associated with accelerated cognitive decline although the underlying mechanism is 
unclear. In the 1999 Rotterdam study Ott and colleagues established that patients with 
DM had almost double the risk of developing dementia (relative risk [RR] 1.9 [1.3 to 
2.8]) and that patients treated with insulin were at the greatest risk (RR 4.3 [1.7 to 
10.5]).550  This increased risk with insulin treatment may reflect the severity of the 
underlying diabetes or it could be due to side effects of the insulin treatment.  A later 
systematic review supports the findings of this study although the underlying 
pathological mechanism remains unclear.551 
In a 2009 paper from the Journal of the American Medical Association, Whitmer and 
colleagues looked for an association between hypoglycaemia and increased risk of 
dementia in a population of patients with Type II Diabetes Mellitus.552  This paper 
was a longitudinal cohort study involving 16667 patients with Type II DM between 
1980 and 2007.  One episode of hypoglycaemia was associated with an increased risk 
of developing dementia (HR, 1.42; 95% CI, 1.12-1.78) while two or more episodes 
were associated with an even greater risk (HR, 2.36; 95% CI, 1.57-3.55).  Obviously 
we cannot say that hypoglycaemia causes dementia as an inability to recognise the 
warning signs of hypoglycaemia may just be an early feature of dementia. 
4.1.7 Insulin therapy in stroke patients     
Therapeutic interventions to lower blood glucose have relied upon insulin infusion, or 
subcutaneous injection  with dose adjusted according to capillary blood glucose 
monitoring, but no single regime is generally agreed upon.553 Both European and 
American guidelines recommend active intervention to lower blood glucose, but 
acknowledge inadequate evidence, and differ in their specific management advice.293, 
294
  The largest single randomised, controlled trial (RCT) of glycaemic control after 
stroke to date was the Glucose-Insulin Stroke Trial (GIST-UK), which used combined 
glucose, potassium and insulin (GKI) infusion, and was neutral.242 Other pilot studies 
using intensive insulin therapy for post-stroke hyperglycemia have been 
completed.246, 259, 283, 554 
We undertook a systematic review of the published data on insulin treatment of post-
stroke hyperglycemia. We examine the feasibility and safety of insulin treatment for 
  138 
 
PSH.  We have also combined data from the published literature to examine the effect 
of insulin on patient outcomes in PSH. 
4.2 Methods 
4.2.1 Identification of papers 
We identified relevant papers with Ovid and Embase searches with a search strategy 
as detailed in appendix 1.  Additional studies were identified from reference lists and 
conference abstracts for additional relevant studies.  We checked the Stroke Trials 
Registry for relevant ongoing trials.555  We used the ISI Web of Science citation index 
to identify papers citing studies that were already identified.   
4.2.2 Data extraction 
Data on study populations, care setting, insulin regimes, time-to-initiation of 
treatment, total insulin doses, change in blood glucose and hypoglycaemia incidence 
were extracted, together with data on mortality and functional outcome. 
4.2.3 Meta-analysis 
Meta-analysis was performed to look for the relationships between insulin exposure 
and mortality or clinical outcome. 
Data from studies with clearly defined control groups that reported at least mortality 
rates were combined. The reporting of clinical outcomes was heterogeneous so we 
defined favourable clinical outcome as modified Rankin score (mRS) 0-2 or Extended 
Glasgow Outcome Score (eGOS) favourable (moderate disability and good 
outcome).to produce a dichotomised ‘good’ clinical outcome.  
StatsDirect, version 2.7.3 (StatsDirect Ltd, Cheshire, UK) was used to generate a 
DerSimonian-Laird random effects model that expresses the difference between 
groups as an odds ratio, and 95% confidence interval.  
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4.3 Results 
4.3.1 Papers identified 
We identified 17 studies involving 2587 patients.246, 266, 273, 283, 284, 298, 299, 554, 556-561 
These included one randomised control trial (RCT) of 933 patients, 9 pilot studies 
containing between 10 and 116 patients, and 6 cohort studies, one of which included 
851 patients.  One RCT involved a mixed population of neuroscience intensive care 
unit patients with a subset of 15 stroke patients.561  One paper used the control group 
from another paper by the same group.264, 560 There were 1421 patients in RCTs and 
1038 in cohort studies 
Data from some recently completed or ongoing trials were not available for analysis 
at the time of this search.   Information on these studies (GRACE, Insulinfarct562)3 can 
be obtained at http://www.strokecenter.org/trials/ 
4.3.2 Study populations  
The study populations are described in Table 4.1.  Thirteen studies included only 
patients with acute ischaemic stroke although GIST and one other study also included 
patients with intracerebral haemorrhage.  One study included ischaemic stroke 
patients as a subgroup of neuro-intensive care patients.   Eight studies included 
patients with type II diabetes mellitus whilst excluding diabetic patients who were 
dependent on insulin.  The proportion of patients with DM varied from 0% to 91% 
whilst the lower limit of plasma blood glucose for inclusion varied between 5.6 
mmol/l and 9.4mmol/l. 
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Table 4-1 Characteristics of included studies 
Study (year) Type 
of 
study 
Setting Number 
of 
Patients 
Number 
with 
diabetes 
Glucose 
level for 
inclusion 
Target 
glucose 
range 
Mean 
onset to 
treatment 
Treatment 
duration 
(h) 
GIST
242
 (2007) RCT Ward 933 154 
(16.5) 
6 4 - 7 13.3 24 
Walters
259
 
(2006) 
RCT Ward 25 13  (52) 8 5 - 8 9.1 48 
THIS
563
 (2008)  RCT Ward 46 42  (91) 8.3 <7.2 <12 Up to 72 
GRASP
246
 
(2009) 
RCT Ward 74 44 (59) 6.1 3.8-61 
tight  
12.3 tight  
10.6 loose   
120 
MISS
298
 (2008) RCT Ward 40 13 
(32.5) 
Unclear 4.4 - 6.1 17.2 
intensive 
19.5 control 
120 
SELESTIAL
554
 
(2010) 
RCT Ward 40 12 (30) 7 4 - 7 20.8 24-72 
Vriesendorp
564
 
(2009)  
RCT Ward 33 10 (30) 6.1 Not 
specified 
13.2 basal  
13.9 meal  
120 
Scott
143
 (1999) RCT Ward 53 10 
(19.9) 
7 4 - 7 <24 24 
Staszewski
266
 
(2011) 
RCT ICU 50 0 7 4.5 - 7 <12 24 
Bruno
284
 
(2004) 
Cohort  Ward 24 21 
(87.5) 
9.4 3.9 - 7.2 Unclear Up to 72 
Kruyt
264
 
(2009) 
Cohort  Ward 10 2 (20) 6.1 4.4 - 6.1 <24 120 
Putaala
565
 
(2010) 
Cohort  Ward 851 113 
(13.3) 
8 <8 ‘with tpa’ At least 48 
Azevedo
558
 
(2009) 
Cohort  ICU 34 Unclear Unclear <7.7 Unclear Unclear 
Kim
273
 (2009) Cohort  ICU 115 47 (41) 5.6 4.4 - 7.2 <48 24 
Kanji
561
 (2009)  Cohort  ICU 15/100 0 9.1 7 - 9 Unclear At least 24 
Fukuda
557
 
(2006) 
Cohort  ICU 116 Unclear 8.3 <8.3 Unclear Unclear 
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4.3.3 Level of care 
In 5 studies patients were managed in ICU while in the remaining 11 studies patients 
were managed in stroke unit or on a ward. 
4.3.4 Description of insulin regimes 
Five studies used a Glucose-Potassium Insulin (GKI) regime while 10 used variable 
rate insulin IV infusions (Table 4.2).  One cohort study used subcutaneous insulin 
injections for glucose levels above 8mmol/L switching to an IV infusion if glucose 
was above 16mmol/L. 
All of the infusion protocols required frequent monitoring of capillary blood glucose.   
Initially CBG was checked every 1-2 hours with every insulin infusion.  In all cases 
CBG was checked at least every 2 hours.  Dose adjustments were required frequently 
for GKI regimes:  in GIST, 41.2% of patients required at least one dose change; in 
SELESTIAL, a mean of 4.8 dose changes per patient was required. RCTs using 
insulin sliding scales have not reported how regularly doses are adjusted.  
Control groups in RCTs were heterogeneous.273, 284  
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Table 4-2 Properties of insulin protocols and glycaemic outcomes 
Study Method of 
insulin 
delivery 
Definition of 
hypoglycaemia 
(mmol/L) 
Incidence of 
hypoglycaemia (%) 
Glucose 
monitoring 
(hours) 
GIST
242
 GKI <4 16 2 
Walters
556
 IVI Not stated 8 2 
3.33 - 4.44 (moderate) THIS trial
283
 IVI 
<3.33 (severe) 
35 1 
Bruno
284
 IVI <3 46 1-2 
MISS trial
298
 IVI <3.3 25 1 
SELESTIAL
554
 GKI <4 80 1-2 
3.8(basal) Vriesendorp 
564
 
IVI Not stated 
1.65 (meal) 
1-2 
Scott
143
 GKI <4 17.9 1-2 
30 tight GRASP
246
 GKI <3 
4 loose 
1-4 
Staszewski
266
 IVI <3.3 8 1-4 
Kruyt
264
 IVI <3.5 20 1-2 
Group A -10 Azevedo
558
  Not stated 
Group B – 46 
Not stated 
Kim
273
 GKI <4.4 79.1 2 
Fukuda
557
 IVI Not stated Not stated Not stated 
Kanji
561
 IVI Mild <5 2 (severe) 1-2 
Putaala
281
 SC and IVI Not stated Not stated 1 
GKI – glucose, potassium and insulin infusion, IVI – intravenous insulin infusion SC – 
subcutaneous insulin 
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4.3.5 Glycaemic outcomes 
Hypoglycaemia incidence was not reported for every study, and definitions varied. 
Three papers reported only symptomatic hyperglycaemia, while 11 studies reported 
incidence of biochemical hypoglycaemia using 7 different definitions, ranging from 
<2.2mmol/l to <5mmol/l. (Table 4.2) Symptomatic hypoglycaemia rates varied 
between 2% and 46%.  In an ITU setting symptomatic hypoglycaemia was present in 
between 2% and 9.6% of cases.  In a ward setting the rate varied from 4% to 46%. 
Biochemical hypoglycaemia was seen in between 4% and 79.1% of patients treated 
with insulin.  In GIST the hypoglycaemia rate was 16%.  . 
Different studies report variable effects of insulin on glucose level.  These differences 
could be due to many factors such as monitoring variations or protocol violations.  
Where stated the mean difference in blood glucose between insulin and control arms 
varied from 0.57mmol/L in GIST to 3.7mmol/L in THIS.  Mean daily insulin dose 
varied from 13.3 units over 24 hours to 81.6 units over 24 hours.   
4.3.6 Meta-analysis of mortality outcomes 
Only RCTs were included in the meta-analysis. Mortality data were reported in 8 
studies, and functional outcomes in eight studies, 7 of which used the modified 
Rankin Scale and one of which used the extended Glasgow Outcome Scale.  
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Insulin had a neutral effect on mortality, odds ratio 1.16 (95% CI 0.89 to 1.51, p= 
0.286, figure 19).  
Odds ratio meta-analysis plot [random effects]
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100 1000
Scott Gist Pilot 1999 0.708 (0.179, 2.774)
Staszewski 0.440 (0.007, 9.140)
GRASP 3.429 (0.247, 187.342)
Selestial 3.298 (0.112, infinity)
MISS trial 2.250 (0.273, 27.481)
THIS trial 2.627 (0.090, infinity)
Walters 3.000 (0.024, infinity)
GIST 1.139 (0.849, 1.530)
combined [random] 1.156 (0.885, 1.510)
odds ratio (95% confidence interval)
 
Figure 20 - Meta-analysis of effect of insulin treatment on mortality 
Insulin also had a neutral effect on favourable functional outcome (odds ratio for 
favourable clinical outcome 1.03 (95% CI 0.69 to 1.54, p=0.8845, figure 20).   
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Odds ratio meta-analysis plot [random effects]
0.001 0.01 0.1 0.2 0.5 1 2 5 10 100
GRASP 1.518 (0.406, 5.752)
Selestial 1.238 (0.151, 15.438)
MISS trial 1.000 (0.012, 82.578)
THIS trial 1.219 (0.299, 5.039)
GIST 0.925 (0.648, 1.320)
Staszewski 2.082 (0.561, 7.997)
Azevedo 0.094 (0.002, 0.921)
combined [random] 1.030 (0.688, 1.543)
odds ratio (95% confidence interval)
 
Figure 21 - Meta-analysis of effect of insulin treatment on clinical outcome 
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4.4 Discussion 
Hyperglycaemia is consistently associated with poor outcomes after stroke, and active 
intervention to lower blood glucose is recommended by all major international 
guidelines on stroke care, although with poor grades of evidence supporting these 
recommendations.146 The small number of patients included in RCTs may reflect in 
part the inclusion of protocols for glucose monitoring and intervention in routine 
stroke unit care, but also may relate to the considerable workload involved in 
delivering intensive insulin protocols, which is itself a consequence of the potential 
risks of hypoglycaemia.566 The only RCT designed to have sufficient size to reliably 
detect even a large effect of intervention on clinical outcomes, the UK Glucose-
Insulin Stroke Trial (GIST), recruited only around one third of the planned sample 
size, in addition to achieving only very minor reductions in glucose concentration in 
the active treatment arm compared to the control arm.242 All other RCTs were small, 
predominantly single centre studies, and were intended as pilot trials only. There was 
marked heterogeneity of target populations, treatment regimes (insulin delivery 
method, target glucose concentration, duration, and monitoring frequency) and 
outcome reporting. Systematic review of the available data should therefore be 
interpreted with caution, but highlights a number of issues that will require to be 
addressed by planned trials. 
4.4.1 Safety and feasibility 
Effects of insulin on both mortality and functional recovery were neutral, but with 
confidence intervals that include the possibilities both of significant benefit and 
significant harm. This is consistent with the absence of any clear effect on outcome in 
a non-randomised cohort of acute thrombolysis patients in whom the majority of 
hyperglycaemic patients were treated with insulin.281  
However, the wider context of trials investigating intensive insulin regimes for 
glycaemic control is important to consider. Meta-analysis of  intensive insulin therapy 
in critically ill patients suggests that there is no overall mortality benefit and an 
increased risk of hypoglycaemia.531 All insulin regimes are labour intensive and 
require close monitoring of patients. Even within intensive care or stroke unit 
environments, and as part of an RCT, the incidence of biochemical hypoglycaemia in 
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stroke patients was reported to be between 4% and 79.1%. In the large meta-analysis 
published by Weiner and colleagues examining the risks of tight glucose control in 
critically ill adults there was a significantly increased risk of hypoglycaemia (glucose 
<2.2mmol/L, 13.7% vs. 2.5%, RR 5.13, 95% CI 4.09 to 6.43).306 Since 
hypoglycaemia may itself exacerbate brain injury, this is a potentially serious side 
effect. The potential harm from biochemical (as opposed to symptomatic) 
hypoglycaemia needs also to be considered.173  In the GIST-UK trial, patients who 
had a decrease in plasma glucose of 2mmol/L or more in the first 24 hours were more 
likely to die than those who had a decrease of less than 2mmol/L (34% vs. 22%; OR 
1.15 (0.86-1.51); p=0.009). Other insulin regimes have achieved greater reductions in 
glucose, for example by a mean of 3.7mmol/L in the THIS trial, but at the penalty of 
an incidence of biochemical hypoglycaemia of 35%.  This was not prevented by 
hourly monitoring  and symptomatic hypoglycaemia was only reported in 13% of 
cases. 
It may be possible in future to improve safety by the use of real-time continuous 
glucose monitoring, but this is expensive and not widely available.214 Computerised 
protocols have also been developed and may be used to improve the safety of insulin 
infusions in the future.567 
4.4.2 Efficacy of regimes  
Stroke trials to date have arguably largely failed to achieve their main biochemical 
goals, and therefore may differ from trials in other therapeutic areas, which have 
either targeted patients with higher blood glucose concentrations, or have more 
aggressively maintained blood glucose within a narrow range, or both.300, 301, 303 The 
populations involved in stroke trials have generally had only mild hyperglycaemia at 
the time of trial entry, and in addition have documented significant decrease in blood 
glucose over time in control groups, probably as a consequence of lack of oral intake 
and avoidance of intravenous fluids containing sugars. These factors have ensured 
that in most trials there was only a small difference in glycaemic control between 
intervention and control arms. In GIST-UK the mean glucose concentration at entry 
was 8.43mmol/L, and the mean difference in glucose concentration between GKI-
treated patients and controls after 24 hours of treatment was only 0.57mmol/L.242  
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The timing of initiation of insulin may be important, but is difficult to define from 
existing literature. Arguments that favour very early intervention are supported by 
observational data from thrombolysis trials and registries, that indicate a poorer 
outcome when hyperglycaemia precedes IV thrombolysis,178, 568 possibly due to 
accelerated ischaemic damage by hyperglycaemia if present before blood vessel 
recanalization post-thrombolysis.197, 198 Exacerbation of infarct growth by 
hyperglycaemia also supports the relevance of an early influence on the evolution of 
ischaemic damage.569  In addition, any neuroprotective effect of insulin would be 
expected to be of greatest benefit if commenced early. Arguably, therefore, a mean 
time to start insulin of at least 9.1 hours after stroke onset in the reviewed trials may 
have missed the potential therapeutic window. Since the majority of the trials 
included here were intended only as pilot studies with biomarkers such as glycaemic 
control as the primary end-point, conclusions regarding effects on clinical end-points 
must be regarded with caution. On the other hand, the detrimental effect of 
hyperglycaemia appears to include patients in whom glucose is increased at any time 
within a much longer period, up to 48h after onset of ischaemia with sustained, rather 
than isolated hyperglycaemia, and later time points, being of much greater prognostic 
relevance than “admission” hyperglycaemia.160, 161, 267, 281 If later intervention is 
undertaken, as may be justified in light of these data, then an additional factor to 
consider is the very high proportion of patients in whom isolated (>80%) or sustained 
(>50%) hyperglycaemia is evident. 
The mechanism by which hyperglycemia exacerbates ischaemic brain damage 
remains unclear. A correlation of ischaemic lesion growth and infarct core lactate 
concentration on MRI supports the hypothesis that exacerbation of lactate 
accumulation due to anaerobic glycolysis in the face of hyperglycaemia is a specific 
mechanism for the harmful effects.176 However, reduced lactate accumulation with 
GKI infusion was not associated with attenuation of infarct growth in the 
SELESTIAL trial,554 and there is doubt regarding the role of lactic acidosis, since 
lactate may have neuroprotectant properties332 and under certain circumstances may 
be the preferred energy substrate for the brain.323  Acidosis in the presence of 
hyperglycemia and not lactate per se may be responsible for the aggravated cerebral 
ischaemia seen with hyperglycemia.331 
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4.4.3 Time of starting insulin 
 
The timing of starting the insulin infusion may be important.  If insulin does have a 
neuroprotective role in acute ischaemic stroke it would be logical to predict that the 
greatest benefit would be gained if insulin was administered in the hyperacute phase 
at the same time as tPA.  While penumbra may persist up to 12 hours after onset of 
ischaemia the size of penumbra will diminish with time reducing any potential 
neuroprotective benefit from insulin. 
The mean time to start insulin was at best 9.1 hours after stroke onset.  There is a need 
for further trials looking at the administration of insulin in hyperglycaemic patients 
who are due to receive thrombolytic therapy.  Hyperglycemia during ischaemia 
rapidly accelerates brain damage in stroke patients treated with tPA.197  In the 
hyperacute setting a small bolus of insulin before tPA administration may have a 
protective benefit and further clinical trials involving insulin boluses instead of 
infusions may be useful. 
4.4.4 Alternative approaches to the treatment of post stroke 
hyperglycemia 
These data raise further questions about potential treatments for post-stroke 
hyperglycaemia. 
4.4.5 Should we be using insulin for post stroke hyperglycemia? 
As I have already discussed in my chapter on animal models of post stroke 
hyperglycemia I do not believe that there is good animal evidence on the relationship 
between hyperglycemia and infarct growth.  There is certainly not satisfactory animal 
evidence on the use of insulin after stroke.  I believe that some further basic scientific 
work is really required before we expose more patients to the potential risks of 
hypoglycaemia from insulin therapy.  The current evidence from clinical trials in 
stroke suggests that there is a clear danger of hypoglycaemia in these patients without 
any evidence of benefit.  Indeed in GIST there appeared to be more benefit from a 
saline infusion than from an insulin infusion.  The evidence from clinical trials of 
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intensive insulin therapy in other clinical areas certainly does not support routine use 
of such protocols. 
4.4.6 Glucagon-like peptide analogues 
The future for the management of post-stroke hyperglycaemia may lie in glucagons-
like peptide analogues and agonists such as liraglutide.  GLP agonists work by 
binding to a membrane GLP receptor increasing insulin release from pancreatic beta 
cells. 
GLP-1 analogues have been given in an infusion to fasted, healthy subjects for 48 
hours with no apparent increased risk of hypoglycaemic episodes.570  This industry 
funded study involved 8 healthy subjects and was a randomised, double-blind 
placebo-controlled crossover study.  Two hypoglycaemic episodes were seen during 
GLP-1 infusion and 1 hypoglycaemic episode was seen during placebo infusion.  
Hypoglycaemia was defined as plasma glucose less than or equal to 2.8nM with 
neuroglycopaenic symptoms.  After the infusion of the study drug a 3 hour oral 
glucose tolerance test was carried out to identify possible reactive hypoglycaemia on 
re-feeding.   
In another pilot study with a prospective open randomised crossover design 8 
clinically stable subjects with type II DM were given insulin infusions and GLP-1 
regimes to normalize blood glucose after breakfast.571  GLP-1 was found to achieve 
normoglycaemia more rapidly than insulin.  GLP-1 also produces lower maximum 
glucose levels and lower glucose levels at 2 hours and 4 hours.  One symptomatic 
episode of hypoglycaemia occurred in the insulin group and no symptomatic 
hypoglycaemia was observed in the GLP-1 group. 
4.4.7 Insulin or GLP-1 analogue bolus before tPA 
Another therapeutic option may be to give a small bolus dose of insulin before 
initiation of tPA therapy in patients who are clearly hyperglycaemia (i.e. blood 
glucose >10mmol/l).  In such cases only a very small dose of insulin may be 
necessary and hopefully the risk of hypoglycaemia associated with insulin infusion 
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would be reduced.    It may even be more sensible to try a bolus of a GLP-1 analogue 
in the acute situation to further reduce the potential risk of hypoglycaemia. 
4.5 Conclusions 
Despite the consistent association of hyperglycaemia in the 48h after stroke with 
higher risk of death or dependence, there is no evidence that insulin treatment is 
associated with reduced mortality or favourable functional outcome in randomised 
controlled trials to date, although the majority of RCTs have not been designed as 
efficacy trials, recruited only small numbers of subjects, and the confidence intervals 
for clinical endpoints include the possibility of both significant benefit and significant 
harm. All insulin regimes tested to date in stroke have been labour-intensive, 
requiring frequent monitoring and dose adjustment. Fluid volumes infused are large 
when insulin and dextrose are used in combination regimes such as glucose-
potassium-insulin infusion. Differences in blood glucose have been small in most 
trials and the risk of biochemical hypoglycaemia moderately high. There is wide 
variation in treatment threshold, target, and duration, and in reporting standards for 
hypoglycaemia.  Large differences in blood glucose have been achieved only in very 
small numbers of patient
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5 The prognostic outcome of stroke based on 
blood glucose measurement 
5.1 Introduction 
While it is known that post stroke hyperglycemia is common and linked with poor clinical 
outcomes there are still many uncertainties.146, 147  It is not known if there is a clear cut-off 
level at which blood glucose becomes pathogenic and we do not know the best way to 
measure blood glucose level to accurately predict prognosis. 
Depending on definition, between 50 and 80% of patients may be classified as 
hyperglycaemic.146  Different methods of measuring glucose have been used although it is 
unclear which method is most practical and prognostically accurate.214   
Historically interest has focused on the admission blood glucose level although blood 
glucose is a constantly changing physiological parameter and can change markedly in a 
short period of time.160  The definition of ‘admission’ is vague and can represent an 
uncertain period of time.  Admission can mean the time at which a patient arrives in the 
hospital emergency department or it can mean the time at which a patient arrives in an 
Acute Stroke Unit.  Indeed, sustained hyperglycemia predicts infarct expansion and 
hyperglycemia within 48h is more prognostically important than single measures 
Post-stroke hyperglycemia (PSH) predicts poor outcome from stroke, but there is no 
agreed definition of PSH. Hyperglycemia is an independent predictor of lesion growth and 
poor functional outcome, although intervention to reduce glucose levels does not appear to 
affect lesion growth.176, 336   
The GLIAS study suggested that a blood glucose of  >155 mg/dL (>8.6mmol/L) at any 
time within the first 48 hours from stroke onset, and not the isolated value of admission 
glycaemia is associated with poor outcome independently of stroke severity, infarct 
volume, diabetes, or age.161 
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5.1.1 The definition of post-stroke hyperglycemia 
There is no clear, formally agreed definition of post-stroke hyperglycemia.  In acute stroke 
research there is some variation in definition of hyperglycemia.  Blood glucose values 
ranging from 6mmol/L to 11mmol/L have been used to define hyperglycemia. .242, 243, 246, 
285
  I have discussed this in my introductory chapter and I have tabulated 99 studies that 
demonstrate the range of glucose values that have been used to define PSH (see Table 1.1 
in Chapter 1).   
The American Diabetes Association defines diabetes by a fasting plasma glucose level of 
greater than 7mmol/L.  The guidelines also suggest that this value should be used in 
epidemiological studies.572  
Epidemiological studies looking at the prevalence of admission hyperglycemia in acute 
stroke patients cannot guarantee that all patients are fasting and many may present 
immediately after eating, increasing blood glucose to postprandial levels.  One may 
conclude that admission blood glucose above 7mmol/L is not automatically diagnostic of a 
dysglycaemic state.  Pragmatically a cut off value of 7mM based on the ADA guidelines 
may be sensible to use in studies while acknowledging that various uncontrollable factors 
will affect admission glucose level. 
5.1.2 Continuous blood glucose measurement 
One observational study from Australia looked at the influence of hyperglycemia on infarct 
growth.160  In this study 25 patients underwent MRI scanning within 24 hours of stroke 
onset (median imaging time – 15 hours).  Follow-up MRI examinations were carried out at 
approximately 5 and 85 days.  Using a continuous glucose monitoring system (CGMS) 
plasma glucose was monitored every 5 minutes for 72 hours.  Additional capillary blood 
glucose was monitored every 4 hours. 
Baird and colleagues were able to ascertain that the mean glucose produced by the CGMS 
and the mean capillary blood glucose correlated with infarct volume change on acute and 
sub-acute diffusion weighted MRI. Multiple regression analysis was performed for change 
in infarct volume as a continuous variable.  Mean capillary glucose and mean CGMS 
levels above 7mmol/L were found to be independent variables that appear to influence 
infarct growth.  Other variables included in the model were NIHSS score dichotomised at 
13, prior glycaemic control represented by dichotomised HbA1C, treatment with rt-PA and 
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time to initial imaging.  The relationship between mean glucose level and infarct growth 
appeared to be independent of these other variables.160   
While this study is small it does provide some possible pathophysiological evidence to 
support the hypothesis that persistent hyperglycemia is associated with greater infarct 
growth. 
A later paper by the same group attempted to more clearly define the temporal profile of 
hyperglycemia after stroke.214  A total of 59 patients were monitored with the continuous 
glucose monitoring system for 72 hours.  Monitoring began between 5 and 44 hours after 
stroke onset and continued for a median of 69 hours. 
This paper found that at 8 hours after stroke onset 100% of 21 patients with known 
diabetes and 50% of 38 patients without known diabetes had blood glucose levels above 
7mmol/l.  Presence of diabetes was defined by a clear history or use of anti-diabetic 
medication.  After an early phase of hyperglycemia glucose levels dropped in most patients 
by 14-16 hours by which point only 11% of non-diabetic and 27% of diabetic patients were 
hyperglycemic.  There was a further late phase of hyperglycemia at between 48 and 88 
hours after stroke onset that was observed in 27% of non-diabetic and 78% of diabetic 
patients.  I have reproduced a figure from this paper below (Figure 21).   It was also noted 
that 34% of the non-diabetic patients and 86% of the diabetic patients were 
hyperglycaemic for at least a quarter of the monitoring period. 
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Figure 22 - Temporal profile of glucose levels after stroke (from Allport et al) 
5.1.3 The GLIAS approach 
The Glycemia in Acute Stroke study (GLIAS) organised by the Spanish Society of 
Neurology investigated the prognostic value of capillary blood glucose levels in acute 
stroke patients.161  A total of 476 patients were recruited into the study within 24 hours of 
stroke onset.  The median time between stroke onset and emergency department arrival 
was 5 hours.  Capillary blood glucose was checked on admission and 3 times per day over 
the initial 48 hours.   
The GLIAS study aimed to find the glucose threshold value that had the highest predictive 
power for a poor outcome.  Receiver operating characteristic curves were determined to 
show the predictive value of maximum capillary glucose values during the first 48 hours.  
The area under the curve was 0.656 (95% confidence interval 0.592 to 0.720, p<0.01) and 
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a glucose value of 155 mg/dl (8.6mmol/l) was identified as the optimum cut-off level for 
poor outcome at 3 months.  This level was associated with a hazard ratio of 2.7 (95% CI 
1.42-5.24) for poor outcome after adjustment for factors such as age, diabetes, admission 
blood glucose level, infarct volume and baseline stroke severity.  There was also a hazard 
ratio of 3.8 (95% CI 1.79-8.1) for death at 3 months. 
5.1.4 Which blood glucose level best predicts outcome in stroke 
thrombolysis patients? 
The Australian studies make mechanistic sense. It may be more plausible that a sustained 
high average blood glucose level would affect patient outcomes more profoundly than a 
single high reading.  While the GLIAS study does report that patients with diabetes have a 
higher mean glucose level over 48 hours and while it is mentioned that diabetes does not 
correlate with poor outcome there is no explicit analysis of the relationship between mean 
glucose level and outcome. 
Neither of these studies focused on patients undergoing IV thrombolysis.  The proportion 
of patients treated with thrombolysis was not stated in the GLIAS study while in the 2003 
paper by Baird and colleagues only 16% received IV rt-PA.160, 161 Elevated blood glucose 
pre-thrombolysis has been identified as a predictor of poor outcomes including outcome at 
24 hours,181 mortality,183 functional outcomes179 and symptomatic intracranial 
haemorrhage.178, 182   
We therefore undertook an analysis of the relationship between glucose profiles and 
clinical outcome in a population receiving IV thrombolysis for acute ischaemic stroke, 
specifically exploring alternative indices of glycaemic state to compare the optimal 
predictive index for functional outcome as measured by the modified Rankin scale. 
5.2 Methods 
Patients treated with r-tPA, between May 2003 and November 2008, were identified from 
our local Safe Implementation of Thrombolysis in Stroke (SITS) database.14-16 Capillary 
blood glucose is checked as part of routine clinical care every 4 hours in our unit.  Case 
notes were obtained where possible and glucose profile data were extracted.  Additional 
glycaemic indices (diabetic state, insulin treatment, HbA1C level were noted where 
available.   
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Capillary blood glucose (CBG) was measured 4 hourly for 48h in acute patients. We 
reviewed all patients with complete 48h CBG records who received IV rt-PA and 
compared the relative risk (RR) of unfavourable 3 month modified Rankin score (mRS)>1 
using admission blood glucose (ABG), weighted mean 48h CBG (MCBG), and 
hyperglycemia defined as two or more elevated CBG (THBG) readings. Hyperglycemia 
was defined as glucose >126mg/dl (7mmol/L). Additionally patients with a single blood 
glucose level of above 8.6mmol/L were identified. 
Patient outcome was recorded with a 3 month modified Rankin score. Data on patient age, 
pre-treatment National Institutes of Health Stroke Scale (NIHSS) score and onset to 
treatment time were also extracted from the database.   
Rankin scores were dichotomised to show favourable outcome (mRS<2) and poor outcome 
(mR≥2).   
5.2.1 Statistical analysis 
Statistical analysis was performed using SPSS 15 (SPSS Inc, Chicago, USA) and 
STATSDIRECT (StatsDirect Ltd, Cheshire, UK) software.  Fisher’s exact test was used to 
compare proportions in 2 by 2 tabulated data. Binary logistic regression analysis was 
carried out using SPSS. 
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5.3 Results 
 
Figure 23 - Population profile for SITS database glucose profile study 
Data from 69 patients were analysed.  In this group 9 patients (13%) had a diagnosis of 
diabetes while 12 patients (17%) were treated with some form of insulin infusion.  
Glycosylated haemoglobin (HbA1c) was checked in 11 patients.  In these 11 patients the 
mean HbA1c was 7.3 (range 5.9-12.3).  Outcome data in the form of a 3 month modified 
Rankin score (mRS) were available for 67 patients. 
319 patients 
treated 
69 glucose 
profiles 
250 patients no glucose 
profile available 
67 patients had 3 month 
Rankin data 
12 mRs 0-1 37 mRs 2-5 18 mRs 6 
2 patients missing 
follow-up data 
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Table 5-1 Population characteristics for patients included in study 
Male  35 (50.7%) 
Mean Age   68 (66-70) 
Known DM  9 (13%) 
Median NIHSS (IQR)  14 (7-19) 
tPA treatment <3h  50 (72.5%) 
Median time to t-PA treatment (minutes) 170 (165-175) 
Smoking History 18 (26.1%) 
Known AF 20 (29%) 
Hypertension 41 (59.4%) 
Known cardiac failure 2 (2.9%) 
Previous stroke 12 (17.4%) 
 
The relative risk of mRS>1 was greatest with MCBG (RR 4.04, 95% CI 1.46-14.46, p = 
0.0013) compared to ABG (RR 3.49, 1.25-12.57, p = 0.0092) or THBG (RR 0.93, CI 0.64-
1.63, p=0.753).  Using the GLIAS value of 8.6mmol/L the RR was 0.97, CI 0.77-1.26, 
p=0.811.  
Relative risk of death was also greatest with MCBG (RR 2.72, 1.35-5.35, p=0.0053) 
compared to either ABG (RR 1.68, 0.77-3.59, p=0.19) or THBG (RR 1.54, 0.67-3.85, 
p=0.33). Using the GLIAS value of 8.6mmol/L the RR was 1.27, CI 0.58-2.88, p=0.557). 
  160 
 
Outcome data for each of the glucose measurement groups is graphically represented in 
Figures 5.2-5.4. 
5.4 Conclusion 
In a stroke thrombolysis population, relative risk of both unfavourable functional outcome 
and death was greatest for mean capillary blood glucose over 48h compared to either 
admission blood glucose or two elevated blood glucose readings. 
If outcome from stroke is dependent on amount of glucose exposure it seems logical that a 
mean glucose value should have more prognostic significance than an arbitrary isolated 
glucose value.  Certainly the mean capillary glucose value appears to have a greater 
positive predictive value than an isolated admission glucose, two glucose values above 7 or 
the presence of one glucose reading of greater than of equal to 8.6mmol/L, the cut-off 
point identified by the GLIAS study.161 The results presented here are not definitive.  This 
is a small study population so it is difficult to adjust for other known prognostic factors that 
could confound the outcomes. 
We still do not know if a causal relationship exists between PSH and outcome for stroke.  
PSH is certainly associated with a poor outcome but there is no reliable evidence that any 
clinical intervention to alter glycaemic state improves outcome.6, 10, 242, 283, 573  
Ours study suggests that reliance on single admission blood glucose readings to risk 
stratify patients in randomised controls trials of insulin may be ill advised.  Our small study 
suggested that a mean 48 hour blood glucose value may help risk stratify although we are 
left with a therapeutic black hole.  The relationship between mean capillary blood glucose, 
admission blood glucose and outcomes is further explored in Chapters 6 to 9. 
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6 Demographics and clinical outcomes for stroke 
patients recruited to the post-stroke 
hyperglycaemia and brain arterial patency study 
(POSH study) 
6.1 Introduction 
Post-stroke hyperglycaemia (PSH) is consistently associated with poorer outcome in terms of 
survival, disability and markers of brain injury such as infarct expansion. 
Even modest post-stroke hyperglycaemia (PSH) is associated with a three-fold increase in 
odds of death at 30 days in non-diabetic patients.146 However, in most previous studies, 
blood glucose (often single measurements) has been evaluated more than 12 hours after 
stroke onset, and sometimes as late as 72h after onset. Several studies have suggested that 
the adverse prognostic impact of PSH may simply reflect an association with stroke 
severity.218, 219  
Continuous monitoring of tissue glucose concentration using a subcutaneous probe has 
shown that the profile of glucose over the first 48h after stroke is a better predictor of 
infarct expansion than point measurements.160  
In analysis of routine observational data from a more intensive glucose monitoring regime 
commenced predominantly <6h after stroke onset 78% of patients develop PSH within 48h 
of stroke. For those with complete data commencing within 6h of onset, 100% of diabetics 
and 75% of non-diabetics developed hyperglycaemia within the first 48h after stroke.521 
Further, pre-stroke glycaemic status (defined by glycosylated haemoglobin concentration 
[HbA1c]), and not stroke severity, predicted PSH within the first 6 hours, whereas PSH 6-
48h after onset showed trends towards an association with stroke severity. At later time-
points, complex interactions between stroke severity, blood glucose and feeding 
emerged.521  
The detrimental effects of PSH may be restricted to specific groups of patients, defined by 
pathophysiological processes, and that intervention to lower glucose may therefore be 
unnecessary (and might indeed be harmful) in patients who do not share these features.528   
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Firstly, only patients with metabolically compromised brain tissue (an ischaemic 
penumbra) on MRI were susceptible to infarct expansion with PSH.160, 176 The likelihood of 
a penumbra being present declines over the first few hours after stroke onset, and clinical 
outcome correlates strongly with the volume of penumbral tissue that is salvaged through 
spontaneous or therapeutic reperfusion.  
Secondly, PSH was associated with poorer outcome after IV alteplase only in patients with 
early arterial recanalization (<3h after treatment)271 this might explain the association of PSH 
with poorer outcome after IV thrombolysis overall.179 Both these sets of data support a more 
specific mechanism by which PSH may adversely influence the probability of survival of the 
ischaemic penumbra in patients within the first few hours after stroke.  
Animal model evidence of the adverse impact of hyperglycaemia on infarct volume 
evolution may have limited relevance to the clinical presentation due to very high glucose 
concentrations and models representing type I diabetes predominantly (Chapter 3). In 
addition, evidence for the efficacy of insulin in preventing  this adverse influence is 
inconclusive.206 A recent clinical trial of insulin treatment for PSH reported divergent effects 
of treatment dependent on arterial patency, being associated with greater infarct expansion in 
patients with persistent occlusion, but less expansion than placebo in those with 
recanalization.554 It appears therefore that early and late PSH may differ in their causes and 
pathophysiological significance, and that individual brain tissue vulnerability and vessel 
status further influence the effects of PSH 
In the post stroke hyperglycaemia and brain arterial patency study (POSH) we aimed to 
investigate the relationship between post-stroke hyperglycaemia, infarct growth and brain 
arterial patency.  The main results of this study are presented and discussed over the next few 
chapters.  In this chapter I have presented the baseline demographics and clinical outcomes 
for the entire population of stroke patients recruited into the study.  Later chapters 
concentrate on smaller subgroups of patients based on the availability and quality of the 
study imaging or on imaging findings. 
6.2 Methods 
The general methods for the POSH study are detailed in chapter 2.  Patients were recruited 
prospectively as they were admitted to the Acute Stroke Unit in the Institute of 
Neurological Sciences at the Southern General Hospital in Glasgow. 
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6.2.1 Image analysis 
The imaging for each patient was reviewed by two researchers (NM and XH). Clinically 
relevant data were additionally reported by experienced neuroradiologists. Discrepancies in 
imaging interpretation were adjudicated by an experienced stroke neurologist (KM). 
6.2.2 Statistical analysis 
Differences between groups were analysed using ANOVA for scale variables and 
Pearson’s chi squared for categorical variables.  If a significant difference between groups 
was discovered using ANOVA it was further analysed using the least significant difference 
method. 
Binary logistic regression analysis was also carried out using SPSS to seek predictors of 
mortality. Univariate analysis included age, admission blood glucose, mean capillary blood 
glucose, atrial fibrillation, HbA1c, NIHSS score, systolic and diastolic blood pressure and 
thrombolytic treatment as a binary variable. All variables with p<0.1 in univariate analysis 
were entered into a forward stepwise conditional model. Findings were confirmed in a 
backwards stepping model beginning with all potentially predictive variables 
Additionally we used SAS version 9.3 to perform a Rankin shift analysis using Cochran-
Mantel-Haenzel statistics to look for a relationship between glycaemic status and outcome 
while correcting for admission variables (NIHSS, age).574 
6.3 Results 
Between January 1st 2009 and December 31st 2011 the acute stroke unit admitted 2128 
patients.   
The study recruited 113 patients between the 1st of January 2009 and the 31st of December 
2011.  From this group 108 had a clinical diagnosis of ischaemic stroke.  The baseline 
demographics for this group are included in Table 6.1 below. 
Serial capillary blood glucose concentrations were used to define 3 subgroups: admission 
hyperglycaemia (blood glucose >7mmol/l within 6h of stroke onset), delayed 
hyperglycaemia (blood glucose >7mmol/l 6-48h after stroke onset), and normoglycaemia.  
A recruitment flowchart in Figure 24 illustrates the different groups of patients. 
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Figure 24 - Recruitment flowchart for patients in the POSH study 
One subgroup contained 17 patients who were normoglycaemic during their admission, 
with blood glucose levels consistently below 7mmol/L. The 59 patients in the second 
subgroup were hyperglycaemic on admission with a blood glucose level of 7mmol/L or 
greater within 6 hours of stroke onset.  The final subgroup of 32 patients became 
hyperglycaemic later during admission with a blood glucose level of 7mmol/L or greater 6 
or more hours after stroke onset. 
2128 
Admissions 
212 Non-Stroke 
93 Haemorrhagic Stroke 
11 Unstable 
10 Renal Failure 
3 Pregnant 
4 Unable to consent 
3 CADASIL 
4 Lung Cancer 
2 Acute Myocardial Infarction 
113 
Consented 
5 non-strokes excluded 
4 Migraine 
1 Peripheral Nerve Palsy 
108 patients with clinical 
diagnosis of stroke 
17 Euglycaemic 
at all times 
59 Admission 
Hyperglycaemia 
32 late 
Hyperglycaemia 
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Table 6-1 Baseline demographics and clinical outcomes of stroke patients recruited into the 
POSH study 
Hyperglycaemia Group (n) All 
patients 
(108) 
None (17) Admission 
(59) 
Late (32) 
 
Male Gender (n/%) 66 (61.1) 10 (59) 34 (57) 22 (69)  
Age  ± SD (mean/years) 69.7 ± 
11.5 
62 ± 14.3 * 
*** 
70.5 ± 10.5 * 72 ± 10.4  
*** 
p=0.009 
Admission blood glucose ± SD 
(Mean mmol/L) 
7.42 ± 
3.28 
5.82 ± 0.6 * 8.66 ± 3.92 * 
** 
6.03 ± 1.48 
** 
p<0.001 
Mean capillary blood glucose ± 
SD (Mean, mmol/L) 
6.73 ± 1.6 5.4 ± 0.59* 7.41 ± 1.64* 
** 
6.17 ± 1.27 
** 
p<0.001 
HbA1c ± SD (Mean) 5.9 ± 1.1 5.4 ± 0.5 * 6.19 ± 1.3 * 5.72 ± 0.7 p=0.016 
Pre-morbid Rankin (Median/IQR) 0 (0-0) 0  (0-0) 0 (0-1) 0 (0-0)  
Admission NIHSS (Median/IQR) 9 (5-18) 11 (4-17) 10 (6-19) 8 (5-16) p=0.701 
Admission Blood pressure ± SD 
(mmHg) 
150/78 ± 
23/15 
152/78 ± 
21/12 
147/77 ± 
25/18 
154/79 ±  
21/10 
p=0.442 
Smoking history (n/%)   50 (55.6) 10 (58.8) 32 (54.2) 18 (56.3) p=0.941 
Previous stroke (n/%) 27 (25) 3 (17.6) 14 (23.7) 10 (31.3) p=0.547 
Previous TIA (n/%) 24 (22.2) 2 (11.8) 12(20.3) 10 (31.3) p=0.258 
Atrial Fibrillation (n/%) 28 (25.8) 4 (23.5) 16 (27.1) 8 (25) p=0.947 
Hyperlipidaemia (n/%) 53 (49.1) 7 (41.2) 32 (54.2) 14 (43.8) p=0.492 
Diabetes (n/%) 20 (18.5) 0 18 (30.5) 2 (6.3) p=0.002 
Impaired glucose tolerance (n/%) 20 (18.5) 0 17 (28.8) 3 (9.4) p=0.007 
Peripheral vascular disease (n/%) 11 (10.2) 1 (5.9) 7(11.9) 3 (9.4) p=0.76 
Hypertension (n/%) 53 (49.1) 4 (23.5) 34 (57.6) 15 (46.9) p=0.044
Stroke on imaging (n/%) 93 (86.1) 13 (76.4) 54 (91.5) 26 (81.3) p=0.182 
Occlusion (n/%) 71 (65.7) 10 (58.8) 41 (69.5) 20 (62.5) p=0.644 
Recanalization (n/%) 39/67 4/10(40) 24/41 (58.5) 11/20 (55) p=0.4 
Thrombolytic treatment (n/%) 76 (70) 10 (58.8) 44 (74.6) 22 (69) p=0.44 
Rankin 0-1 Day 30 (n/%) 17(15.7) 5 (29.4) 8 (13.6) 4(12.5) 
Rankin 2-5 Day 30 (n/%) 79 (73.1) 11 (64.7) 43 (72.9) 25 (78.1) 
Rankin 6 Day 30 (n/%) 12 (11) 1(6) 8(14) 3(9) 
p=0.48 
Supra-aortic large artery 
atherosclerosis (n/%) 
31(28.7) 4 (23.5) 18 (30.5) 9 (28.1) 
Cardio-aortic embolism (n/%) 27 (25) 4 (23.5) 16 (27.1) 7 (21.8) 
Small artery occlusion (n/%) 9 (8.3) 2 (11.8) 4 (6.8) 3 (9.4) 
Other causes (n/%) 5 (4.6) 2 (11.8) 3 (5.1) 0 
Undetermined causes (n/%) 36 (33.3) 5 (29.4) 18 (30.5) 13 (40.6) 
 
 
 p=0.754 
Using LSD analysis there was a significant difference between the following groups - *AHG vs. EG, 
** AHG vs. LHG, *** EG vs. LHG.  
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6.3.1 Differences in baseline characteristics 
There were significant differences in age between the 3 groups.  Euglycaemic patients 
were younger than those with admission hyperglycemia or later development of 
hyperglycemia (p=0.009).  There was also an expected significant difference in admission 
blood glucose level (p<0.001) and mean capillary blood glucose (p<0.001).  Baseline 
HbA1c level was also significantly different between the 3 groups (p=0.016).  On post hoc 
analysis a significant difference in HbA1c was seen between the euglycaemic and 
admission hyperglycaemia groups (p=0.009). 
 
Figure 25 Scatter plot of mean glucose level against age 
While there was a significant difference between age and mean glucose across glycaemic 
groups there was no statistical evidence of a correlation between these two variables using 
Pearson’s correlation coefficient (p=0.233).  Similarly age did not correlate with HbA1c 
(p=0.848) or admission blood glucose (p=0.835) although there was a correlation between 
age and systolic blood pressure (p=0.041).  
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Diabetes strongly predicted admission hyperglycaemia in binary logistic regression 
(p=0.003, OR 10.3, 95% CI 2.26 to 47.2) as did HbA1c (p=0.013, OR 2.1, 95% CI 1.16 to 
3.64).  Admission hyperglycaemia was not predicted by admission blood pressure although 
binary logistic regression for the absence of a history of hypertension gave an odds ratio of 
0.47 with p=0.053 (95% CI 0.22 to 1.01).  
Significant differences were also seen between glycaemic groups for past history of 
diabetes mellitus (p=0.002) and impaired glucose tolerance (p=0.007). 
 
Figure 26 - Admission NIHSS in different glycaemic groups 
There was no significant difference in median admission NIHSS between glycaemic 
groups (p=0.701) although there was a trend to lower NIHSS scores in the late 
hyperglycaemia group.  This is illustrated in Figure 26. 
6.3.2 Glucose Profiles 
Detailed glucose profiles were collected for all the patients included in the study.  The 
median number of glucose readings per patient was 12.   The mean time to initial blood 
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glucose measurement was 1 hour and 25 minutes from stroke onset (standard deviation 
1:02) and the maximum time to initial measurement was 4 hours and 45 minutes. 
The glucose kinetics of the three glycaemic groups are illustrated in Figure 27.  The mean 
glucose level of the euglycaemic group is consistently less than 6mmol/L.  The admission 
hyperglycaemia group have an initial mean glucose level of 8.96mmol/L falling to a nadir 
of 6.49mmol/L at around 15 hours after stroke onset before rising again.  The late 
hyperglycaemia group had a mean initial glucose level of 5.81mmol/L with levels staying 
below 6mmol/L until 16 hours after stroke onset when levels began to rise. 
A high proportion of patients became hyperglycaemic during this study.  The proportion of 
hyperglycaemic patients increased with time and increased as the threshold for 
hyperglycaemia was reduced (see Figure 28).  With a threshold of 7mmol/L 83% of 
patients became hyperglycaemic within 48 hours while a threshold of 8mmol/L led to 63% 
of patients being classified as hyperglycaemic during that period.   
Repeated measures ANOVA revealed a significant difference between groups based on 
glycaemic status (p=0.001).  There was a significant difference on repeated measures 
between the euglycaemic group and the admission hyperglycaemia group (mean difference 
2.32, 95% CI 1.16 to 3.47, p<0.001) although the difference between the euglycaemic 
group and the late hyperglycaemia group was not significant (mean difference 1.149, 95% 
CI -0.04 to 2.34, p=0.059).
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Figure 27 - Mean capillary blood glucose against time with error bars showing 95% CI 
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Figure 28 - Proportion of patients who have been hyperglycaemic increases with time and varies with glucose threshold
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6.3.3 Treatment for Diabetes Mellitus 
Of the 20 patients with diabetes mellitus 12 were treated with metformin.  Five of these 
patients were treated with metformin and gliclazide.  Three patients were treated with 
gliclazide alone. Four patients were treated with insulin.  Two of these patients were 
treated with insulin and metformin.  Three patients were on no treatment for DM. 
No other patients in the cohort were treated for hyperglycaemia.  Where possible, patients 
continued with their normal medications.  One patient was given Lucozade for 
hypoglycaemia (CBG 2.2mmol/L). 
6.3.4 Swallow and fluid management 
Initial screening for problems with swallowing was carried out in the Acute Stroke Unit on 
the day of admission.  Seven patients (40%) in the euglycaemic group had an initial 
swallowing problem, compared to 14 patients (44%) in the late hyperglycaemia group and 
19 patients (32%) of the admission hyperglycaemia group.  Information was missing in 
24% of the normoglycaemia group, 27% of the admission hyperglycaemia group and 9% 
of the late hyperglycaemia group. 
Four normoglycaemic patients, fifteen admission hyperglycaemia patients and two late 
hyperglycaemia patients were declared ‘nil by mouth’. 
Intravenous fluids were prescribed to 12 normoglycaemic patients (70%), 43 admission 
hyperglycaemia patients (73%) and 23 late hyperglycaemia patients (73%).  Two patients 
in the admission hyperglycaemia group and one patient in the late hyperglycaemia group 
were given 5% dextrose solution.  All other patients were given saline solution.  The mean 
volume of fluid given in 24 hours was 1853ml with no significant difference in volumes 
between groups (p=0.647) or infusion rate (p=0.647). 
In chi-squared testing there was no significant difference in scores for point 10 on the 
NIHSS score (for dysarthria) between groups (p=0.85). 
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6.3.5 Cause of stroke 
There were no significant differences in the cause of stroke between groups.  In the cohort 
as a whole 29% of strokes were due to supra-aortic large artery atherosclerosis while 25% 
were due to cardio-aortic embolism.  One third of strokes were of undetermined aetiology 
while smaller proportions were due to small artery occlusion (8.3%) or other causes 
(4.6%).   
 
Figure 29 - Cause of stroke in general population using CCS classification 
6.3.6 Clinical outcomes 
There were no significant differences in clinical outcomes between groups.  Overall 11% 
of patients died by day 30, 16% of patients had a ‘good’ outcome with modified Rankin 
scores of between 0 and 1 while 73% of patients had a ‘poor’ outcome with Rankin scores 
of 2 to 5.  
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We subsequently performed a shift analysis using Cochran-Mantel-Haenszel statistics to 
see if glycaemic status predicted outcome as graded by day 30 Rankin score.  We corrected 
the analysis for age and admission NIHSS but we found no significant relationship 
between PSH and outcome Rankin score (p=0.308).  
We also repeated the Cochran-Mantel-Haenszel shift analysis to see if admission NIHSS 
score was predicted by glucose group when corrected for age.  Again there was no 
significant relationship (p=0.457). 
We also used the Cochran-Mantel-Haenszel shift analysis to see if glycaemic category was 
predicted by admission NIHSS but again there was no significant relationship (p=0.549).   
Binary regression analysis suggested that NIHSS score was a strong predictor of mortality 
(P=0.001, OR 1.2, 95%CI 1.078-1.359) in combination with mean capillary blood glucose 
(P=0.028, OR 2.36, 95%CI 1.1- 5.08) and HbA1c (P=0.023, OR 0.19, 95% CI 0.046-
0.792).  Other factors included in the regression did not have a significant effect. 
6.4 Discussion 
In this prospectively recruited series of stroke patients we found that a large proportion 
(54.6%) of patients became hyperglycaemic within 6 hours of stroke onset.  Another 
29.6% became hyperglycaemic over the subsequent 48 hours and only 15.7% of patients 
were observed to have glucose levels below 7mmol/L at all times.   
These three groups appear to be very distinct.  There are significant differences in 
admission glucose, mean capillary blood glucose and HbA1c between groups.  The glucose 
kinetics of the 3 groups look different as graphically represented in Figure 6.3.  In this 
group post stroke hyperglycaemia does not appear to be a regression to the mean as 
suggested by Wong and colleagues.190  In their study they excluded all patients with 
diabetes which does not really reflect the reality of the acute stroke patient.  They also did 
not check HbA1c leaving prior glycaemic status beyond a reported history of diabetes 
unexplored. 
Repeated measures ANOVA confirmed that the euglycaemia group and the late 
hyperglycaemia group were significantly different.  The difference between the 
euglycaemic group and the late hyperglycaemic group was not significant (p=0.059) 
although patients who were improving in some cases would have left hospital or 
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transferred to another resulting in missing capillary blood glucose values towards the end 
of the first 48 hours and exclusion from the model. 
Despite this high incidence of hyperglycaemia after stroke only 18.5% of this cohort had 
an existing diagnosis of diabetes mellitus and the mean glycosylated haemoglobin level for 
the group was only 5.9%.  There was a significant difference in mean glycosylated 
haemoglobin levels between group with the largest difference existing between the 
euglycaemic group and the admission hyperglycaemia group.  This would suggest that the 
admission hyperglycaemia group had higher blood glucose levels over the weeks before 
their strokes.  It is possible that the patients in the admission hyperglycaemia group had 
undiagnosed insulin resistance but we did not test fasting insulin levels on admission so we 
cannot perform a homeostasis model assessment to assess insulin sensitivity.50 
The incidence of hyperglycaemia alters depending on the threshold chosen for 
hyperglycaemia.  In this population 96% of patients were hyperglycaemic within 48 hours 
if a threshold of 6mmol/L was chosen, 83% with a threshold of 7mmol/L, 63% with a 
threshold of 8mmol/L and 29% with a threshold of 10mmol/L.  If this was an acute study 
31% of patients could have been recruited at 4 hours if 8mmol/L was the chosen threshold 
and 45% of patients with a threshold of 7mmol/L.  This is in keeping with observations 
from the VISTA database.267  
Some other observational studies have been unclear in the reporting of patients treated with 
insulin or oral hypoglycaemic agents during the study period.197  In this population only 4 
patients with known DM were treated with insulin during the admission.  These patients 
were in the admission hyperglycaemia group.  All patients who were using oral 
hypoglycaemic agents were in the admission hyperglycaemia group. 
A very small proportion of the patients in this study had strokes that were felt to be due to 
small artery occlusion or other causes.  This may be a factor of the nature of the inclusion 
criteria.  All patients had to present to hospital within 6 hours of stroke onset and a patient 
with a small vessel or lacunar stroke may have less of a deficit leading to a delayed 
presentation.  It is also possible that patients with small vessel occlusion were missed by 
the screening researchers who did not think that the presenting symptoms and signs 
represented an acute stroke.  Almost all patients admitted to the Acute Stroke Unit at the 
Southern General come in an emergency ambulance and it is possible that doctors outside 
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the unit would not feel that a patient with a minor stroke related to small vessel disease 
needed such urgent attention. 
Some differences were seen between different glycaemic groups.  The euglycaemic 
patients were significantly younger than hyperglycaemic patients (p=0.009). The oldest 
patients were those who developed hyperglycaemia at a later time point in the admission.  
The admission hyperglycaemia patients were more likely to have a past history of diabetes 
mellitus or impaired glucose tolerance.  They also had significantly higher glycosylated 
haemoglobin levels.  The age related differences seen in these data may be explained by 
the increasing  prevalence of type 2 diabetes mellitus with age.575  Undiagnosed diabetes is 
often offered as an explanation for post-stroke hyperglycaemia.230-233    
Known risk factors for stroke such as atrial fibrillation, hyperlipidaemia and hypertension 
were not significantly different between groups. Despite this the absence of a history of 
hypertension trended towards reducing the risk of admission hyperglycaemia (p=0.053, 
OR 0.47, 95% CI 0.22 to 1.01).  In a meta-analysis of a large volume of clinical trial data 
from the VISTA archive a history of hypertension was seen to be predictive of post stroke 
hyperglycaemia within 48 hours of stroke.267 
A non-significantly smaller proportion of patients had definite stroke on imaging, proven 
occlusions and thrombolytic treatment in the normoglycaemia group compared to the other 
groups.  Baseline clinical stroke severity as assessed by NIHSS scale was similar with no 
significant statistical differences seen.  There was nothing to suggest that stroke severity 
correlated with hyperglycaemia.  This is in keeping with previous observations.221, 222, 576 
In the regression analysis we see NIHSS as a strong predictor of 30 day mortality.  This fits 
with the role of the NIHSS as an indicator of baseline stroke severity.  Mean capillary 
blood glucose also appears to predict 30 day mortality as did HbA1c.  This is in keeping 
with previous studies.160, 176  Rankin shift analysis using Cochran-Mantel-Haenszel 
statistics to correct for age and baseline NIHSS did not show any relationship between 
glycaemic groups and 30 day outcome.
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7 Assessment of the relationship between infarct 
growth and post stroke hyperglycaemia 
7.1 Introduction 
In this chapter I have tried to identify differences in the growth of irreversibly damaged 
tissue (infarct) after a stroke between patients in whom blood glucose remains consistently 
normal after a stroke, patients in whom blood glucose is increased early (within 6 hours of 
onset), and patients who develop hyperglycemia >6 hours after stroke onset. 
7.2 Methods 
7.2.1 Baseline demographics 
The baseline demographics have been represented and reanalysed due to the change in 
population size between this chapter and chapter 6.  Analysis of these demographics was 
performed in the same way as before. 
7.2.2 Image analysis 
Scans from all patients were analysed independently by two observers (NM and XH), who 
measured core and penumbra volume on  CTP 24-28h infarct volume on the co-registered 
slices of the follow-up non-contrast CT (i.e. limited to the coverage of the CTP) and total 
brain 24-48h infarct volume using all slices. The mean of the volumes measured by the two 
observers was used in statistical analysis. 
Infarct growth was calculated as 24-28h infarct volume – core volume and expressed both 
as absolute growth (ml) and as a percentage of CTP core volume. 
Inter-observer agreement had already been established as detailed in Chapter 2. 
7.2.3 Statistical analysis 
Differences between groups were analysed using one way ANOVA for scale variables and 
chi squared for categorical variables.  If a significant group effect was found by ANOVA, 
post-hoc between-groups comparisons were undertaken using the least significant 
difference (LSD) method 
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Linear regression analysis was carried out using SPSS to seek predictors of infarct growth, 
penumbral salvage and final infarct volumes. Univariate analysis included age, 
hypertension, Hba1c, atrial fibrillation, admission blood glucose, NIHSS score, systolic 
and diastolic blood pressure, thrombolytic treatment, occlusion status and evidence of 
recanalization. All variables with p<0.1 in univariate analysis were entered into a forward 
stepwise conditional model. Findings were confirmed in a backwards stepping model 
beginning with all potentially predictive variables. 
Binary logistic regression analysis was also carried out using SPSS to seek predictors of 
recanalization and 30 day mortality. Univariate analysis included age, admission blood 
glucose, mean capillary blood glucose, atrial fibrillation, HbA1c, NIHSS score, systolic 
and diastolic blood pressure and thrombolytic treatment as a binary variable. All variables 
with p<0.1 in univariate analysis were entered into a forward stepwise conditional model. 
Findings were confirmed in a backwards stepping model beginning with all potentially 
predictive variables 
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7.3 Results 
 
7.3.1 Population in subgroup analysis 
 
Figure 30 – Recruitment flowchart for patients with good quality CTP imaging 
In 4 patients, CT perfusion imaging could not be processed due to movement artefact or 
other technical problems, leaving 104 patients with ischaemic stroke and analysable CT 
perfusion imaging.  These patients were divided into 3 subgroups based on glycaemic 
status.  Fifty six patients had admission hyperglycemia, 31 subsequently developed 
hyperglycemia and 17 were normoglycemic at all times. 
108 stroke 
patients 
104 with good quality CT 
Perfusion imaging 
17 Euglycaemic 
at all times 
56 Admission 
Hyperglycaemia 
31 late 
Hyperglycaemia 
4 CTP unusable 
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Table 7-1 Demographics, clinical outcomes and imaging data for patients with CTP imaging 
Hyperglycaemia Group (n) All 
patients 
(104) 
None(17) Admission 
(56) 
Late (31) 
 
Male Gender (n/%) 63 (60.6) 10 (59) 32 (57.2) 21(68)  
Age ± SD (mean/years) 69.53 62 ±1 4 * 70.5 ± 10.5 * 71.8 ± 10.5 p=0.01 
Admission blood glucose ± SD (Mean 
mmol/L) 
7.47 ± 3.3 5.82 ±0.6 * 8.79 ±3 .98  *  
** 
6.05 ± 0.67 
** 
p<0.001 
Mean capillary glucose ± SD  (Mean, 
mmol/L) 
6.75 ± 1.6 5.4 ± 0.59 * 7.47 ± 1.66 * 
** 
6.17 ±1.29 
** 
p<0.001 
HbA1c ± SD (Mean) 5.9 ± 1.1 5.4 ±0.5 * 6.2 ± 1.4 * ** 5.7 ± 0.7 ** p=0.016 
Admission NIHSS (Median/IQR) 9 (5-18) 11 (4-17) 9.5 (6-19) 8 (5-15) p=0.659 
Admission Blood pressure ± SD 
(mmHg) 
151/78 152/78 
±21/12 
148/77 ± 
26/18 
155/80 ± 
21/10 
p=0.801 
Diabetes (n/%) 19 (18.3) 0 18 (32.1) 1 (3.2) p<0.001 
Impaired glucose tolerance (n/%) 19 (18.3) 0 17 (30.4) 2 (6.5)  
Thrombolytic treatment (n/%) 73 (70.2) 10 (59) 42 (75) 21 (67.7) p=0.415 
Occlusion on imaging (n/%) 67 (64.4) 10 (58.8) 38 (67.9) 19 (61.3) p=0.644 
Recanalization on imaging (n/%) 37/67 
(55) 
4/10(40) 23/38 (60.5) 10/19 (53) p=0.4 
Supra-aortic large artery 
atherosclerosis (n/%) 
28 (27) 4 (23.5) 16 (29) 8 (26) 
Cardio-aortic embolism (n/%) 26 (25) 4 (23.5) 15 (26.8) 7 (22.6) 
Small artery occlusion (n/%) 9 (8.7) 2 (11.8) 4 (7.1) 3 (9.7) 
Other causes (n/%) 5 (4.8) 2 (11.8) 3 (5.4) 0 
Undetermined causes (n/%) 36 (34.6) 5 (29.4) 18 (32.1) 13 (42) 
p=0.797 
 
CT Perfusion Core volume  (Mean± 
SD, ml) 
18.9 ± 
25.6 
20.2 ± 19.5 21.3 ± 29.3 13.8 ± 20.7 p=0.409 
CT Perfusion Penumbra volume  
(Mean± SD, ml) 
23 ± 24.4 25.9 ± 26.5 22.2 ± 23.4 22.9 ± 25.5 p=0.868 
Total Perfusion Lesion Volume ± SD 
(Mean, ml) 
41.9 ± 
45.3 
46.1 ± 40 43.6 ± 48.4 36.6 ± 43.1 p=0.730 
Co-registered 24-48h infarct volume ± 
SD (Mean, ml) 
41.9 ± 
55.7 
33.5 ± 39.8 51.9 ± 63.2 28.5 ± 45.6 p=0.135 
24-48h Infarct Volume ± SD (Mean, 
ml) 
78.2 ± 
97.1 
56 ± 66.5 85.3 ± 11.7 44.3 ± 76.9 p=0.144 
Infarct Growth ± SD (Mean, ml) 23.6 ± 14.6 ± 21.7 31.1 ± 46.1 14.7 ± 28.5 p=0.1 
Penumbral salvage ± SD (Mean, ml) 0 ± 41.8 12.6 ± 32 -8.4 ± 48 8.2 ± 29.9 p=0.083 
Rankin 0-1 Day 30 (n/%) 17 (16.3) 5 (29.4) 8 (14.3) 4 (12.9) 
Rankin 2-5 Day 30 (n/%) 75 (72.1) 11 (64.7) 40 (71.4) 24 (77.4) 
Rankin 6 Day 30 (n/%) 12 (11.5) 1(6) 8 (14.3) 3 (9.7) 
p=0.504 
Using LSD analysis there was a significant difference between the following groups - *AHG vs. EG, ** AHG 
vs. LHG, *** EG vs. LHG 
  180 
 
7.3.2 Baseline demographics 
As seen in the entire study population, euglycaemic patients were significantly younger 
than hyperglycaemic patients (p=0.01) in the CTP sub-group.  
Unsurprisingly the admission blood glucose level was significantly different between 
groups (p<0.001).  Prior glycaemic status as defined by glycosylated haemoglobin was 
also significantly different between groups (p=0.016). There were also significantly more 
patients in the admission hyperglycaemia group who had a pre-existing diagnosis of 
diabetes mellitus or impaired glucose tolerance before admission.  
There were no significant differences in cause of stroke between groups. (p=0.797) 
There was no difference in baseline stroke severity as assessed by NIHSS score (p=0.659).  
Similar proportions of patients had angiographic evidence of occlusion between the groups 
(P=0.644) and similar proportions received thrombolytic treatment (p=0.415) 
7.3.3 Occlusion counts 
Overall 64% of patients had an occlusion on CTA.  Thirty-five patients had M1 occlusions 
while 18 had M2 occlusion.  Fifteen had an intracranial ICA occlusion while 13 had 
extracranial ICA occlusions. Twenty patients (19%) had tandem occlusions (2 or more 
sites of occlusion).  There were no significant differences in occlusion counts between 
glycaemic groups  More details are available in Table 7.2. 
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Table 7-2 Site of occlusion 
Hyperglycaemia Occlusion Overall 
(n/%) 
None (n/%) Admission (n/%) Late (n/%) 
 
M1 35 (32) 6 (35) 18 (31) 11 (34) p=0.897 
M2 18 (17) 2 (12) 12 (20) 4 (12.5) p=0.531 
M3 7 (6.5) 1 (6) 3 (5) 3 (9) p=0.725 
Extracranial 
ICA 
13 (12) 3 (18) 6 (10) 4 (12.5) p=0.703 
Intracranial 
ICA 
15 (14) 3 (18) 7 (12) 5 (16) p=0.785 
Vertebral 1 (0.9) 1 (6) 0 0 p=0.067 
PCA 7 (6) 0 4 (7) 2 (6) p=0.549 
Tandem 
occlusion 
20 (19) 3 (18) 9 (15) 8 (25) p=0.518 
 
7.3.4 Infarct growth 
There were no significant differences in baseline CTP core or penumbra volumes.  There 
were no significant differences in follow-up infarct volumes between groups. However, 
despite the lack of statistical significance, mean co-registered follow-up infarct volumes 
and mean total follow-up infarct volumes were larger in the group with admission 
hyperglycaemia.  The admission hyperglycaemia group also appeared to have greater 
infarct progression than the other groups. I have illustrated the distribution of infarct 
growth and 24-48 hour infarct volumes as box plots (Figures 7.3 and 7.4).  
The difference between the mean infarct growth in the admission hyperglycaemia group 
and the late hyperglycaemia group was just non-significant, with p=0.058 in post-hoc 
analysis.  
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Figure 31 – Scatter plot of outcome infarct volume against mean glucose level 
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Figure 32 - Natural log of 24-48 hour infarct volume in glycaemic groups 
 
  184 
 
 
Figure 33 - Infarct growth in glycaemic groups 
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Figure 34 - Infarct growth in relation to admission NIHSS 
In linear regression, admission NIHSS (p<0.001, OR 1.81, 95% CI 0.86 to 2.76), 
admission blood glucose (p=0.030, OR 2.493, 95% CI 0.25 to 4.74) and systolic blood 
pressure (p=0.066, OR 0.268, 95% CI -0.18 to 0.55) were predictive of infarct growth. R 
squared was 0.234. Variables excluded in the forward and backward regressions included 
thrombolysis, Hba1c, diastolic blood pressure, presence or absence of occlusion.  When the 
model was repeated, substituting mean capillary blood glucose (MCBG) for admission 
blood glucose (ABG) R squared was 0.378.  This model included admission NIHSS 
(p<0.001, OR 2.08, 95% CI 1.34 to 2.81), mean blood glucose (p=0.007, OR 5.17, 95% CI 
1.43 to 8.9) and admission systolic blood pressure (p=0.004, OR 0.31, 95% CI 0.11 to 
0.57).  Age was forced into this model to correct for baseline imbalances. 
Table 7-3 Coefficients in backwards regression for Infarct growth 
Variable P value Odds ratio 95% Confidence interval 
Admission NIHSS <0.001 2.02 1.29 – 2.75 
Admission Systolic blood pressure 0.008 0.3 0.08 – 0.53 
Mean capillary blood glucose 0.009 5.06 1.3 – 8.81 
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7.3.5 Infarct growth in patients with initial core volumes of more than 
10 ml 
To look at infarct growth as a percentage we restricted the analysis to patients with a 
baseline core volume of 10ml or greater to reduce the influence of measurement error. 
When intra-observer reliability is assessed repeated measurements are often less consistent 
on smaller volumes.  The baseline demographics and outcomes for this subset are shown in 
table 7.4. 
In this selected subpopulation of patients with core lesions of 10ml or larger on perfusion 
imaging there were significant differences in age and glucose levels (admission and mean) 
as seen in the cohort as a whole. A high proportion of these patients had an occlusion on 
imaging (94%) with 100% of the admission hyperglycaemia patients having an occlusion 
compared to 91% of the late hyperglycaemia patients and 83% of the normoglycaemia 
patients (p=0.09).  Core lesions were smaller in the normoglycaemia group but not 
significantly so. 
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Table 7-4 - Baseline demographics, imaging outcomes and clinical outcomes for patients 
with initial core volumes of more than 10ml 
Hyperglycaemia Group (n) All 
patients 
(52) 
None (12) Admission 
(29) 
Late (11) 
 
Male Gender (n/%) 28 (53.8) 10 (59) 32 (57.2) 21(68)  
Age ± SD (mean/years) 70 ± 12.3 62.6 ± 14.9 * 
*** 
73 ± 10.6 * 70.1 ± 11 *** p=0.044 
Admission blood glucose ± 
SD (Mean mmol/L) 
7.54 ± 
3.68 
6.02 ± 0.5 * 8.81 ±  4.55* 
** 
5.94 ±  0.88 ** p=0 .02 
Mean capillary glucose ± 
SD  (Mean, mmol/L) 
6.59 ± 1.4 5.3 ±0.53 * 7.27 ± 1.47 * 
** 
6.2 ± 0.66 ** p<0.001 
HbA1c ± SD (Mean) 5.9 ±1.2 5.5 ± 0.5 * 6.3 ± 1.6 * ** 5.6 ± 0.4 ** p=0 
.130 Admission NIHSS 
(Median/IQR) 
16 (10-19) 13.5 (11-
18.75) 
18 (11.5-19.5) 11 (9-20) p=0.271 
Admission Blood pressure 
± SD (mmHg) 
149/24 ± 
3/2 
157/83±21/10 147/75 ± 
29/19 
144/79 ±22/10 p=0.408 
Thrombolytic treatment 
(n/%) 
45 (86.5) 9 (75) 27 (93.1) 9 (81.8) p=0.265 
Occlusion on imaging 
(n/%) 
49 (94.2) 10 (83) 29 (100) 10 (91) p=0.099 
Recanalization on imaging 
(n/%) 
26/49 
(53.1) 
4/10 (40) 18/29 (62.1) 4/10 (40) p=0.147 
CT Perfusion Core volume  
(Mean± SD, ml) 
36.2±26.6 28.6 ± 17 39.8 ± 30.9 34.9 ±22.5 p=0.477 
CT Perfusion Penumbra 
volume  (Mean± SD, ml) 
40.3 ± 
22.3 
36.6 ± 24.3 39.2 ± 20.6 47.3 ± 25.1 p=0.484 
Total Perfusion Lesion 
Volume ± SD (Mean, ml) 
76.5  ± 
39.9 
65.3 ± 31 78.9 ±43.1 82.2 ± 40.4 p=0.533 
Co-registered 24-48h 
infarct volume ± SD (Mean, 
ml) 
71.9 ± 
61.5 
47.5 ± 39.8 83.4 ± 68.5 68.3 ± 57.4 p=0.233 
24-48h Infarct Volume ± 
SD (Mean, ml) 
113.5 ± 
112.1 
79.4 ± 66.4 135.7 ± 129.4 92.4 ± 95.3 p=0.273 
Infarct Growth ± SD 
(Mean, ml) 
36.8 ± 
45.7 
21 ± 23.3 44.6 ± 53.2 33.3 ± 40.5 p=0.314 
Infarct growth as 
percentage of core (%) 
--10.5 ± 
214 
32.2  ± 27 -0.3 ± 134 -83.9 ± 418 p=0.408 
Penumbral salvage ± SD 
(Mean, ml) 
2 ± 51 17.8 ± 37 -4.4 ± 60 14 ± 46 p=0.386 
Rankin 0-1 Day 30 (n/%) 6  (11.5) 2 (16.7) 3 (10.3) 1 (9.1) 
Rankin 2-5 Day 30 (n/%) 35 (67.3) 9 (75) 18 (62.1) 8 (72.3) 
Rankin 6 Day 30 (n/%) 11 (21.2) 1(8.3) 8 (27.6) 2 (18.3) 
 
p=0.70 
Using LSD analysis there was a significant difference between the following groups - *AHG vs. EG, 
** AHG vs. LHG, *** EG vs. LHG.  
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Outcome infarct volumes were on average smaller in the normoglycaemia group than the 
other groups (79.4ml vs. 135.7ml and 92.4ml, p=0.273).  There was a non-significant trend 
for patients in the normoglycaemia group to have a higher percentage of infarct growth.  
Logarithmic transformation did not make this relationship significant. 
 
Figure 35 - Infarct growth in patients with an initial perfusion core volume of >10ml 
I also looked for a relationship between mean capillary blood glucose and transformed 
infarct growth as illustrated below (Figure 36). 
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Figure 36 - Relationship between mean capillary blood glucose and transformed infarct 
growth in patients with baseline core perfusion lesion >10ml 
There was a trend towards a difference in mean transformed infarct growth although this 
was not significant (p=0.16). 
7.3.6 Penumbral salvage 
As illustrated in the bar chart in Figure 37 there was a tendency for less penumbra to be 
salvaged in the admission hyperglycaemia group.  This trend is non-significant. 
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Figure 37 - Glycaemic status and imaging findings 
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Figure 38 - Scatter plot of penumbral salvage and admission blood glucose 
7.3.7 Recanalization 
Using binary logistic regression a model containing admission blood glucose (p=0.005, OR 
1.4, 95% CI 1.1 to 1.78), thrombolytic treatment (p=0.005, OR 5.29, 95% CI 1.66 to 16.8) 
and HbA1c (p=0.017, OR 0.41, 95%CI 0.19 to 0.85) was predictive of recanalization in 
70.1% of cases. 
Table 7-5 Variables in backward regression for prediction of recanalization 
Variable p value Odds ratio 95% Confidence interval 
HbA1c 0.017 0.41 0.19 – 0.85 
Thrombolysis 0.005 5.29 1.66 – 16.8 
Admission blood glucose 0.005 1.4 1.1 – 1.78 
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7.3.8 Clinical outcomes 
There were no significant differences in clinical outcomes between groups based on day 30 
modified Rankin scores when analysed with a 3x3 chi squared test when mRs was split 
into three groups.  Modified Rankin score was divided into 0-1, 2-5 and 6 as well as 0-2, 3-
5 and 6 but was still non-significant.  The distribution of Rankin scores between glycaemic 
groups is illustrated in Figure 39.  Rankin shift analysis using Cochran-Mantel-Haenszel 
statistics found no significant relationship between glycaemic status and outcome when 
corrected for age and admission NIHSS (p=0.329). 
Binary logistic regression showed that mean core volume was a predictor for mortality at 
30 days with an odds ratio of 2.27 (95% CI 1.41 to 3.67, p<0.001,) per 10 ml in a model 
that also included systolic blood pressure (OR 0.95, p=0.047, 95% CI 0.9 to 0.99).  This 
model had a p value of <0.001.  
 
Table 7-6 Variables in binary logistic regression for 30 day mortality 
Variable P 
value 
Odds 
ratio 
95% Confidence 
interval 
Admission systolic blood pressure 0.047 0.95 0.9 - 0.99 
Core perfusion lesion volume (per 10 ml 
increment) 
<0.001 2.27 1.41 - 3.67 
 
I repeated this regression in the subset of patients with a baseline core lesion of more than 
10ml.  Again a 10ml incremental increase in core volume was associated with increased 
risk of day 30 mortality (p=0.007, OR 1.53, 95% CI 1.12 to 2.09).
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Figure 39 - Day 30 Rankin scores by glycaemic groups 
 
194 
 
7.4 Discussion 
This chapter explores infarct growth in relation to blood glucose. The core lesion defined 
on CT perfusion imaging was compared with 24-48h infarct volume on  co-registered non-
contrast CT slices that covered the same area of brain as the CT perfusion scan. 
Several interesting correlations were observed.  Higher admission glucose and higher mean 
glucose were correlated with larger follow-up infarct volumes.  Higher NIHSS scores 
correlated with greater infarct growth.  It was also interesting to note that increasing core 
volume correlated with mortality while increasing systolic blood pressure was associated 
with reduced mortality. 
Baseline demographics in the subgroup analysed in this population were similar to those 
described in Chapter 6 despite the loss of 4 patients due to inadequate CTP imaging. As 
before, significant differences were seen between glycaemic groups for age, admission 
blood glucose level and prior glycaemic status.    Mean capillary blood glucose was 
significantly different between admission hyperglycaemia group and the other groups but 
not between the euglycaemic group and the later hyperglycaemic group. Other baseline 
clinical variables did not differ significantly across groups. 
No significant difference in infarct growth between groups was seen although there was 
certainly a trend towards increased infarct growth in patients with admission 
hyperglycaemia when compared to the other groups. Follow up infarct volumes also trend 
towards being larger in patients with higher mean glucose levels.  This trend was 
consistent when analysis was restricted to patients with a baseline core lesion volume of 
more than 10ml. 
Overall penumbral salvage was not significantly different between groups (p=0.075).  
However, there was a trend towards less penumbral salvage in the admission 
hyperglycaemia group (AHG) compared to the late hyperglycaemia group  and the 
normoglycaemia group (mean volume salvaged -8.4ml compared to 8.2ml and 12.6ml, 
post hoc p-values 0.076 and 0.07). Expressed as absolute difference in volume between 
baseline and 24-48h scans,  infarct growth was twice as great in the AHG group compared 
to the LHG group, (mean AHG growth 31.1ml vs. mean LHG growth 14.7ml) but was just 
non-significant (p=0.058).    
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Interestingly in the group of patients with a baseline core perfusion lesion of more than 
10ml the highest percentage of infarct growth was seen in the normoglycaemia group 
(32.2%) whilst the lowest percentage was seen in the late hyperglycaemia group (-89.3%).   
There is a definite trend towards patients with admission hyperglycaemia having larger 
final infarcts with greater infarct growth despite similar baseline core volumes despite the 
lack of clearly significant results.  Future studies should reproduce this result in a larger 
population to confirm a difference between these groups.   
Both admission blood glucose and mean capillary blood glucose were correlated with 24-
48h infarct volume.  A higher admission NIHSS was associated with greater infarct growth 
while increased systolic blood pressure was associated with reduced infarct growth.   
Admission blood glucose, HbA1c and thrombolytic therapy were predictors of 
recanalization.   
Admission hyperglycaemia was associated with reduced penumbral salvage although this 
finding should be confirmed in other studies. Late hyperglycaemia does not appear to be as 
damaging.  The patients with late hyperglycaemia who had baseline core volumes of more 
than 10ml had the lowest percentage of infarct growth.  The late rise in glucose levels 
could be an artefact of a patient recovering from a stroke and returning to a normal diet.  
Certainly hyperglycaemia developing only after 6 hours does not appear to have adversely 
affected the evolution of brain ischaemia in these patients. 
Despite looking at outcome Rankin scores with different iterations and methods no 
significant correlation between glycaemic group and mRs was seen.  The highest 
proportion of patients died in the admission hyperglycaemia group while the smallest 
proportion died in the normoglycaemia group. 
Mortality was predicted by increasing core perfusion volume.  The predictive value of 
perfusion core lesions has been described before.577, 578  It is interesting to note that 
increasing admission systolic blood pressure was associated with reduced mortality.  It is 
unclear why this may be although one could hypothesize that this may be a healthy 
physiological response where the brain is trying to increase cerebral blood flow to salvage 
penumbral tissue.  It is also possible that patients with higher blood pressure will distribute 
rt-PA to a clot more efficiently.  
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Core volumes were not significantly different between glycaemic groups although when 
the analysis was restricted to baseline core volumes of 10ml or greater a trend emerged for 
the patients with admission hyperglycaemia to have larger core lesions.  Repeated binary 
regression analysis in this population demonstrated the relationship between increasing 
core volume and risk of death. 
Parsons and colleagues176 performed acute MRI in 40 patients at a median of 4.5 hours 
after stroke onset, a similar time point to the patients included in this study,176 and also 
reported a correlation between acute (admission) hyperglycaemia (glucose measured 
within 1h of MRI) and reduced penumbral salvage, consistent with our observations using 
different imaging methodology. While we also found greater final infarct size among those 
with admission hyperglycaemia, this was not statistically significant, and may reflect a 
more heterogeneous population.  Our larger population sample had a lower median NIHSS 
with a wider intra-quartile range.  The mean age of our population was lower at 69 (vs. 73) 
and we had a larger intra-quartile age range (61-78 vs. 64-78).  Many factors may make 
our population different from the population in the Australian paper. 
.The observation that hyperglycaemia is associated with increased transformation of 
penumbra into core has been made several times.160, 202, 203 Certainly the EPITHET 
investigators felt that the beneficial effects of rt-PA were attenuated in diabetes.203  The 
results in this chapter do support the theory that hyperglycaemia may increase infarct 
growth in many patients.  They additionally suggest that not all hyperglycaemia is bad and 
that some patterns of hyperglycaemia may be better than others. 
In the population studied in this chapter recanalization was predicted by a model including 
admission blood glucose, thrombolytic treatment and HbA1c.  Recanalization will be 
looked at in more detail in Chapter 8 and Chapter 9. 
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8 Infarct growth in the context of arterial patency 
and glycaemic status 
8.1 Introduction 
The harmful effects of post stroke hyperglycemia may be restricted to specific groups of 
patients, defined by pathophysiological processes. Treatment to lower glucose may be 
unnecessary or even harmful in patients who do not share these features.  
One important pathophysiological variable is the presence or absence of arterial occlusion.  
Patients with an arterial occlusion have worse outcomes than those who do not.  A 
persistent arterial occlusion is associated with poorer outcomes while recanalization 
generally confers a better prognosis. 
A recent clinical trial of insulin treatment for PSH reported divergent effects of treatment 
dependent on arterial patency, being associated with greater infarct expansion in patients 
with persistent occlusion, but less expansion than placebo in those with recanalization.554  
The InsulInfarct study with compared a subcutaneous insulin treatment regime with an 
intensive insulin infusion regime found that the more intensive insulin regime was 
associated with greater infarct growth in patients with arterial occlusions.562 It appears 
therefore that early and late PSH may differ in their causes and pathophysiological 
significance, and that individual brain tissue vulnerability and vessel status further 
influence the effects of PSH. 
In this section of the study we aimed to define the interaction of early and delayed 
hyperglycaemia with arterial patency and brain perfusion in acute stroke patients. 
8.2 Methods 
As detailed previously all patients underwent CTP and CTA on admission, in addition to 
routine CT. Plain CT and CTA (limited to Intracranial vessels) were repeated at 24-48h to 
establish final infarct volume and arterial patency (persistent occlusion or recanalization).  
Angiographic imaging was only repeated if there was evidence of an occlusion on the 
initial scan. 
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8.2.1 Image analysis 
The analysis of the CTP scans and the plain CT scans was performed as detailed in the 
previous chapter.  The admission and follow-up scans were again read by two observers 
(NM and XH) who looked for presence or absence of an arterial occlusion on the 
admission scan and for evidence of recanalization in the follow-up imaging.  If there was 
any disparity between observers a final decision was made by an experienced stroke 
neurologist who could also make reference to neuroradiology reports (KM). 
8.2.2 Analysis of infarct growth 
Infarct growth was defined as the difference between core perfusion volume lesion and 
final co-registered infarct volume.  Patients were divided into groups based on glycaemic 
status as described in the previous chapters.  These groups were further subdivided by 
presence or absence of arterial occlusion and then by recanalization status. 
8.2.3 Statistical analysis 
Differences between groups were analysed using ANOVA for scale variables and chi 
squared for categorical variables.  If a significant difference between groups was 
discovered using ANOVA it was further analysed using the least significant difference 
method. 
Linear regression analysis was carried out using SPSS to seek predictors of infarct growth, 
penumbral salvage and final infarct volumes. Univariate analysis included age, 
hypertension, Hba1c, atrial fibrillation, admission blood glucose, mean capillary blood 
glucose, NIHSS score, systolic and diastolic blood pressure, thrombolytic treatment, 
occlusion status and evidence of recanalization. All variables with p<0.1 in univariate 
analysis were entered into a forward stepwise conditional model. Findings were confirmed 
in a backwards stepping model beginning with all potentially predictive variables. 
8.3 Results 
8.3.1 Patients 
104 patients had ischaemic strokes with analysable CT perfusion imaging.  These patients 
were divided into 3 subgroups based on glycaemic status. 
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8.3.2 Patients with occlusions 
Sixty seven patients had angiographic evidence of arterial occlusion while 37 patients had 
no evidence of occlusion.  Of the patients with occlusions 38 (56.7%) were 
hyperglycaemic on admission, 19 (28.4%) subsequently became hyperglycaemic and 10 
(14.9%) were euglycaemic at all times. 
 
Figure 40 - Flowchart for occlusion status 
108 stroke 
patients 
104 with good quality CT 
Perfusion imaging 
17 Euglycaemic 
at all times 
56 Admission 
Hyperglycaemia 
 
31 late 
Hyperglycaemia 
4 CTP unusable 
 
10 
occlusion
s 
38 
occlusion
s 
19 
occlusion
s 
7 No 
occlusion 
18 No 
occlusion 
12 No 
occlusion 
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Table 8-1 Baseline demographics, clinical outcomes and imaging data for patients with 
occlusions 
Hyperglycaemia Group (n) All  (67) 
None (10) Admission (38) Late (19) 
 
Male Gender (n/%) 40 (59.7.) 5 (50) 23 (60.5) 12(63.2)  
Age  ± SD (mean/years) 71 ± 11.1 62.9 ±  16.4 
*  *** 
71.7 ± 10.5 * 73.8 ± 6.7  
*** 
p= 0.032 
Admission blood glucose ± SD 
(Mean mmol/L) 
7.52 ± 
3.36 
5.99 ± 0.55 
* 
8.76 ± 4.05 * ** 5.93 ± 0.81 
** 
p=0.002 
Mean capillary blood glucose ± 
SD (Mean, mmol/L) 
6.6 ± 1.29 5.23 ± 0.55 
* *** 
7.16 ± 1.33 * ** 6.22 ± 0.69 
** *** 
p<0.001 
HbA1c ± SD (Mean) 5.86 ± 1.1 5.51 ± 0.58 6.1 ± 1.4 5.6 ± 0.44 p=0.167 
Admission NIHSS (Median/IQR) 15 (8-19) 15 (11-20) 15.5 (8-19) 10 (8-18) p=0.646 
Admission Blood pressure ± SD 
(mmHg) 
150/78 ± 
23/15 
156/85 ± 
23/9 
150/76 ± 26/18 148/79 ± 
19/10 
p=0.721 
Diabetes (n/%) 9 (13.4) 0 9 (23.7) 0 p=0.022 
Impaired glucose tolerance 
(n/%) 
10 (14.9) 0 9 (23.7) 1 (5.3) p=0.092 
Thrombolytic treatment (n/%) 56 (83.6) 8 (80) 35 (92.1) 13(68.4) p=0.076 
Supra-aortic large artery 
atherosclerosis (n/%) 
22 (32.8) 3 (30) 11 (28.9) 8 (25.8) 
Cardio-aortic embolism (n/%) 24 (35.8) 4 (40) 13 (34.2) 7 (22.6) 
Small artery occlusion (n/%) 3 (4.5) 0 0 3 (9.7) 
Other causes (n/%) 4 (6) 1 (10) 3 (7.9) 0 
Undetermined causes (n/%) 26(38.9) 2 (20) 11 (28.9) 13 (42) 
 
 
p=0.795 
Recanalization (n/%) 37 (55.2) 4 (40) 23 (60.5) 10 (52.6) p=0.488 
CT Perfusion Core volume ±SD 
(Mean, ml) 
26.9 ± 27 27.9 ± 16.4 31 ± 31.3 18.2 ± 20.4 p=0.242 
CT Perfusion Penumbra volume 
±SD (Mean, ml) 
33 ± 23.4 34.9 ± 22.7 32 ± 22.5 33.9 ± 26.6 p=0.925 
Total Perfusion Lesion Volume 
±SD (Mean, ml) 
60 ± 43.8 62.8 ± 25 63 ± 47.5 52.1 ± 44.5 p=0.664 
Co-registered 24-48h infarct 
volume ± SD (Mean, ml) 
55.54 ± 
57.9 
33.5 ± 40.9 69.2 ± 65.8 ** 33.4 ± 40 ** p=0.073 
24-48h Infarct Volume ±SD 
(Mean, ml) 
89.3 ± 
103.2 
56 ± 69.9 115 ± 120.6 ** 43.1 ± 55 ** p=0.041 
Infarct Growth ± SD (Mean, ml) 29.4 ± 
41.1 
14.6 ± 14.8 39 ± 48.5 ** 15.2 ± 24.4 
** 
p=0.088 
Penumbral salvage ± SD (Mean, 
ml) 
4.4 ± 46.5 17.3 ± 40.6 -6.2 ± 53.6 18.7 ± 25.4 p=0.103 
Rankin 0-1 Day 30 (n/%) 9 (13.4) 2(20) 5 (13.2) 2(10.5) 
Rankin 2-5 Day 30 (n/%) 46 (68.7) 7(70) 25 (65.8) 14 (73.7) 
Rankin 6 Day 30 (n/%) 12 (17.9) 1(10) 8 (21.1) 3 (15.8) 
 
p= 0.80 
Using LSD analysis there was a significant difference between the following groups - *AHG vs. EG, 
** AHG vs. LHG, *** EG vs. LHG.  
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8.3.3 Infarct growth in patients with occlusions 
There was a significant difference in 24-48h infarct volume (p= 0.041) that was most 
pronounced, in post hoc analysis, between patients who were hyperglycaemic on 
admission and those who became hyperglycemic at a later time (p=0.039). 
 
 
Figure 41 - 24-48h total infarct volume in patients with occlusions subdivided by glycaemic 
status and recanalization 
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Figure 42 - Infarct growth in patients with arterial occlusions divided by glycaemic status 
and recanalization 
There was no significant difference in recanalization rates between groups (p=0.488) and 
clinical outcomes were similar.  Overall 55.2% of patients recanalized. 
Using the Pearson method significant correlations were found between mean capillary 
blood glucose and infarct growth (p=0.001), co-registered infarct volume (p<0.001), total 
24-48h infarct volume (p<0.001) and penumbral salvage (p=0.006). 
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Figure 43 - Mean capillary blood glucose and infarct growth in patients with arterial 
occlusions 
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Figure 44 - Co-registered 24-48h infarct volume and mean glucose in patients with 
occlusions 
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Figure 45 - Total 24-48h infarct volume and mean glucose in patients with occlusions 
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Figure 46 - Scatter plot of penumbral salvage and mean glucose in patients with occlusions 
Linear regression for infarct growth suggested a model containing admission NIHSS score 
(p=0.003, OR 1.95, 95%CI 0.699 to 3.22), mean capillary blood glucose (p=0.003, OR 
10.6, 95%CI 3.8 to 17.3) and admission systolic blood pressure (p=0.062, OR 0.36, 95%CI 
-0.02 to 0.73).  This model had an R squared of 0.359. 
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Figure 47 - Scatterplot of admission NIHSS against infarct growth in patients with 
occlusions 
For penumbral salvage linear regression showed that mean capillary blood glucose was 
inversely associated with tissue salvage with an odds ratio of 11.6 (p=0.006, 95%CI 3.5 to 
19.8).  The model was moderately predictive with R squared=0.111.  Other factors that I 
tried to fit into the model were not significant. 
The linear regression model for 24-48h infarct volume had R squared=0.532 with 
predictive variables including mean capillary blood glucose (p<0.001, OR 31.1, 95%CI 
16.6 to 45.7), admission NIHSS score (p<0.001, OR 6.5, 95%CI 3.8 to 9.2) and admission 
systolic blood pressure (p=0.021, OR 0.97, 95%CI 0.2 to 1.8).   
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Figure 48 - 24-48h infarct volume against admission NIHSS in patients with occlusions 
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Figure 49 - Change in NIHSS at 24 hours in relation to recanalization status and penumbral 
salvage 
A scatter plot of change in NIHSS at 24 hours (24 hour NIHSS – admission NIHSS) 
suggests that a fall in NIHSS at 24 hours is associated with increased penumbral salvage. 
8.3.4 Recanalization in patients with occlusions 
A binary logistic regression model for recanalization correctly predicted arterial patency in 
67.7% of cases with a p value of 0.049.  The model contained admission blood glucose 
(p=0.023, OR 1.4, 95%CI 1.05 to 1.89) and HbA1c (p=0.041, OR 0.43, 95%CI 0.19 to 
0.97.  Thrombolytic therapy was in the model but did not have a significant effect.   
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8.3.5 Patients without occlusions 
Thirty seven patients had strokes without a radiologically documented occlusion.  Eighteen 
of these patients were hyperglycaemic on admission, 12 became hyperglycaemic at a later 
point and 7 were consistently euglycaemic.   
The euglycaemic patients had a significantly lower Hba1c than patients who were 
hyperglycaemic on admission (p=0.029).  Patients who were hyperglycaemic were more 
likely to have an existing diagnosis of diabetes mellitus (p=0.008) or impaired glucose 
tolerance (p=0.019).  The late hyperglycaemia group had a significantly higher admission 
blood pressure than the admission hyperglycemia group (p=0.039) 
 
Figure 50 - Perfusion core volumes by glycaemic status in patients without occlusions 
There was a non-significant trend towards patients with normoglycaemia having larger 
core volumes (mean 19.9ml) than those with admission hyperglycaemia (0.9ml) or late 
hyperglycaemia (6.7ml) in the absence of an occlusion (p=0.331).   See Figure 50 above. 
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There were no significant differences in lesion volumes, lesion growth, stroke aetiology or 
clinical outcome between glycaemic groups in this sample.    
 
 
Figure 51 – Mean core volume, 24-48h infarct volume and infarct growth by glycaemic status 
in patients with no occlusions 
While there was no significant difference in 24-48h infarct volumes the bar chart (Figure 
51) comparing volumes between glycaemic groups suggests that core volumes were larger 
in the normoglycaemic group.  A scatter plot of mean glucose against outcome infarct 
volume suggested a trend towards larger infarcts with lower blood glucose levels in 
patients who do not have occlusions.  
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Figure 52 - Scatterplot of mean glucose against 24-48h infarct volume in patients without 
occlusions 
One way ANOVA showed that 24-48h infarct volumes were significantly larger in patients 
with admission hyperglycaemia and an occlusion that did not recanalize than in patients 
with recanalization or patients who had no documented occlusion (p=0.001).  Post hoc 
analysis showed significant differences in infarct volume between the no recanalization 
group and the no occlusion group (p<0.001) and between the no recanalization group and 
the recanalization group (0.035).  The difference in infarct volume was not significant 
between the no occlusion group and the recanalization group (p=0.056).  There were no 
significant differences in outcome infarct volumes based on occlusion status amongst the 
euglycaemia patients or the late hyperglycaemia patients.
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Table 8-2 Demographics, clinical outcomes and imaging data for patients with no occlusion 
Hyperglycaemia Group (n) All 
patients None (7) Admission (18) Late (12) 
 
Male Gender (n/%) 23 (62.1) 5 (71.4) 9 (50) 9 (75)  
Age ± SD (mean/years) 66.8 ± 60.7 ± 11.8 68 ± 10.4 68.7 ± 14.4 p=0.339 
Admission blood glucose ± SD  
(Mean mmol/L) 
7.38 ± 
3.32 
5.58 ± 0.63 
* 
8.85 ± 3.93 * 
** 
6.22 ± 2.2 ** p=0.025 
Mean capillary blood glucose ± 
SD (Mean, mmol/L) 
7 ± 2.1 5.64 ± 0.6* 8.14 ± 2.08* 
** 
6.11 ± 0.96 ** p=0.004 
HbA1c ± SD (Mean) 5.9 ± 1.1 5.27 ± 0.38* 6.37  ± 1.3 * 5.8 ± 0.96 p=0.073 
Admission NIHSS 
(Median/IQR) 
6 (4-8) 5 (3-9) 6 (4-8) 5.5 (4-8) p=0.847 
Admission Blood pressure ± SD 
(mmHg) 
151/78 ± 
25/14 
147/69 ± 
20/9 
143/80 ± 
25/17 ** 
163/81 ± 
24/10 ** 
p=0.105 
Diabetes (n/%) 10 (26.5) 0 9 (50) 1 (8.3) p=0.008 
Impaired glucose tolerance 
(n/%) 
9 (24.3) 0 8 (44.4) 1 (8.3) p=0.019 
Thrombolytic treatment (n/%) 17 (46) 2 (28.6) 7 (38.9) 8 (66.7) p=0.193 
Supra-aortic large artery 
atherosclerosis (n/%) 
10 1 (14.3) 5 (27.8) 4 (33.3) 
Cardio-aortic embolism (n/%) 26 (70.3) 2 (28.6) 2 (11.1) 0 (0) 
Small artery occlusion (n/%) 9 (24.3) 1 (14.3) 4 (22.2) 3 (25) 
Other causes (n/%) 2 (5.4) 2 (11.8) 0 0 
Undetermined causes (n/%) 15 (40.5) 3 (42.9) 7 (38.9) 5 (41.7) 
p=0.525 
 
CT Perfusion Core volume ± SD 
(Mean/ml) 
4.35 ± 14 9.19 ± 19.1 0.9 ± 1.67 6.7 ± 19.9 p=0.331 
CT Perfusion Penumbra 
volume ± SD (Mean/ml) 
5 ± 13.1 12.9 ± 27.8 1.6 ± 2.72 5.4 ± 8.3 p=0.150 
Total Perfusion Lesion Volume 
± SD (Mean/ml) 
9.3 ± 25.8 22.1 ± 46.8 2.5 ± 4.3 12.1 ±  27.5 p=0.213 
Co-registered 24-48h infarct 
volume ±SD  (Mean/ml) 
17.27 ± 42 16.31± 33.7 15.44 ± 37.6 20.6 ± 54.2 p=0.948 
24-48h Infarct Volume ± SD 
(Mean/ml) 
30.2 ± 
71.6 
22.5 ± 47.3 22.49 ±50.6 46.2 ± 46.2 p=0.654 
Infarct Growth ± SD (Mean/ml) 12.9 ± 
32.3 
7.11 ± 14.6 14.55 ± 36.3 13.9 ± 35.3 p=0.875 
Penumbral salvage ± SD 
(Mean/ml) 
-7.9 ± 30.5 5.8 ± 13.2 -12.9 ± 35.1 -8.5 ±  29.8 p=0.395 
Rankin 0-1 Day 30 (n/%) 8 (21.6) 3 (42.9) 3 (16.7) 2 (16.7) 
Rankin 2-5 Day 30 (n/%) 29 (78.4) 4 (57.1) 15 (83.3) 10 (83.3) 
Rankin 6 Day 30 (n/%) 0 0 0 0 
 
p=0.317 
Using LSD analysis there was a significant difference between the following groups - *AHG vs. EG, 
** AHG vs. LHG, *** EG vs. LHG 
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8.3.6 Baseline characteristics compared with occlusion group 
Patients without occlusion have lower initial NIHSS scores that patients with occlusions 
(p<0.001).  Patients without occlusion were significantly less likely (p=0.02) to have atrial 
fibrillation (5/37) than patients who had occlusions (23/67).  No significant differences 
were otherwise detected in age, mean capillary blood glucose level, admission blood 
glucose, HbA1c or blood pressure using ANOVA. 
8.3.7 Comparison of day 30 modified Rankin score depending on 
occlusion status 
Generally the patients with no evidence of angiographic occlusion had better day 30 
clinical outcomes than those with occlusions.  Chi-squared testing showed that patients 
without occlusion were more likely to have a day 30 Rankin score of 2 or less at 30 days 
(p=0.004) and less likely to be dead at 30 days (p=0.006). 
The distribution of 30 day Rankin scores is illustrated in Figures 53 and 54 on the 
following two pages. 
  215 
 
 
Figure 53 - 30 Day Rankin scores in patients with occlusions 
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Figure 54 – 30 Day Rankin scores in patients with no occlusion
217 
8.3.8 Patients with evidence of recanalization 
Thirty-seven patients had radiological evidence of recanalization.  Twenty-three of these 
patients were hyperglycaemic on admission, 10 became hyperglycaemic later and 4 were 
consistently euglycaemic.  Overall there was no significant difference in admission blood 
glucose level between these groups although in post-hoc analysis a statistically significant 
difference in admission blood glucose level between patients who were hyperglycaemic on 
admission and those who became hyperglycaemic later (p=0.012). 
 
Figure 55 - Flow chart for patients who had evidence of recanalization 
 
In the population as a whole there was no statistically significant difference in core 
perfusion volumes.  Post hoc analysis did suggest that core perfusion lesions were 
significantly larger in patients who were hyperglycaemic on admission with a mean 
volume of 26.1ml compared to a mean volume of 10.7ml in patients who became 
hyperglycaemic later (p=0.035).  
67 occlusions and 
complete imaging 
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38 Admission 
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19 late 
Hyperglycaemia 
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recanalization  
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recanalization  
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Figure 56 - Core perfusion volumes varies with glycaemic status and final recanalization 
status 
While initial analysis showed no significant difference between groups for co-registered 
24-48h infarct volume (p=0.127) and total infarct volume (p=0.072) post hoc analysis 
suggested that both co-registered 24-48h infarct volume and total 24-48h infarct volume 
were significantly larger in the admission hyperglycaemia group when compared with the 
late hyperglycaemia group (p=0.045, p=0.024). 
219 
 
 
Figure 57 - 24-48h infarct volumes varies with glycaemic status and recanalization 
While there was no overall significant difference in 24-48h total infarct volume between 
groups post hoc analysis suggested a significant difference did exist between patients with 
admission hyperglycaemia and patients with late hyperglycaemia (p=0.024). 
There were no significant differences in clinical outcomes at 30 days between groups. 
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Table 8-3 Demographics, clinical outcomes and imaging data from recanalization cohort 
Hyperglycaemia Group (n) All 
patients 
(37) 
None (4) Admission 
(23) 
Late (10) 
 
Male Gender (n/%) 24 (64.9) 2 (50) 13 (56.5) 9 (90)  
Age ± SD (mean/years) 66.84 ± 
11.9 
58.3 ± 18.4  
*** 
70.4 ± 11.  7 75.8 ± 5.3 
*** 
p=0.41 
Admission blood glucose ± SD  
(Mean mmol/L) 
7.38 ± 
4.18 
6.3 ± 0.45 9.25 ± 4.98 
** 
6.01 ± 0.65 
** 
p=0.084 
Mean capillary blood glucose ± 
SD (Mean, mmol/L) 
6.5 ±  1.2 5.23 ±  0.71 6.94 ±  1.29 5.99 ± 1.3 p=0.007 
HbA1c ± SD (Mean) 5.9 ± 1.3 5.43 ± 0.8 6.1 ± 1.6 5.4±  1.6 p=0.365 
Admission NIHSS (Median/IQR) 6 (4-8) 18.5 (12.75-
22) 
16 (7-19) 8.5 (3.5-
12.25) 
p=0.743 
Admission Blood pressure ± SD 
(mmHg) 
151/78 ± 
21/13 
156/91 ± 29/3 142/72 ± 
21/12 
149/79 ± 
19/10 
p=0.463 
Diabetes (n/%) 10 (27) 0 4 (17.4) 0 p=0.236 
Impaired glucose tolerance (n/%) 9 (24.3) 0 4 (17.4) 1 (10) p=0.655 
Thrombolytic treatment (n/%) 32 (86.4) 4 (100) 21 (91.3) 7 (70) p=0.266 
Supra-aortic large artery 
atherosclerosis (n/%) 
11 1 (25) 8 (34.8) 2 (20) 
Cardio-aortic embolism (n/%) 13 (35.1) 2 (50) 7 (30.4) 4 (40) 
Small artery occlusion (n/%) 0 0 0 0 
Other causes (n/%) 3 (8.1) 1 (25) 2 (8.7) 0 
Undetermined causes (n/%) 10 (27) 0 6 (26.1) 4 (40 
p=0.594 
 
CT Perfusion Core volume ± SD 
(Mean, ml) 
4.35 ± 
19.2 
19.1 ± 6.8 26.1 ± 21.7  
** 
10.7 ± 11.2  
** 
p=0.103 
CT Perfusion Penumbra volume ± 
SD (Mean, ml) 
5 ± 23.5 32.4 ± 31 29.4 ± 22.1 27.8 ± 26.2 p=0.949 
Total Perfusion Lesion Volume ±  
SD (Mean, ml) 
9.34 ± 
36.4 
51.5 ± 27.4 55.4 ± 38.1 38.5 ± 36.1 p=0.482 
Co-registered Final infarct 
volume ± SD  (Mean, ml) 
17.27 ± 
43.9 
38.2 ± 21.2 53.2 ± 49.7 
** 
19.6 ± 25.1 
** 
p=0.127 
Final Infarct Volume ± SD (Mean, 
ml) 
30.2 ± 
70.3 
80.2 ± 54.9 84.7 ± 79 ** 25 ± 25.7 ** p=0.072 
Infarct Growth ± SD (Mean, ml) 12.9 ± 
38.8 
19.1 ± 15.5 28.4 ± 46.6 9 ± 18.4 p=0.424 
Penumbral salvage ± SD (Mean, 
ml) 
7.9 ± 51.7 13.3 ± 37.2 2.3 ± 62 18.8 ± 25 p=0.695 
Rankin 0-1 Day 30 (n/%) 6 (16.2) 1 (25) 7 (30.4) 6 (60) 
Rankin 2-5 Day 30 (n/%) 27 (73) 3 (75) 14 (60.8) 2 (20) 
Rankin 6 Day 30 (n/%) 4 (10.8) 0 2 (8.7) 2 (20) 
 
p=0.21 
Using LSD analysis there was a significant difference between the following groups - *AHG vs. EG, 
** AHG vs. LHG, *** EG vs. LHG 
221 
 
8.3.9 Patients with occlusions who did not recanalize 
Thirty patients had occlusions but did not recanalize.  Fifteen of these patients were 
hyperglycaemic on admission, 9 became hyperglycaemic at a later point and 6 were never 
observed to be hyperglycaemic. 
Penumbral salvage was significantly different between groups in this population 
(p=0.036).  A significant difference in penumbral salvage was observed in post hoc 
analysis between the admission hyperglycemia and late hyperglycaemia groups (p=0.016) 
although there was no significant difference between final infarct sizes in these groups. 
 
Figure 58 - Penumbral salvage varies with glycaemic status and recanalization 
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Table 8-4 Baseline demographics, clinical outcomes and imaging data from patients who 
did not recanalize 
Hyperglycaemia Group (n) All patients 
(30) None  (6) Admission 
(15) 
Late (9) 
 
Male Gender (n/%) 23 (76.6) 3 (50) 10 (66.7) 3 (33.3)  
Age ± SD (mean/years) 66.8 ±10.1   66 ±  16 73.9 ± 8.2   71.67 ± 7.7  p=0.282 
Admission blood glucose ± SD  
(Mean mmol/L) 
7.38 ± 1.9   5.78 ± 0.54 
* 
8.05 ± 2.03 * 
** 
5.85 ± 1 ** p=0.003 
Mean capillary blood glucose ± SD 
(Mean, mmol/L) 
6.7 ±  1.4 5.22  ±  
0.49 
7.5 1 ±  1.4 6.5 ±  0.93 p=0.001 
HbA1c ± SD (Mean) 5.9 ± 0.8   5.56 ± 0.5   6.19 ± 1.1  5.84 ± 0.5   p=0.287 
Admission NIHSS (Median/IQR) 6 (4-8) 13.5 (8.5-
18.5) 
15 (8-19) 15 (8.5-
20.5) 
p=0.575 
Admission Blood pressure ± SD 
(mmHg) 
151/78 ± 
24/18  
156/81 ±  
21/10 
163/82 ± 
30/24  
147/78 ± 
16/11  
p=0.889 
Diabetes (n/%) 10 (33.3) 0 4 (33.3) 0 p=0.91 
Impaired glucose tolerance (n/%) 9 (30) 0 5 (33.3) 0 p=0.91 
Thrombolytic treatment (n/%) 24 (80) 4 (66.7) 14 (93.3)  6 (66.7) p=0.275 
Supra-aortic large artery 
atherosclerosis (n/%) 
7  2 (33.3) 3 (20) 2 (22,2) 
Cardio-aortic embolism (n/%) 11 (36.6) 2 (33.3) 6 (40) 3 (33.3) 
Small artery occlusion (n/%) 0 0 0 0 
Other causes (n/%)  1 (3.33) 0  1 (6.7) 0 
Undetermined causes (n/%) 11 (36.6) 2 (33.3) 5 (33.3) 4 (44.4) 
 
 
p=1 
CT Perfusion Core volume ± SD 
(Mean, ml) 
4.35 ± 33.2  33.8 ± 18.8   38.7±   26.6 ± 25  p=0.706 
CT Perfusion Penumbra volume ± 
SD (Mean, ml) 
5 ± 23  36.5 ± 18.8   36 ± 41.7  40.6 ± 26.9  p=0.894 
Total Perfusion Lesion Volume ±  
SD (Mean, ml) 
9.34 ± 49.6  70.3 ± 22.4  74.7 ± 23.3  67.2 ± 50  p=0.940 
Co-registered Final infarct volume 
± SD  (Mean, ml) 
17.27 ± 69  50.43 ± 
51.7   
93.86 ± 80.5  48.7 ± 48.9  p=0.216 
Final Infarct Volume ± SD (Mean, 
ml) 
30.2 ± 129.7  79 ± 83.6   161.38 ± 
157.5  
63.2 ± 72  p=0.149 
Infarct Growth ± SD (Mean, ml) 12.9 ± 42.7   20.9 ± 31   55.2  ± 48.4  63.2 ± 29.2  p=0.096 
Penumbral salvage ± SD (Mean, 
ml) 
-0.03 ± 39.5   19.9 ± 46*   -19.1 ± 35.7 * 
** 
18.5 ± 27.4 
** 
p=0.024 
Rankin 0-1 Day 30 (n/%) 3 (10)  2 (33.3) 1 (6.7) 0  
Rankin 2-5 Day 30 (n/%) 19 (63.3) 3 (50) 8 (53.3) 8 (88.9) 
Rankin 6 Day 30 (n/%) 8 (26.6) 1 (16.7) 6 (40) 1 (11.1) 
 
p=0.363 
Using LSD analysis there was a significant difference between the following groups - *AHG vs. EG, 
** AHG vs. LHG, *** EG vs. LHG 
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8.4 Discussion 
This chapter focuses on the interaction between arterial patency, glycaemic status and 
infarct growth.  The most interesting finding when focusing on patients with angiographic 
evidence of arterial occlusion is the statistically significant difference in final infarct 
volume seen between groups (p=0.041). 
As seen in the previous chapter there is a trend for the biggest different in final infarct 
volumes to be between the patients who are hyperglycaemic within 6 hours of stroke onset 
and those who become hyperglycaemic at a later time point (p=0.041 in post hoc analysis).  
Indeed on post hoc analysis statistically significant differences were also seen between 
these two groups for co-registered final infarct volume (p=0.027), total final infarct volume 
(p=0.013) and infarct growth (p=0.039).   
It is also interesting to note that there is no statistically significant difference in infarct 
volumes or growth between the euglycaemic group and the other groups.  This may be due 
to the low number of patients in the euglycaemic group as only 10 patients with 
documented occlusions were recruited.  It is possible that data from the euglycaemic group 
has been skewed by a particularly severe stroke but when I review the raw data I can see 
that four patients in this group had final infarct volumes of 110ml or greater with initial 
NIHSS scores of 16 or more suggesting that they were not outliers.  These patients all had 
complete glucose profiles with 12 or more capillary blood glucose measurements within 48 
hours.  They appear to have been truly euglycaemic with severe strokes. 
While early hyperglycaemia does appear to have a negative impact on infarct growth these 
data presented in this chapter do not support the notion that euglycaemia automatically 
makes things better.  Indeed, if anything a late rise in plasma blood glucose may be a good 
sign.  Certainly Ntaios and colleagues found that hypoglycaemia (a blood glucose below 
3.7mmol/L) could be associated with worse outcomes in acute ischaemic stroke.173  While 
there were no patients who were found to be consistently hypoglycaemic several had 
documented glucose levels below 4mmol/L, at least 4 of the 10 patients were documented 
as being ‘nil by mouth’ at some point while 6/10 are documented as having an impaired 
swallow.  All 10 of the euglycaemic patients were prescribed intravenous normal saline to 
maintain hydration after their stroke.  The five patients with the worst outcomes all had 
dysarthria documented in their admission NIHSS scores.  
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Mean capillary blood glucose strongly correlates with final infarct volume and related 
variables in this population of patients with a documented arterial occlusion. 
In the group of patients with arterial occlusions linear regression was able to create a 
moderately predictive model for infarct growth containing admission NIHSS score, mean 
capillary blood glucose and admission systolic blood pressure.  Several factors that I would 
have expected to be in this model including thrombolytic treatment and final recanalization 
did not fit in this model.  This could be explained by missing values for some variables, 
small total sample size (N=67) and the fact that a high proportion of patients (83.6%) 
received thrombolytic treatment. There may also be a confounding factor that I have been 
unable to identify.  Unusually admission blood glucose was associated with recanalization 
which also suggests the presence of an unidentified confounding factor.  Again, it would be 
interesting to repeat this analysis in another larger population to see if the model would 
remain valid and if factors such as thrombolytic treatment or recanalization status would 
have a more significant effect. 
The model for final infarct volume had a larger R squared.  This model contained the same 
factors as before, again omitting thrombolytic treatment and recanalization.  A further 
binary logistic regression model (p=0.049) for angiographic recanalization in this 
population was made to include thrombolytic therapy although thrombolysis was not a 
significant variable in the model (p=0.27).  The model which also contained admission 
blood glucose level (p=0.023) and HbA1c (p=0.041) became more significant (p=0.037) 
when thrombolysis was removed.  It is possible that glycaemic status interferes with the 
fibrinolytic activity of rt-PA and this has been suggested by pre-clinical studies.349  Ribo 
and colleagues suggested in their 2005 paper that acute hyperglycaemia may interfere with 
the fibrinolytic process.200  The presence of HbA1c as a significant factor in this regression 
model may hint that chronic dysglycaemia is important too.  Certainly clinical studies have 
suggested that plasminogen activator may be inhibited in Type 2 diabetes mellitus.365 
Initial analysis of patients who recanalized did not show significant differences for 
anything other than admission glucose (which had been used to select groups anyway) and 
mean capillary blood glucose.  Post hoc analysis suggested that core perfusion lesions, co-
registered final infarct volume and total final infarct volume were all significantly larger in 
the admission hyperglycaemia group compared to the late hyperglycaemia group.  In this 
subgroup analysis the numbers in the glycaemic subgroups are very small (10 late 
hyperglycaemia patients and 4 normoglycaemia patients) so it is not surprising that we 
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have not seen any strongly significant results.  The trend suggested by the post hoc analysis 
would become clearer if this study were to be repeated in a larger population 
Basic outcome comparisons between the patients without occlusions and the patients with 
occlusions suggest that you are more likely to die with an occlusion and less likely to have 
a good recovery.  The only significant baseline differences between the groups are the 
lower incidence of atrial fibrillation and lower baseline NIHSS score in the no occlusion 
group. 
One interesting trend that was observed in the patients without occlusions was the 
tendency for normoglycaemia to be associated with larger core perfusion lesions and larger 
follow-up infarct volumes than patients who were hyperglycaemic on admission or at a 
later point.  This could be in keeping with the observations of Uyttenboogaart and 
colleagues found a dichotomous relationship between hyperglycemia and clinical outcome 
when lacunar strokes were compared to non-lacunar strokes.260  Data from 168 lacunar 
stroke patients and 1207 non-lacunar patients were available.  In their analysis 
hyperglycemia (defined as a blood glucose above 8mmol/L) was associated with a lower 
chance of a good outcome (mRs<2) at 3 months in non-lacunar stroke (OR for good 
outcome 0.60; 95% CI 0.41–0.88, p=0.009).  However in lacunar patients hyperglycemia 
was associated with a good outcome (OR 2.70, 95% CI 1.01- 7.13, p=0.048). 
Finally, when looking at the patients who did not recanalize we see a statistically 
significant difference in penumbral salvage between groups (p=0.024) with post hoc 
analysis suggesting that this difference is most significant between the admission 
hyperglycaemia group and the late hyperglycaemia group (p=0.016). 
These results, as a whole, suggest that in the presence of arterial occlusion admission 
hyperglycaemia reduces penumbral survival and increases final infarct volume.  The 
interesting new finding is the suggestion that late hyperglycaemia after 6 hours may be 
associated with better imaging outcomes and improved penumbral survival.   
Arterial patency appears to be a key determinant of the interaction between the ischaemic 
penumbra and blood glucose.  The presence of an occlusion makes admission 
hyperglycaemia harmful although later hyperglycaemia may be beneficial.  The absence of 
an occlusion may be associated with a beneficial effect from admission hyperglycaemia. 
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Taken in the context of the results of the SELESTIAL trial,554  the INSULINFARCT 
trial,562 my reassessment of the animal evidence in chapter 3206 and the systematic review 
of the clinical trials of insulin for post stroke hyperglycemia presented in chapter 4 there is 
at present little justification for further human trials of insulin treatment for post-stroke 
hyperglycaemia after the initial 6 hour window.  Any trials of insulin for PSH within 6 
hours of stroke onset should also be considered very carefully.  Larger scale studies 
examining the pathophysiology of post stroke hyperglycaemia and its interaction with 
brain arterial may be of more value in the first instance
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9 Interaction between post stroke hyperglycaemia 
and brain arterial patency in more homogenous 
subpopulations - M1 occlusions only 
9.1 Introduction 
Heterogeneity of patients with stroke may obscure biologically relevant interactions due to 
dilution of the sample. Effects may be evident if a more homogeneous patient population 
can be identified. In previous studies an effect of recanalization on final infarct volume 
was only seen in a subgroup analysis looking at M1 occlusions.579  It has certainly been 
suggested that neuroprotective stroke trials may have failed due to heterogeneous 
populations of patients (among other issues).580 Pathophysiological mechanisms may be 
obscured in a highly heterogeneous population and in this exploratory chapter I have tried 
to focus on a more uniform patient group.    
The EPITHET study showed that the site of arterial occlusion strongly predicts outcome in 
treatment with intravenous thrombolysis.581 In this study ICA occlusions were seen to be 
associated with poor outcomes while MCA obstructions were associated with better 
outcomes.  A recent pilot study comparing tenecteplase and alteplase for the treatment of 
acute ischaemic stroke had pre-determined stringent imaging inclusion criteria based on 
site of occlusion.582 An earlier pilot study found that differences in occlusion sites between 
treatment groups prevented accurate comparison of the two drugs.583  
In order to explore the potential interaction of early and delayed hyperglycaemia with 
arterial patency and brain perfusion further, this analysis was restricted to those patients 
with acute occlusion of the proximal segment of the middle cerebral artery (an M1 
occlusion). This group represents a more homogeneous population with respect to the 
expected volumes of ischaemia, clinical severity, response to IV rtPA treatment, and 
outcomes.  
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9.2 Methods 
9.2.1 Image analysis 
Analysis of CTP and plain CT was performed as detailed in the previous chapter.  
Admission and follow-up scans were again read by two observers (NM and XH) for 
presence of an arterial occlusion on the admission scan and for recanalization on follow-up 
imaging.  If there was any disparity between observers a final decision was made by an 
experienced stroke neurologist who could also make reference to neuroradiology reports 
(KM). 
9.2.2 Case selection 
In this chapter all analysis was carried out on patients with CTA confirmed M1 occlusion.  
Initially it looks at all patients with M1 occlusions before comparing patients with pure M1 
occlusions against patients with tandem occlusions (M1 plus another arterial occlusion).  
Finally it focuses on the pure M1 occlusions. 
9.2.3 Analysis 
Infarct growth was defined as the difference between core perfusion volume lesion and 
final co-registered infarct volume.  Patients were divided into groups based on glycaemic 
status as described in the previous chapters.   
9.2.4 Statistical analysis 
Differences between groups were analysed using ANOVA for scale variables and 
Pearson’s chi squared for categorical variables.  If a significant difference between groups 
was discovered using ANOVA it was further analysed using the least significant difference 
method. 
Linear regression analysis and binary logistic regression analysis were carried out as in 
previous chapters to seek predictors of infarct growth, final infarct volumes and 
recanalization. 
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9.3 Results 
9.3.1 Patient characteristics 
Thirty three patients had CT angiographic evidence of an M1 occlusion on baseline CTA.   
 
  
Figure 59 – Recruitment flowchart for patients with an M1 occlusion 
Seventeen of these patients were hyperglycaemic on admission, 10 became 
hyperglycaemic at a later point in the admission and 6 were euglycaemic at all times. 
Tandem occlusions were present in 16 patients.  
In post hoc analysis there was a significant difference in penumbral volume between the 
patients who were euglycaemic at all times and the group who became hyperglycemic at a 
later point.  The mean penumbral volume was significantly larger in the late hyperglycemia 
group compared to the euglycaemic group. 
113 
Consented 
5 non-strokes excluded 
4 Migraine 
1 Peripheral Nerve Palsy 
33 M1 occlusions and 
complete imaging 
6 Euglycaemic at 
all times 
17 Admission 
Hyperglycaemia 
10 late 
Hyperglycaemia 
4 CTP unusable 
37 No occlusion 
38 Other site of occlusion 
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There was no significant difference in recanalization rates between groups (p=0.447) and 
clinical outcomes were not significantly different although a larger proportion of patients 
died in the hyperglycaemic groups compared to the consistently euglycaemic group.  
Overall 55% of patients recanalized while 85% received thrombolytic treatment. 
There was no significant difference in clinical outcome as graded with the modified 
Rankin scale at 30 day follow-up. 
The data from these patients are summarized in Table 9.1. 
231 
 
 
Table 9-1 Demographics, clinical outcomes and imaging results with M1 occlusion 
Hyperglycaemia Group (n) All patients 
(33) None (6) Admission 
(17) 
Late (10) 
 
Male Gender (n/%) 15 (45.4.) 2 (33.3) 7 (41.2) 6 (60)  
Age ± SD (mean/years) 71.5 ± 61.8 ± 15.6  * 75.1 ± 9 * 71.1 ± p=0.053 
Admission blood glucose ± SD 
(Mean mmol/L) 
7.28 ± 11.8 6.18 ± 0.5 *  8.48 ± 1.93 * 
** 
5.91  ± 
0.91  ** 
p<0.001 
Mean capillary blood glucose ± 
SD  (Mean, mmol/L) 
6.57 ± 1.31 5.3 ± 0.58* 7.23 ± 1.38* 
** 
6.21  ± 
0.7** 
p=0.002 
HbA1c ± SD (Mean) 5.7 ± 0.8 5.6 ± 0.7 5.9 ± 0.9 5.44  ± 0.3 P=0.387 
Admission NIHSS (Median/IQR) 15 (8-19) 17 (12.5-
23.75) 
19 (13.5-21.5) 13.5 
(9.75-
p=0.587 
Admission Blood pressure ± SD 
(mmHg) 
150/78 ± 
26/17 
159/87 ± 21/9 146/75 ± 
29/21 
149/77  ± 
22/8 
p=0.585 
Diabetes (n/%) 3 (9.1) 0 3 (17.6) 0 p=0.212 
Impaired glucose tolerance (n/%) 3 (9.1) 0 3 (17.6) 0 p=0.212 
Thrombolytic treatment (n/%) 28 (84.8) 5 (83.3) 15 (88.2) 8(80) p=0.841 
Supra-aortic large artery 
atherosclerosis (n/%) 
10 (30.3) 2 (33.3) 4 (23.5) 4 (40) 
Cardio-aortic embolism (n/%) 15 (45.4) 3 (50) 9 (52.9) 3 (30) 
Small artery occlusion (n/%) 0 0 0 0 
Other causes (n/%) 0 0 0 0 
Undetermined causes (n/%) 8 (24.2) 1 (16.7) 4 (23.5) 3 (30) 
 
p=0.803 
 
Recanalization (n/%) 18 (54.5) 3 (50) 11 (64.7) 4 (40) p=0.447 
Tandem occlusions (n/%) 16 (48.5) 4 (66) 6 (35.3) 6 (60) p=0.447 
Internal ICA occlusion (n/%) 12 (36.4) 3 (50) 5 (29.4) 4 (40) p=0.639 
External ICA occlusion (n/%) 9 (23.3) 2 (33) 4  (23.5) 3 (30) p=0.874 
CT Perfusion Core volume ± SD 
(Mean, ml) 
41.1± 30.2 32.4 ± 19.3 47.8 ± 35.6 35.2  ± 
24.6 
p=0.437 
CT Perfusion Penumbra volume ± 
SD (Mean, ml) 
42.1 ± 22.4 28.7 ± 22.1 
***  
40.4 ± 21.3 53 ± 21.3  
*** 
p=0.97 
Total Perfusion Lesion Volume ±  
SD (Mean, ml) 
83.2 ± 41.9 61.1 ± 28.8 88.1 ± 47.3 88.1 ± 
37.5 
p=0.370 
Co-registered Final infarct 
volume ± SD  (Mean, ml) 
77.5 ± 67.2 65.2 ± 41.7 87  ± 78.1 68.7  ± 
62.1 
p=0.713 
Final Infarct Volume ± SD (Mean, 
ml) 
118.9 ± 
120.8 
114.1 ± 69 135  ± 145.7 94.3 ±  
101.6 
p=0.709 
Infarct Growth ± SD (Mean, ml) 37.2± 46.6 32.8 ± 24.8 40.9 ± 55.4 33.5 ± p=0.898 
Penumbral salvage ± SD (Mean, 
ml) 
8.8 ± 49.6 -4.1± 37.1 1.2  ±  55.5 31.7  ± 
31.2 
p=0.263 
Rankin 0-1 Day 30 (n/%) 4 (12.1) 0 3 (17.6) 1 (10) 
Rankin 2-5 Day 30 (n/%) 20 (60.6) 5 (83.3) 9 (52.9) 6 (60) 
Rankin 6 Day 30 (n/%) 9 (27.3) 1(16.7) 5 (29.4) 3 (30) 
p= 0.70 
Using LSD analysis there was a significant difference between the following groups - *AHG vs. EG, ** AHG 
vs. LHG, *** EG vs. LHG 
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Figure 60 Boxplot of penumbral volume dependant on glycaemic status in patients with M1 
occlusions 
There was a non-significant trend for patients with normoglycaemia to have smaller 
volumes of penumbral tissue than patients who had admission hyperglycaemia or late 
hyperglycaemia. 
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Figure 61 - Relationship between mean glucose and penumbral salvage in patients with M1 
occlusions 
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Figure 62 - Relationship between infarct growth and mean glucose in patients with M1 
occlusions 
A scatter plot suggests that there is a trend towards greater infarct growth with increasing 
mean glucose levels.  
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Figure 63 – Imaging results for patients with M1 occlusions vary with recanalization and 
glycaemic status 
 
9.3.2 Regression analysis for all patients with M1 occlusions 
Linear regression analysis suggested that the presence of recanalization was a predictor of 
final infarct volume (p=0.001, 95% CI -197.9 to -58.5) as was admission blood glucose 
(p=0.018, 95%CI 4.1 to 40.7).   
Binary logistic regression for the prediction of recanalization showed that the presence or 
absence of a tandem occlusion predicted final recanalization status with p=0.03 (OR 5.2, 
95% CI 1.17 to 23).  Other factors that were not significant in this model included 
admission hyperglycaemia, age, HbA1c, thrombolytic treatment, systolic blood pressure, 
diastolic blood pressure and admission NIHSS. 
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9.3.3 Tandem occlusions 
Overall 16 patients (48.5%) in this group had 2 or more occlusions.  There was no 
significant difference in the presence of tandem occlusions between groups.  Patients with 
tandem occlusions were less likely to recanalize than patients with only one occlusion 
(p=0.025 using chi squared).  Patients with tandem occlusions also tended to have a higher 
baseline NIHSS although this was non-significant. 
 
Figure 64 - Perfusion lesion and outcome infarct volumes vary with glycaemic status and 
presence of tandem occlusion 
Outcomes were compared between patients with M1 occlusions only and patients with 
tandem occlusions.  In the admission hyperglycaemia group patients with tandem 
occlusions had significantly larger core perfusion lesions (p=0.008), total perfusion lesion 
volumes (p=0.033), co-registered infarct volumes (p=0.001), total infarct volumes 
(p=0.001) with greater infarct growth (p=0.011) and reduced penumbral salvage (p=0.033).  
Day 30 clinical outcomes were also worse in the tandem occlusion group (p=0.035).  
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Glucose variables (admission blood glucose, mean capillary blood glucose, HbA1c) were 
slightly higher in the tandem occlusion group but not significantly so. 
 
Figure 65 - Imaging findings vary with occlusion type 
In the euglycaemic patients smaller perfusion lesions were seen in the M1 occlusion group 
than the tandem occlusion group (p=0.049) although these groups were both small.  No 
other significant differences were seen. 
There were no significant differences in the late hyperglycaemia patients although patients 
with tandem occlusions tended to have larger infarct volumes with more infarct growth and 
less penumbral salvage.  
There was a significant difference in penumbral salvage between glycaemic groups in the 
tandem occlusion group (p=0.026).
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Table 9-2 Tandem occlusions compared with M1 only in admission hyperglycaemia group  
Group (n) AHG tandem (6) AHG M1 only (11)  
Age ± SD (mean/years) 75 ± 11 75.2 ± 8.3 P=0.970 
Admission blood glucose ± SD (Mean mmol/L) 9.13 ± 1.98 8.12 ± 1.89 P=0.314 
Mean capillary blood glucose ± SD  (Mean, mmol/L) 7.86 ± 1.97 6.89 ± 0.86 P=0.177 
HbA1c ± SD (Mean) 6.3 ± 1.5 5.7 ± 0.6 P=0.336 
Admission NIHSS (Median/IQR) 21 (13-26) 18 (13-20)  
Admission Blood pressure ± SD (mmHg) 161/86 ± 42/30 138/69 ± 17/12 P=0.133 
Thrombolytic treatment (n/%) 5 (83) 10 (91) P=0.596 
Recanalization (n/%) 2 (33) 9 (82) P=0.072 
CT Perfusion Core volume ± SD (Mean, ml)) 76.9 ± 43.3 31.9 ± 17.4 P=0.008 
CT Perfusion Penumbra volume ± SD (Mean, ml) 43.6 ± 25.3 38.7 ± 19.8 P=0.662 
Total Perfusion Lesion Volume ±  SD (Mean, ml) 120.5 ± 54.4 70.6 ± 33.7 P=0.033 
Co-registered Final infarct volume ± SD  (Mean, ml)) 161.4 ± 81.7 46.4  ± 36.1 P=0.001 
Final Infarct Volume ± SD (Mean, ml) 271.7 ± 167.1 60.4  ± 48.6 P=0.001 
Infarct Growth ± SD (Mean, ml) 84.5± 63.7 17.2 ± 33.4 P=0.011 
Penumbral salvage ± SD (Mean, ml) -40.9 ± 49.36 17.5 ±  48.8 P=0.033 
Rankin 0-1 Day 30 (n/%) 0 3 (27.3) 
Rankin 2-5 Day 30 (n/%) 2 (33.3) 7 (63.6) 
Rankin 6 Day 30 (n/%) 4 (66.7) 1 (9.1) 
 
, 
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Table 9-3 Tandem occlusions compared with M1 only in late hyperglycaemia group 
Group (n) LHG tandem (6) LHG  M1 only (4)  
Age ± SD (mean/years) 75.3 ± 7.3 64.8 ± 14 p=0.151 
Admission blood glucose ± SD (Mean mmol/L) 5.87 ± 0.86 5.98 ± 1.12 p=0.866 
Mean capillary blood glucose ± SD  (Mean, mmol/L) 6.35 ± 0.86 6 ± 0.39 p=0.472 
HbA1c ± SD (Mean) 5.5 ± 0.3 5.4 ± 0.4 P=0.770 
Admission NIHSS (Median/IQR) 15.5 (9.75-23.5) 13.5 (9.5-19.75)  
Admission Blood pressure ± SD (mmHg) 154/79 ± 10/4 143/73 ± 34/12 p=0.543 
Thrombolytic treatment (n/%) 5 (83.3) 3 (75) p=0.667 
Recanalization (n/%) 2 (33) 2 (50) p=0.548 
CT Perfusion Core volume ± SD (Mean, ml)) 36.5 ± 25.6 33.2 ± 26.9 p=0.850 
CT Perfusion Penumbra volume ± SD (Mean, ml) 54.9 ± 14.5 50.1 ± 31.4 p=0.752 
Total Perfusion Lesion Volume ±  SD (Mean, ml) 91.4 ± 39.3 83.4 ± 39.9 p=0.761 
Co-registered Final infarct volume ± SD  (Mean, ml)) 92.1 ± 65.1 53.1  ± 60.5 p=0.361 
Final Infarct Volume ± SD (Mean, ml) 126.4 ± 124.8 73  ± 88.7 p=0.448 
Infarct Growth ± SD (Mean, ml) 58.9± 39.7 16.6 ± 39.3 p=0.136 
Penumbral salvage ± SD (Mean, ml) -8.7 ± 61.25 38.3 ±  30.6 p=0.141 
Rankin 0-1 Day 30 (n/%) 0 1 (25) 
Rankin 2-5 Day 30 (n/%) 3  (50) 3 (75) 
Rankin 6 Day 30 (n/%) 3 (50) 0 
 
p= 0.153 
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Table 9-4 Tandem occlusions compared with M1 occlusion only in euglycaemia group 
Group (n) Euglycaem1a tandem 
(4) 
Euglycaemia  M1 only 
(2) 
 
Age ± SD (mean/years) 52.5 ± 14.8 60.5 ± 23.3 p=0.901 
Admission blood glucose ± SD (Mean 
mmol/L) 
6 ± 0.5 6.55 ± 0.35 p=0.244 
Mean capillary blood glucose ± SD  (Mean, 
mmol/L) 
5.22 ± 0.5 5.46 ± 1 p=0.682 
HbA1c ± SD (Mean) 5.9 ± 0.7 5.1± 0.6 P=0.211 
Admission NIHSS (Median) 19.5 (13.75 – 25.25) 14.5  
Admission Blood pressure ± SD (mmHg) 161/86 ± 17/10 157/91 ± 35/1 p=0.673 
Thrombolytic treatment (n/%) 3 (75) 2 (100) p=0.667 
Recanalization (n/%) 1 (25) 0 p=0.2 
CT Perfusion Core volume ± SD (Mean, ml)) 39 ± 20.8 19 ± 5.6 p=0.274 
CT Perfusion Penumbra volume ± SD (Mean, 
ml) 
37.2 ± 22.9 11.7 ± 2.7 p=0.212 
Total Perfusion Lesion Volume ±  SD (Mean, 
ml) 
76.2 ± 21.4 30.7 ± 2.9 p=0.047 
Co-registered Final infarct volume ± SD  
(Mean, ml)) 
81.7 ± 42.5 32.3  ± 5.4 p=0.197 
Final Infarct Volume ± SD (Mean, ml) 133.7 ± 71.8 75  ± 61.4 p=0.383 
Infarct Growth ± SD (Mean, ml) 22.6 ± 25.3 13.3 ± 0.2 p=0.197 
Penumbral salvage ± SD (Mean, ml) -5.4 ± 47.8 -1.6 ±  2.5 p=0.920 
Rankin 0-1 Day 30 (n/%) 0 0 
Rankin 2-5 Day 30 (n/%) 3 (75) 2 (100) 
Rankin 6 Day 30 (n/%) 1 (25) 0 
 
p=0.439 
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9.3.4 Pure M1 occlusions 
Seventeen patients had ‘pure’ M1 MCA occlusions with no evidence of occlusion of 
another blood vessel.  Eleven of these patients had admission hyperglycaemia, 4 had late 
hyperglycaemia and 2 were consistently euglycaemic. 
 
Figure 66 - Flowchart for 'pure' M1 occlusions 
There was no significant difference in age although there was a trend for the admission 
hyperglycaemia patients to be older.  Admission blood glucose was not significantly 
different between groups although there were significant differences for mean blood 
glucose. 
The perfusion lesions in the euglycaemic group were smaller than those in the other groups 
although this was not significant.  There was no significant difference between infarct 
volumes in the follow-up imaging. 
113 
Consented 
5 non-strokes excluded 
4 Migraine 
1 Peripheral Nerve Palsy 
17 ‘pure’ M1 occlusions 
2 Euglycaemic at 
all times 
11 Admission 
Hyperglycaemia 
4 late 
Hyperglycaemia 
4 CTP unusable 
37 No occlusion 
38 Other site of occlusion 
16 tandem occlusions 
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Figure 67 - 24-48 hour infarct volumes in patients with 'pure' M1 occlusions 
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Table 9-5 Outcomes for patients with pure M1 occlusions 
Hyperglycaemia Group (n) All patients 
(17) 
None(2) Admission (11) Late (4) 
 
Male Gender (n/%) 8 (47) 2 (100) 4 (36) 2 (50)  
Age ± SD (mean/years) 71 ± 12.2 60.5 ± 23.3 75.2 ± 8.3 64.8 ± 14 p=0.149 
Admission blood glucose ± SD 
(Mean mmol/L) 
7.43 ± 1.85 6.55 ± 0.35 8.12 ± 1.89 5.98 ± 1.12 p=0.103 
Mean capillary blood glucose ± 
SD  (Mean, mmol/L) 
6.52 ± 0.93 5.46 ± 1 6.89 ± 0.86 6 ± 0.39 p=0.047 
HbA1c ± SD (Mean) 5.6 ± 0.6 5.1± 0.6 5.7 ± 0.6 5.4 ± 0.4 P=0.297 
Admission NIHSS 
(Median/IQR) 
16 (11-19.5) 14.5 18 (13-20) 13.5 (9.5-
19.75) 
p=0.477 
Admission Blood pressure ± SD 
(mmHg) 
142/73 ± 
22/13 
157/91 ± 
35/1 
138/69 ± 17/12 143/73 ± 
34/12 
p=0.578 
Thrombolytic treatment (n/%) 15 (88) 2 (100) 10 (91) 3 (75) p=0.601 
Recanalization (n/%) 11 (65) 0 9 (82) 2 (50) p=0.309 
CT Perfusion Core volume ± SD 
(Mean, ml)) 
30.7± 18.6 19 ± 5.6 31.9 ± 17.4 33.2 ± 26.9 p=0.665 
CT Perfusion Penumbra 
volume ± SD (Mean, ml) 
38.2 ± 23.5 11.7 ± 2.7 38.7 ± 19.8 50.1 ± 31.4 p=0.171 
Total Perfusion Lesion Volume 
±  SD (Mean, ml) 
68.9 ± 35.3 30.7 ± 2.9 70.6 ± 33.7 83.4 ± 39.9 p=0.229 
Co-registered 24-48h infarct 
volume ± SD  (Mean, ml)) 
55.5 ± 45.5 32.3  ± 5.4 46.4  ± 36.1 53.1  ± 60.5 p=0.174 
24-48h Infarct Volume ± SD 
(Mean, ml) 
77.7 ± 73.7 75  ± 61.4 60.4  ± 48.6 73  ± 88.7 p=0.329 
Infarct Growth ± SD (Mean, 
ml) 
26.6± 36.6 13.3 ± 0.2 17.2 ± 33.4 16.6 ± 39.3 p=0.126 
Penumbral salvage ± SD 
(Mean, ml) 
15.1 ± 47.3 -21.5 ±  34.6 24.2 ±  51.1 18.5 ±  34.2 p=0.352 
Rankin 0-2 Day 30 (n/%) 4 (24) 0 3 (27.3) 1 (25) 
Rankin 3-5 Day 30 (n/%) 12 (71) 2 (100) 7 (63.6) 3 (75) 
Rankin 6 Day 30 (n/%) 1 (6) 0 1 (9.1) 0 
 
P=0.841 
 
9.4 Discussion 
The exploratory analyses presented in this chapter are limited by the small number of 
patients with evidence of a proximal M1 middle cerebral artery occlusion and imaging that 
was adequate for full analysis.  Of the 113 patients initially recruited into this study only 
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33 met the criteria for analysis in this section.  If we exclude patients with tandem 
occlusions (M1 occlusion with at least one other occlusion) we are left with 17 patients..   
In these data follow-up infarct volume was predicted by recanalization and admission 
blood glucose.  The relationship between recanalization and final infarct size is interesting 
and in keeping with what we know of the pathophysiology of stroke.  It is unusual that 
thrombolytic treatment did not emerge as a significant predictor of infarct size but the 
sample size is small and a large proportion of the patients were treated with alteplase. The 
relationship between admission glucose and final infarct volume is also of interest although 
we saw no significant relationship between glycaemic status and final infarct volume.   
The trend to larger infarct volumes may have been partially masked by the small number 
of euglycaemic patients with M1 occlusions and the large proportion of these patients who 
had tandem occlusions.  It is also interesting to note that only one of the four euglycaemic 
patients recanalized.  Larger proportions of patients recanalized in the other groups which 
may again skew the trend.  While none of these patients received insulin treatment their 
low mean blood glucose levels and larger infarct sizes may reflect the situation seen in the 
SELESTIAL and InsulInfarct studies where larger infarct volumes were seen after insulin 
treatment in patients who did not recanalize.554, 562 
It is recognised that tandem occlusions are associated with poor outcome after stroke 
thrombolysis.584-586  Recanalization rates are often reduced in patients with tandem 
occlusions.587  Ipsilateral internal carotid artery occlusion has also been associated with 
early arterial re-occlusion after treatment with alteplase.588  Case reports have described 
good results with intra-arterial intervention but there is no good evidence based treatment 
strategy for these patients at present.589  
In patients with admission hyperglycaemia the presence of a tandem occlusion 
significantly influences both baseline imaging findings and outcome infarct volumes.  The 
patients with tandem occlusions also had significantly worse outcomes as graded by 
Rankin score.  This significant effect was not seen in the late hyperglycaemia group or the 
euglycaemia group although there was a trend towards a similar pattern.  The small 
numbers in the late hyperglycaemia and euglycaemia groups mean that our results are 
slightly limited. 
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It is also interesting to note that euglycaemic patients with M1 occlusions are rare.  Only 
2/17 of patients with proven M1 occlusions were hyperglycaemic.  Overall only 16% of 
the patients we recruited were euglycaemic for the 48 hours after their strokes.  This may 
reflect the poor health and bad dietary habits of the West of Scotland population although 
it may also suggest that a degree of hyperglycaemia in the days after acute ischaemic 
stroke is very common.  
In the population of all 33 patients with M1 occlusions (including those with tandem 
occlusions) the difference in penumbral volumes between the late hyperglycemia group 
and the euglycaemic group may indicate that larger volumes of tissue at risk could create a 
demand for glucose as time goes on..  Post stroke hyperglycaemia may be the body trying 
to attain physiological homeostasis by getting glucose to dead or dying brain tissue.  We 
may be witnessing a failing protective mechanism as opposed to a pathogenic process. 
In Table 9.1 (all M1 occlusions) post hoc analysis of penumbra volumes suggested that 
euglycaemic patients may have smaller volumes of penumbra compared to the late 
hyperglycaemic group.  One hypothesis could be that the late hyperglycaemic group is 
stimulated to mount a hyperglycaemic response to salvage penumbra while the 
euglycaemic group with the smaller volume of tissue at risk does not. 
These data presented in this chapter show us how heterogeneous the pathophysiology of 
acute ischaemic stroke is.  A wide variety of arterial occlusions can cause a stroke on a 
background of variable prior glycaemic states.  The hyperglycaemic response that the body 
will mount after a stroke is also highly variable and is influenced by factors such as 
dysphagia, glucose metabolism and medical intervention with drugs and IV fluids.  The 
number of permutations of factors that may influence the growth of an infarct is vast.  With 
advanced imaging techniques and close observation of physiological variables we are only 
beginning to understand these interactions.  To allow large studies of more homogenous 
populations of stroke victims we must recruit even larger numbers of patients.  We will 
reach a more complete understanding of the pathophysiology of post stroke 
hyperglycaemia and its interaction with brain arterial patency through such studies. 
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10 Post-Stroke Hyperglycemia and brain arterial 
patency – Discussion 
10.1 Anecdotal background to thesis 
Before I started working on this thesis in 2008 I knew very little about the importance of 
hyperglycaemia in stroke.  As I have worked on this thesis I have learned a lot about the 
relationship between blood glucose levels and stroke.  When I consider the results of my 
research I realise that there is still much that we do not understand about this relationship. 
I had certain preconceived notions before I started as a research fellow.  I thought that post 
stroke hyperglycaemia was implicitly a bad thing and that insulin treatment would 
therefore be a good thing.  The stroke physician that I worked for before I started the 
project told me that there was nothing else to know about post stroke hyperglycaemia and 
that insulin didn’t work!  He was joking but there main have been a grain of truth in his 
joke. 
10.2 Scientific background to thesis 
For my introduction I reviewed the literature on hyperglycaemia and stroke.  There have 
been over 400 clinical papers published on this relationship and I have a spreadsheet 
detailing 424 of them. 
To make sense of the volume of papers I broke them down into two broad groups.  The 
first group dealt with pre-stroke hyperglycaemia; hyperglycaemia, impaired glucose 
tolerance, insulin resistance and diabetes as risk factors for ischaemic stroke.  There is 
certainly strong evidence suggesting that these risk factors are very real and if abnormal 
glucose metabolism is a risk factor for stroke we should not discuss post-stroke 
hyperglycaemia without at least being aware of pre-stroke hyperglycaemia. 
I then wrote about post-stroke hyperglycaemia starting with the earliest references that I 
could find in the literature of the 1960’s and 1970’s.71, 148, 151  A correlation between PSH 
and poor outcomes was well established and clearly delineated in the meta-analysis 
published by Capes et al in 2001.146  However the mechanisms by which PSH worsens 
outcome from stroke (if indeed it really does worsen outcome) are still at least partially 
unclear. 
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Indeed dissenting voices have suggested that PSH may actually be a protective mechanism 
and that therapeutic intervention to achieve normoglycaemia is inappropriate until we 
know more about the phenomenon.287  Uyttenboogaart and colleagues have suggested that 
PSH may be associated with better outcomes after lacunar stroke.260 
We are not even sure what PSH is.  It has been suggested that PSH is a stress response153, 
218, 221
 PSH may represent undiagnosed diabetes mellitus.130, 231, 233, 236, 237  It seems less 
likely that PSH is related to specific neuroanatomical lesions.226 My own theory is that 
PSH is partly unrecognised abnormal glucose metabolism and partly a stress response.  
The significant difference I observed in the HbA1c levels between the admission 
hyperglycaemia group and the euglycaemic group in the POSH cohort would support this 
hypothesis (Chapter 6). 
We are learning more about the pathophysiology of post-stroke hyperglycaemia.  This has 
been partly as a side-effect of advances in the acute treatment of ischaemic stroke with 
thrombolytic therapy.  PSH has been found to predict a poor outcome after thrombolysis 
175, 176, 179-181, 183-185
 although the association is not always clear cut.186  Intracerebral 
haemorrhage after thrombolytic treatment is associated with hyperglycaemia.34, 182, 189, 191   
A similar relationship has also been noted after intra-arterial procedures for stroke.193, 194, 
196
 
A more interesting finding for me (or at least one that is more directly relevant to my 
thesis) is the suggestion that hyperglycaemia accelerates the deterioration of ischaemic 
penumbra into infarcted core after rt-PA treatment for acute stroke.160, 176, 202, 590  This 
effect may mediated by hyperglycaemia reducing the recanalization rate after alteplase 
treatment.180, 198, 200, 201 
Interventions to control hyperglycaemia in acute stroke have not attenuated infarct growth 
and indeed insulin appears to have accelerated infarct growth in some patients.554, 562 
Indeed one study that purports to be an observational study claiming to demonstrate that 
hyperglycaemia quickens penumbral loss is confounded by the fact that patients were 
treated with an insulin sliding scale.197 
It has also been hypothesised that alteplase have a reduced effect on penumbral salvage in 
diabetic patients due to a impaired collateral circulation.590  This theory is in keeping with 
an observational study published by Toni and colleagues in 1994.204 Although I have not 
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had time to look at this in POSH cohort we do have good data on collateral circulation and 
glycaemic status so it is something that we may be able to revisit in the future. 
Another interesting concept is the possibility that hyperglycaemia is not a negative 
prognostic factor in TIA patients175, 207.  This observation may be because non-diabetic 
patients have been transiently hyperglycaemic as a physiological response to their TIA 
while diabetic patient have gone on to tissue infarction and stroke.209-212  My hypothesis is 
that diabetic patients may be more likely to have a stroke than a TIA due to a lack of 
collateral circulation in their cerebral vasculature. 
10.3  Conclusions of thesis 
In Chapter 3 I systematically reviewed the existing animal data on models of stroke and 
hyperglycaemia.  I had started this review expecting to find good evidence of a strong 
relationship between hyperglycemia and infarct growth in animal models of stroke.  I also 
expected to find clear evidence of the utility of insulin in preventing infarct growth.  
However when I looked at things systematically I found that the available evidence did not 
fully support my preconceived ideas.  The animal models for hyperglycaemia did not really 
match the human patient with post-stroke hyperglycaemia and the evidence for the use of 
insulin was very limited. 
I subsequently undertook a systematic review on the clinical use of insulin for post-stroke 
hyperglycaemia (Chapter 4).  The available clinical trials examining the use of insulin for 
post-stroke hyperglycaemia show no benefit from intervention.  Indeed, insulin may be 
harmful for many patients.  I presented these data at the European Stroke Conference in 
Hamburg in 2011 and a Cochrane Review with very similar findings has subsequently 
been published by another group.591 
Chapter 5 was a retrospective study looking at patients who had been treated with alteplase 
and entered into the SITS database in the Southern General Hospital.  I was able to 48 hour 
obtain glucose profiles for a subgroup of this population and we were able to look at the 
relationship between different patterns of hyperglycaemia and clinical outcomes.   
We found that, in this population, patients with a mean capillary blood glucose (MCBG) of 
above 7mmol/L had poorer outcomes than those who had an admission glucose level of 
above 7mmol/L or those who had two isolated glucose levels above 7mmol/L.  This 
retrospective study had been partially inspired by the GLIAS paper161 which suggested that 
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a ‘cut-off ‘ glucose level of 8.6mmol/L was associated with the poorest outcomes after 
stroke so we also used this value in our analysis and found it to be less predictive that the 
48 hour mean capillary blood glucose.  
In Chapter 6 I established the demographics of the patients in the different glycaemic 
categories.  We divided patients into 3 groups.  The first group was labelled as having 
admission hyperglycaemia with a glucose level of 7mmol/L or more within 6 hours of 
stroke onset.  This group of patients would have been hyperglycaemic while a potentially 
salvageable ischaemic penumbra existed. 
The second group became hyperglycaemic 6 or more hours after stroke onset.   This late 
hyperglycaemia group were less likely to have been hyperglycaemic whilst the ischaemic 
penumbra was in existence. 
The third group of normoglycaemic patients had no evidence of a blood glucose level of 
7mmol/L during the first 48 hours after stroke onset. 
The normoglycaemic patients were significantly younger than the other patients and were 
less likely to have a history of diabetes.  All glycaemic parameters (HbA1c, admission 
blood glucose, mean capillary blood glucose) were significantly different between groups.  
Only 15.7% of patients were normoglycaemic for the entire study period.  I suspect that the 
younger patients may be more likely to be normoglycaemic with a lower HbA1c as the 
incidence of diabetes increases with age.575 
In Chapter 7 I looked at the interaction between glycaemic status and infarct growth.  We 
defined infarct growth as the difference between the volume of infracted ‘core’ tissue seen 
on perfusion CT and the volume of co-registered infarct seen in a follow-up CT scan at 24-
48 hours. 
In this population there was a trend towards larger 24-48 hour infarct volumes in the 
admission hyperglycaemia patients when compared to patients with late hyperglycaemia or 
normoglycaemia.  The trend was more apparent when I focused on patients who had a core 
perfusion lesion of more than 10ml.   
There was also a trend towards reduced survival of penumbra in the patients with 
admission hyperglycaemia.  Post hoc analysis suggested that there was significantly more 
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penumbral survival in the late hyperglycaemia group than the admission hyperglycaemia 
group. 
Interestingly the patients with late hyperglycaemia had smaller mean core perfusion lesions 
and smaller follow-up mean infarct volumes than the normoglycaemic patients although 
this difference was non-significant.   
The population in this chapter is still very heterogeneous as the underlying vascular status 
of the patients has not been defined.  Arterial patency was clearly defined in chapter 8 and 
some interesting patterns began to appear.  I’ve illustrated these patterns in Table 10.1 on 
the next page.
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Table 10-1 - Summary table of interactions between arterial patency, blood glucose kinetics and infarct volume 
Mean Infarct volume ± SD (ml)  
Admission Hyperglycaemia Normoglycaemia Late Hyperglycaemia 
Recanalization  infarct volume * 
(84.7 ± 79) 
 infarct volume 
(80.2 ± 54.9) 
 infarct volume 
(25 ± 25.7) 
 
 
 
Occlusion 
No recanalization  infarct volume * 
(156.4.38 ± 153.4) 
 infarct volume 
(79 ± 83.6) 
 infarct volume 
(63.2 ± 72) 
 
No occlusion 
 infarct volume * 
(22.49 ±50.6) 
 infarct volume 
(46.2 ± 46.2) 
 infarct volume 
(22.5 ± 47.3) 
* Significant difference (p<0.001) 
252 
In Chapter 8 I initially looked at the subgroup of patients with arterial occlusions in the 
POSH study.  In the subgroup of patients with arterial occlusions admission 
hyperglycaemia reduces penumbral survival and increases final infarct volume.  The 
interesting new finding is the suggestion that late hyperglycaemia after 6 hours may be 
associated with better imaging outcomes and improved penumbral survival.   
These findings are somewhat in conflict with those published in a prospective 
observational study by Dziedzic and colleagues who found that patients with late 
hyperglycaemia had an increased risk of mortality.247 However Dziedzic and colleagues 
did not have the extensive imaging data that we have used to characterise the pathological 
progression of acute stroke.  They also had less measurement of glucose levels in the first 
48 hours and they may have missed physiological fluctuations in a critical time period.   
I subsequently looked at the patients with no evidence of arterial occlusion.  In these 
patients the relationship between 24-48 hour infarct volume and glucose appears to be 
different.  There was a trend towards normoglycaemic patients having larger infarcts than 
patients with hyperglycaemia.  This trend may be in keeping with the suggestion made by 
Uyttenboogaart that hyperglycaemia may be associated with better outcomes in lacunar 
stroke.260  A degree of hyperglycaemia may support tissue at risk of infarction in the 
absence of visible cerebral artery occlusion. 
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Figure 68 - Final infarct volume is influenced by the presence of arterial occlusion and blood 
glucose profile 
In Chapter 9 I tried to delineate a very homogeneous population based on subtype of 
arterial occlusion.  Initially I looked at all patients with proximal middle cerebral artery 
occlusions (M1 occlusions) before excluding patients with any other occlusions (tandem 
occlusions) to obtain a population of ‘pure’ M1 occlusions. 
The presence of a tandem occlusion is associated with larger infarct volumes and worse 
clinical outcomes, in keeping with previous observations.584, 585  In patients with admission 
hyperglycaemia follow up infarct volumes were 4 times larger in the presence of more than 
one occlusion.  In the late hyperglycaemia and normoglycaemia groups tandem occlusions 
were associated with infarcts of approximately double the volume of those seen in ‘pure’ 
M1 occlusions.  There were no significant differences in admission glucose, HbA1c or 
mean capillary blood glucose when patients with tandem occlusions were compared to 
‘pure’ M1 occlusions or the POSH cohort as a whole. 
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Patients with late hyperglycaemia tended to have larger penumbral volumes than patients 
with normoglycaemia when we looked at all M1 occlusions (including tandem occlusions).  
This observation was only significant on post-hoc analysis.  I would hypothesise that a 
larger penumbra may stimulate a physiological increase in blood glucose levels in an 
attempt to save dying brain tissue.  The euglycaemic patients may fail to mount this 
response for some reason.  Patients with late hyperglycaemia also tended to salvage more 
penumbra.   
10.4  The findings of this thesis in the context of future stroke 
research 
Taken in the context of the results of the SELESTIAL trial,554  the INSULINFARCT 
trial,562 my reassessment of the animal evidence in chapter 3206 and the systematic review 
of the clinical trials of insulin for post stroke hyperglycemia presented in chapter 4 there is 
at present little justification for further human trials of insulin treatment for post-stroke 
hyperglycaemia after the initial 6 hour window.  Trials of insulin for post stroke 
hyperglycaemia have failed to take account of the heterogeneous and acutely evolving 
pathophysiology of ischaemic stroke.  Future ‘blind’ trials are unlikely to be helpful.  
Any trials of insulin for hyperglycaemia within 6 hours of stroke onset should also be 
considered very carefully.  There may even be a role for inducing hyperglycaemia in 
patients with no evidence of arterial occlusion. 
The presence of ‘tandem’ occlusions is associated with very poor outcomes and these 
outcomes are worsened by admission hyperglycaemia.  The identification of multiple 
occlusions of the cerebral vasculature is important for prognostication and appropriate 
treatment strategies need to be developed.   
Larger scale studies examining the pathophysiology of post stroke hyperglycaemia and its 
interaction with brain arterial patency may be of more value in the first instance.  Potential 
therapeutic interventions must be based on a solid understanding of the underlying 
pathophysiological mechanisms. 
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Appendices 
Appendix 1 – Literature search strategy 
exp *Stroke/ or cerebrovascular.mp. or exp Cerebrovascular Disorders/ or Thrombosis/ or Intracranial 
Thrombosis/ or "Intracranial Embolism and Thrombosis"/ or Brain Ischemia/ or Brain/ or Brain 
Infarction/ or Infarction, Posterior Cerebral Artery/ or Cerebral Infarction/ or Infarction, Middle 
Cerebral Artery/ or Middle Cerebral Artery/ or Infarction, Anterior Cerebral Artery/ or Brain 
Ischemia/ or "Intracranial Embolism and Thrombosis"/ or Middle Cerebral Artery/ or Brain Ischemia/ 
or Ischemia/ or isch?emia.mp. or Intracranial Embolism/ or Embolism/ or "Intracranial Embolism and 
Thrombosis"/ or neuron.mp. or exp *Neurons/or Nervous System/ or Central Nervous System/ or 
neuronal.mp. or exp *Brain Ischemia/ or exp *Ischemia/ or ischemia.mp. or exp *Ischemic Attack, 
Transient/ or exp *Ischemia/ or ischaemia.mp. or exp *Infarction, Posterior Cerebral Artery/ or exp 
*Cerebral Infarction/ or exp *Infarction, Anterior Cerebral Artery/ or exp *Brain Infarction/ or exp 
*Infarction/ or infarction.mp. or exp *Infarction, Middle Cerebral Artery/ or exp *Cerebrovascular 
Disorders/ or cva.mp. and exp *Blood Glucose/ or glucose.mp. or exp *Glucose/ or *Hyperglycemia/ 
or *Insulin/ 
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Post-script 
The soundtrack to this thesis included Philip Glass, Neutral Milk Hotel, Fugazi, Mogwai, 
the Yeah Yeah Yeahs, Sonic Youth and 12 Crass Songs by Jeffery Lewis.  Initial parts of 
this thesis were written in August 2008 and this last section is being typed on Sunday 28th 
of July 2013, two days after I have received confirmation that the minor corrections to this 
thesis have been completed.  I am currently listening to instrumental music by Black Flag. 
This thesis contains work that took up 5 years of my life. It was hard work, but mostly 
enjoyable and mostly worthwhile.  If any reader of this thesis has not undertaken a period 
of academic research I would urge the reader to do so as it expands your worldview. I 
believe that this work has made me a better clinician and a better person.  Research, like 
most things in life is 99% perspiration and 1% inspiration. 
If anyone is looking for stuff to read I urge them to check out the work of Alan Moore, 
Grant Morrison, Will Eisner, Kurt Vonnegut, Oliver Sachs, Iain (M) Banks and Hunter S. 
Thiompson.  These writers may also expand your worldview. 
Thanks for picking up this book.   
 
Best wishes, 
Niall 
